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ABSTRACT 
Various techniques have been used for modifying the release properties of drugs over the past 
years. Techniques such as liquisolid technology have raised a lot of interest in many researchers 
which can be employed to enhance or sustain dissolution. Various liquisolid (LS) tablets of 
diltiazem containing Polysorbate 80 as a non-volatile solvent for sustained release were 
prepared. Polyox
TM
 is an attractive pharmaceutical polymer used in controlled release dosage 
forms mainly because of its insensitivity to the pH of the biological medium and ease of 
production. The aim of this study was to investigate the influence of several formulation factors 
i.e., the Polyox
TM
 grade at
 
different molecular weight (MW), Polyox
TM
 particle size and ratio, the 
AEROSIL
®
 grade, the use of diluent, polymer type and the drug type as well as their interactions 
on drug release from LS formulation in comparison to their physical mixture (PM). The result 
showed that Polyox
TM
 MW was a key determining step in achieving sustained release, with the 
higher MW of Polyox
TM
 resulting in a more delayed release profile. The delayed DTZ release 
could be related to the rate and extend of hydrogel formation on the tablet surface. The P–CMRs 
and net–CMRs of both LS and PM formulation powders also showed increasing trends with 
increasing the MW of Polyox
TM
. The release of DTZ from both LS and conventional tablets 
showed mostly decreasing trends with increasing Polyox
TM
 concentration and decreasing 
Polyox
TM
 particle size distribution. This could be attributed to the formation of stronger and 
thicker gel layers on the tablet surfaces in the case of higher concentrations of Polyox
TM
. The 
results also showed LS tablets to produce slower release of drug than their PM counterparts, 
regardless of Polyox
TM
 particle size. The release profile of the DTZ from both LS tablets and 
their counterpart PM tablets showed decreasing trends with increasing the surface area of 
hydrophilic AEROSIL
®
 (from 65 m
2
/g to 225 m
2
/g). This could be due to the higher tensile 
strength (TS) of the tablets containing AEROSIL
®
 particles with higher surface area compared to 
those prepared using AEROSIL
® 
particles having lower surface areas. Also, the result showed 
that comparing the different diluents showed that hydrogenated vegetable oil (HVO) provided 
the slowest release pattern of DTZ across diluents used in both the LS compacts and PM tablets.  
This could be attributed to hydrophobicity imparted by HVO to matrix system when in contact 
with aqueous medium it takes a longer time to penetrate into the tablet.  Drug release from LS 
tablets was affected by the polymer type. The release was in the order: Eudragit
®
 RL < Eudragit
®
 
RS < Hypromellose < Polyox
TM 
< Psyllium. Hydrophilic Psyllium provided a slowest DTZ 
release across the different polymers used in the preparation of both the LS and PM compacts. 
The incorporation of Psyllium into Polyox
TM
 further elicited a decrease in drug release rate from 
individual polymer matrices. This was ascribed to the reduced entrance of aqueous media into 
the matrix due to the presence of the stronger viscose gel within the two hydrophilic matrices 
compared to individual Psyllium and Polyox
TM
. The ratio between Polyox
TM
 and Psyllium has 
critically influenced diltiazem release profile. The results showed that matrices containing 
(Psyllium:Polyox
TM
) at 1:1 ratio can slow down the drug release more than the matrices 
compacts containing 1:3 and 3:1 (Psyllium:Polyox
TM
) ratio. The results also suggest that the 
ii 
 
combination of Polyox
TM
 and Psyllium at 1:1 ratio showed robust dissolution against pH and 
rotational speed and therefore indicates an appropriate sustained-release profile. The dissolution 
rate of Polyox
TM
:Psyllium from different pure drugs showed a decreasing trend with an increase 
in their solubility. The solid state analysis studied in this work confirms the presence of a 
fraction of the drug mass in a solubilised state within polysorbate 80 in LS powders. Regardless 
of all variables used in this study, LS formulations showed slower drug release than their PM 
counterparts. In conclusion, the mechanical properties of LS formulation are poor in comparison 
to their counterpart PM. Therefore, further work is required to improve the hardness of LS tablet 
comprehensively. 
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 Drug delivery 1.1
Humankind’s attempts to confront illness date back to early civilization. Substances 
obtained from nature were used and tested to treat dysfunctions of physiological life processes, 
discomfort and pain (Clark, 1996). With the advancement of science, the active ingredients of 
these substances along with their mechanism of action have been illustrated (Sindrup and Jensen, 
1999). Today, new drug candidates are tested to add more effective tools to illness (Zhang et al., 
2006). Drugs, even those drugs proposed to treat the same symptoms, usually exhibit 
dramatically different physicochemical properties such as hydrophobicity, chemical composition, 
size and potency (Fini et al., 1995). At the molecular level, there is an increased knowledge of 
cellular biology that is combined with the (decoding) of the human genome (Venter et al., 2001), 
with a technological discovery in the field of proteomics plus DNA micro–arrays (Cahill and 
Nordhoff, 2003) that has introduced even more applications such as nucleic acids (gene delivery) 
(Naldini et al.,1999) and peptide drug delivery (Morishita and Peppas, 2006). Drug activity is a 
result of molecular interaction(s) in specific cells. It is therefore easily assumed that it is required 
for the drug to reach somehow the site of action following treatment (oral, local, transdermal, 
intravenous, etc.) at adequate concentrations (Sindrup and Jensen, 1999). The process of 
administering a medicinal compound for the purpose to produce a therapeutic outcome for 
animals and humans is called drug delivery. Drug delivery therefore, is a form of technology, 
which alters the absorption, release profile, elimination and distribution of drug for the sake of 
increasing the safety and effectiveness of the dosage form to offer compliance and suitability to 
the patients (Srikanth et al., 2013). Drug delivery aims to deliver the drug at the right 
concentration for the right period and the right place (Langer, 1998). Although this is difficult by 
simply choosing an appropriate administration route, strategies based on the relationship of the 
drug with a carrier (a drug delivery system) are an option (Allen and Cullis, 2004). Additional 
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motives for developing drug delivery systems include the reduction of needed resources for 
therapy, the drug’s therapeutic index and expensive treatments or unpleasant drug achieved by 
the prevention of frequent dosing (Ranade and Cannon, 2011).  
1.1.1 Oral drug delivery 
There are numerous techniques by which a drug can be delivered to the body, such as 
oral (through swallowing), parenteral (through injection), sub-mucosal (through buccal and 
sublingual mucosa), transdermal (through the skin) and pulmonary (through inhalation) drug 
delivery. The centre for the delivery of a large number of essential drugs in various therapeutic 
areas is the oral route of administration (Perrie and Rades, 2012). The oral drug delivery market 
is growing at a compounded 10.3% increase of yearly growth rate from 2010 to 2017. This 
favourite stems from different factors such as the ease-of-use, non-invasiveness and reliability of 
oral dosage forms (Perrie and Rades, 2012). Indeed, oral administration is the most popular route 
due to simplicity of ingestion, pain evasion, flexibility (to accommodate several types of drug 
candidates), and most significantly patient compliance. In addition, solid oral delivery systems 
do not need sterile conditions, and therefore, these systems are less costly to manufacture 
(Spireas, 2002).  
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Table 1.1: Advantage and disadvantages of different type of drug release 
Type of drug release Advantages Disadvantages 
Sustained  Improved control over plasma levels of drug 
o maintaining therapeutic plasma concentrations of a drug 
for (8 to 24) h 
o reduction in drug plasma level fluctuations and thus better 
control of the disease 
o useful for once daily dosing 
 Economic savings 
o For pharmaceutical companies: cheaper to reformulate an 
established drug into a SR drug delivery system than to 
develop new drugs. 
For health care services: fewer doses leads to lower volume 
purchasing of drugs 
 Variable physiological factors (e.g. pH, food, etc.) 
may all affect drug the release, leading to 
o poor in vitro-in vivo correlation 
o increased instability 
o potential dose dumping* 
 GI transit time is usually less than 12 hours. This 
potentially limits time for therapeutic levels to be 
reached and maintained, leading to poor systemic 
drug bioavailability due to incomplete release 
 
Controlled   Therapeutic plasma concentration is maintained for a prolonged 
period of time 
 Higher blood concentration is avoided. 
 Economical: the overall treatment cost will be less due to less 
dosing frequency, although the initial cost of treatment is high. 
 Release rate continuously decreases due to decrease 
in effective area at the diffusion front and enhanced 
diffusional resistance. 
 Food and the rate penetration influence release rates 
through the gut. 
Immediate  Proper for controlled/sustained release actives.   Rapid drug treatment intrusion is not possible. 
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 Enhanced solubility of the pharmaceutical composition. 
 
 Sometimes may need more frequency of 
administration. 
Extended  Extended-release (ER) formulations have the potential to 
develop the patient compliance and convenience. 
 Improve the stability by defending the drug from degradative 
changes or hydrolysis  in GI tract 
 For oral controlled release formulation, effective 
drug release period is limited and determined by 
G.I residence time. 
 Poor systematic availability and Increase 
potential for first pass clearance. 
Enteric  Coatings are needed for tablets providing a smoother finish, 
mask the unpleasant taste and also to produces large tablets 
easier to swallow. 
 Controls of sugar coating such as approximately 
high cost, high bulk and long coating time have 
led to the use of other coating materials. 
 It needs the expertise of extremely skilled 
technician. 
Time–Release  Once-daily dosing is possible with most time-release 
formulations. This improves the ease of dosing and can 
increase drug compliance. 
 Some of these advantages involve reduction in adverse effects 
connected with peak blood levels, reduction in GI adverse 
effects,  and extension of the active half-life of the drug 
 Time-release formulations are connected with 
some limitations. As a result of the continuous 
release, in most cases, the tablet enters the colon 
before absolute dissolution. Absorption from the 
colon is not as great as that of the small intestine 
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In general oral drugs are designed for either immediate release or modified release. Immediate release 
tablets are those that disintegrate quickly and get dissolved to release the drug rapidly. Immediate 
release may be provided for by the use of a suitable pharmaceutically acceptable carrier or diluent, in 
which carrier or diluent does not prolong, to a significant extent, the rate of drug release or absorption 
(Nyol and Gupta, 2013). The term modified release product is used to specify products that change the 
rate and the timing of the release of the drug substance. ER dosage forms offer at least a double 
reduction in dosage rate as compared to that drug given an immediate release form (Leon, 2005). Timed 
release drug delivery is used to achieve the drug release following a delayed time. Enteric release 
dosage forms are those systems that release the drug slower than usual behaviour at proposed rate & 
significantly reduce the dosage frequency by two folds (Ankit et al., 2013). 
 Controlled release 1.2
Controlled release controlled release drug is a drug delivery system that produces the constant 
oral delivery of drugs at reproducible and predictable kinetics for a proposed period during the course 
of GI transit and also the method that target the delivery of a drug to a particular region in the GI tract 
for either a systemic or local action (Rathore et. al. 2013). In the last three decades, controlled release 
oral products have brought the attention of formulation scientists due to an array of advantages 
(Abdelkader et al., 2007). Essentially the term controlled release can be applied to the systems showing 
some type of ‘control’ over the drug release, viz. control over the place of drug release (as in enteric 
coated dosage forms), control over slow and constant release of the drug from the dosage form (as 
sustained release systems) or in targeted drug release to a distinct organ (Lachman et al., 1990). 
However, controlled release dosage forms do have some limitations. Cure cannot be stopped 
immediately should it be required in case of severe adverse effects. Additionally, there is less room for 
dosage alteration. Different factors like pH, motility and contents of the gastrointestinal tract (GIT) 
might change the drug release from the transit time of control release dosage form, and therefore, these 
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factors should be taken into account in order to regulate the drug release and the transition time of the 
dosage form into GIT (Zalte and Saudagar, 2013). Ideally, a controlled release drug delivery system 
strives to deliver drug at a rate administered by the dosage form design. Practically, the controlled drug 
delivery systems attempt to keep the required concentration at the target tissues across the therapeutic 
window (Chen et al., 2013). The controlled release systems try to keep drug plasma concentration at a 
constant state level where ideally the rate of drug display in the blood matches the rate of drug 
clearance from the blood. It is understood in the system that the absorption of the drug is not the rate 
defining step such that the rate of occurrence in the blood meets the rate of release from the dosage 
form. 
 Sustained release 1.3
The new and novel drug delivery systems are replacing conventional drug dosage forms. A 
sustained release (SR) dosage form is a drug delivery system that allows a reduction in dosing 
frequency to that presented by a conventional or immediate release dosage form (Figure 1.1). A SR 
drug delivery system therefore, produces prolonged therapeutic effect by constantly releasing the drug 
over an extended period of time subsequent of single dose administration. SR formulations are 
designed to provide an initial release of drug sufficient enough to achieve the desired therapeutic 
response promptly after administration, and then the remaining (maintenance) dose is released 
gradually over an extended period of time to achieve a therapeutic level that is prolonged but not 
maintained constant. The system is not capable of maintaining constant drug levels. 
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Figure 1. 1: A hypothetical plasma concentration-time profiles from conventional, sustained and zero-
order controlled release delivery systems following single doses. 
The plasma concentration-time profiles of conventional release systems are associated with 
peaks (above the minimum toxic concentration (MTC), potentially resulting in toxic side effects) and 
valleys (below the minimum effective concentration (MEC), potentially resulting in no therapeutic 
outcome) that reduce optimum drug therapy. The main goals of designing a SR form is to achieve a 
steady state blood level that is non-toxic and therapeutically effective for an extended period of time 
(i.e. to reduce fluctuations in drug levels in the blood) and thereby reduce dosing frequency (Figure 
1.1). The design of SR system therefore, requires an understanding of the pharmacokinetic and 
pharmacodynamic properties of the drug (Robinson and Lee, 1997). The ideal SR drug delivery system 
is expected to achieve a release of a highly soluble drug to the target organ or cell at a rate that matches 
an intended purpose. The advantages and limitations of SR dosage forms are summarised in Table 1.1.
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 Common candidate Drugs for Sustained Release 1.4
Certain properties of the drug candidate should be viewed into before developing it into 
sustained release dosage form. Normally, a drug can be formed into a sustained release dosage form if 
it has a comparatively shorter biological half-life, is absorbed and excreted quickly, is completely 
absorbed in the lower intestine, and has a broad therapeutic index. The time taken to eliminate 50% of 
the drug from a systemic circulation is referred to as the drug’s half-life. To achieve a consistent 
therapeutic blood level of the drug the rate of absorption and elimination should be retarded. Biological 
half–life of a drug plays a vital role in this case. In general, a drug with approximately shorter half-life 
is a better candidate for a sustained release dosage form (Lachman and Lieberman, 1990).  
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Table 1. 2: List of some developed drugs for sustained release 
 
Drug Category Water solubility 
at 22 ºC 
Pka Log P Dose (mg) Half-
life (h) 
tmax (h) Commercial 
product(s) 
References 
Alfuzocin HCl Selective 
antagonist of post–
synaptic alpha 
25 14.64 and 7.3 1.4 10 10 8 Extended 
Release 
Nicholas et al., 2011 
Diltiazem HCl Calcium channel 
blocker 
465 12.86 and 8.18 2.8 120 to 180 3 to 5 1 to1.5 Extended-
Release Tablets 
Elkhodairy et al., 
2012 
Gliclazide Anti-diabetic 0.19 mg/mL 4.07 and 1.38 2.6 40 to 120 10-24 2 to 8 Extended-
Release Tablets 
Panchal et al., 2011 
Losartan potassium  
 
Antihypertensive 0.82 mg/L 5.5 6.1 50 to 100 1.5 to 
2.5 
2 to 4 Extended-
Release Tablets 
Vohra et al., 2012 
Metformin HCl Antihyperglycemic  1.38 mg/mL 12.4 -0.5 500 to 2500 1.5-4.5 24 to 48 Extended-
Release Tablets 
Riedmaier, 2013 
Propranolol HCl Beta blocker 61.7 mg/L 9.5 3.48 60 to 160 4 11.5 to 
15.4 
Extended-
Release Tablets 
Reiter, 2004 
Pregabalin Anti-epileptic,  
Anti convulsant 
11.3 mg/mL 4.2 and 10.6 -1.35 25 to 300 6.3 1.5 to 3 Extended-
Release Tablets 
Pawar et al., 2011 
Theophylline Anti-asthmatic 8.0 mg/L 8.81 -0.02 400 to 800 6 to 8 1 to 2 Extended-
Release Tablets 
Shojaee et al., 
2014 
Venlafaxine HCl Anti-depressant 572 mg/mL 14.42 to 8.91 2.69 75 to 225 5-11 5.5 to 9 Extended-
Release Tablets 
Radhika et al.,2011 
Zonisamide Antiepileptic drug 0.8 mg/mL 10.2 0.5 100 to 400 60 2 to 5 Extended-
Release Tablets 
Biton, 2007 
Naproxen Na Nonsteroidal anti-
inflammatory 
drugs (NSAIDs) 
15.9 3.18 4.14 200 to 220 12 to 15 0.5 to 3 Extended-
Release Tablets 
Rashid et al., 2009 
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 Diltiazem hydrochloride (HCl) 
Diltiazem HCl (DTZ) is a calcium channel blocker that is generally employed in the 
treatment of angina pectoris and hypertension (Elkhodairy et al., 2012). DTZ is largely 
metabolized by the liver, excreted by the kidney, and absorbed up to about 80%; however, due to 
an extended first-effect, DTZ is subjected to an entire bioavailability of about 40%. The plasma 
elimination half-life after single or multiple administrations is almost (3–5) h. A sustained and 
slow release of DTZ is useful to patients to maintain sustainable levels of DTZ in the blood 
plasma (Piepho et al., 1982).  
 Theophylline 
Theophylline (THP) is used in therapy of chronic obstructive pulmonary disease 
essentially in bronchial asthma (Yoon et al., 2007). It is given as conventional tablets in a dose of 
400 mg to 800 mg daily in divided doses. It is quickly absorbed and eliminated by a plasma half-
life of 6 to 8 h and a tmax (the amount of time that a drug is present at the maximum concentration 
in serum) of 1 to 2 h. Due to fast absorption and elimination of drug the plasma concentration-
time profile of its proper system results in a regular peak-valley curve, a phenomenon making it 
hard to keep a steady plasma level. Therefore, frequent dosing is needed to maintain a uniform 
concentration of drug in blood to give its therapeutic effect (Yasir et al., 2010).  
 Zonisamide 
Zonisamide (ZNM) is quickly absorbed, with reaching the tmax in (2–5) hrs with 100% 
bioavailability (Sills and Brodie, 2007). Food decreases the rate but not the limit of absorption, 
improving the tmax to (4–6) h (Brodie et al., 2012). ZNM exhibits dose-dependent 
pharmacokinetics, with highest plasma concentrations and the area under the time-plasma 
concentration curve leading linearity following single doses of (100–800) mg and various 
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subsequent doses of (100–400) mg every day (Kochak et al., 1998). It has a long half-life of 60 
hours, leaving for once-daily dosing. The sustaining dosage is (100–600) mg/d in adults and 8 
mg/kg/d in children. It is approximately 40% to 50% protein bound and the therapeutic limit is 
(10–40) μg/mL. There is no clear correlation between clinical efficacy and ZNM serum levels 
(Sills and Brodie, 2007). 
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Figure 1. 2: Schematic, simplified summary of drug–related, polymer–related, and co–excipient variables 
affecting drug release from sustained release matrix systems.
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 Matrix systems 1.5
Matrix (monolithic) systems are one of the most frequently used dosage forms for oral 
controlled drug delivery systems. Matrix SR systems are often administered via the oral 
administration, owing to its advantages including the ease of administration and the high 
acceptance by patients. Historically, hydrophilic matrix systems were first introduced to the 
academic community in the early 1960s, with a patent from (Christensen and Dale, 1969), after 
which the inventors published a research describing the technology and its applications (Huber et 
al., 1996). 
Matrix systems are polymer–based delivery systems that enable a slow controlled drug 
release into the body. Matrix formulations usually consist of (i) drug, (ii) polymer, and (iii) co-
excipient(s). In a matrix system, the drug is dispersed/embedded as solid particles within a 
porous hydrophilic or eroding matrix formed of a soluble or an insoluble polymer, which enables 
the drug release to be controlled. The drug is combined and made into granules with slowly 
dissolving/eroding excipients, progressively releasing the drug for absorption. The direct 
compression of the drug, materials and additives to form a tablet in which the drug is embedded 
in a matrix core of the polymer retardant forms a matrix tablet. The main advantages and 
limitation of matrix systems are summarised in Table 1.3. 
When a matrix that contains swellable glassy polymer is in contact with an aqueous solution (or 
gastric fluid), the hydrophilic matrix takes up water, leading to a decrease in the glass transition 
temperature of the polymer (i.e. water plasticising the polymer) causing a change from a glassy 
state to a rubbery state. Such initial wetting stage of the tablet surface followed by polymer 
swelling/hydration leads to forming a gel layer at the system surface (Figure 1.3). The quick 
formation of such gel layer is important because it helps to hold the structural integrity of the 
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matrix, halts water entering the core of the matrix, and constraints tablet disintegration (Colombo 
et al., 2000). As more water penetrates into the free spaces between the macromolecular chains, 
the thickness of the gel layer increases, the polymer chains become more flexible and the matrix 
swells, this then causes the diffusion of the encapsulated drug out of the matrix (Figure 1.3). A 
water gradient is present within the hydrated gel layer, the outer surface of this layer is the most 
dilute with polymer here approaching complete disentanglement is prone to erosion. Eventually, 
the outer tablet layer reaches a dilution point as it is highly hydrated, causing disentanglement of 
the polymer from the surface of the matrix (Khan et al., 1995). Drug release rate therefore 
depends on polymer swelling rate, length of diffusion pathway, and strength/tortuosity of the gel 
layer. The mechanisms and kinetics of release from hydrophilic matrices are comprehensively 
reviewed elsewhere (8). 
According to the Higuchi equation (Higuchi, 1963), (Eq. 1.1), the release of drug from a 
matrix system is controlled by the initial drug concentration, drug solubility, polymer system, as 
well as matrix porosity, tortuosity, size and shape.  
𝐀 =  [𝐃(𝟐𝐂 −  𝐂𝐜)𝐂𝐜 × 𝐭]
𝟏/𝟐 (1.1), 
where, A is the amount of drug released in time t per unit area, D is the diffusivity of drug 
molecules in the matrix substance, C is the initial drug concentration, and Cs is the drug 
solubility in the matrix media. It is therefore possible to manipulate drug release from sustained 
release matrix systems (SRMS) by manipulating drug-, polymer and formulation related 
variables. This research reviews the influence of drug-, polymer-, and co–excipient–related 
variables and their interactions on the rate and mechanism drug release from SRMS (Figure 1.2). 
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Figure 1. 3: Mechanism of drug release from a hydrophilic matrix tablet. 
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 Drug-related variables 1.6
In a successful SR system, the drug is released from the dosage form at a predetermined 
rate, dissolve in the GI fluids, maintain sufficient GI residence, and absorbed at a rate that will 
replace the amount of drug being metabolized and excreted (Ansel et al., 2000). The 
characteristics for candidate drugs for SR drug delivery systems and examples of drugs 
unsuitable for oral SR dosage forms are summarised in Tables 1.3 and 1.4 respectively. 
The release of drug from its matrix system is reliant on its physicochemical properties 
such as solubility, molecular weight (MW), size and shape, particle size and shape, and chirality 
(Abdou, 1989). Such properties of a drug may determine the type and grade of the retardant 
polymer (Section 1.7) as well as the co–excipient(s) (Section 1.8) that need to be incorporated to 
achieve a desirable drug release. 
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Table1.3: A summary of characteristics for candidate drugs for SRDDSs 
Characteristic Rational 
Exhibit neither very slow nor very 
fast rates of absorption and 
excretion, i.e. half-life should be 
between 2 h and 8 h (ideally 4 h to 
6 h). 
Drugs with long biological half-life are inherently long 
acting, whereas drugs with very fast biological half-live 
require too large dose to be pharmacologically active 
Absorbed reasonably quickly The concentration of drug in the plasma should be limited 
by the release rate rather than the rate of absorption 
Maintain adequate residence time 
in the GIT 
Drugs that are absorbed poorly and at unpredictable rates 
are poor candidates because their release rate and 
absorption depend on drug positioning in the GIT.  
Highly potent (dose usually 2–3× 
that of immediate release system) 
High does reduce the polymer and co-excipient level to the 
extent that it would be difficult to attain a strong gel layer, 
whereas including a sufficiently high level of polymer 
would increase the unit dose to an extent where it becomes 
difficult to swallow by the patient. 
Good margin of safety The level of drugs having narrow therapeutic range may be 
out with the safe or effective plasma concentrations. If dose 
dumping occurred, then narrow therapeutic index drugs 
lead to overdose 
Intended to treat chronic rather 
than acute diseases 
SR systems are not suitable for acute conditions 
Absorbed uniformly from the GIT Drugs absorbed by active transport in selected regions of 
the GIT are not good candidates for SR dosage forms  
Intermediate water solubility  The dissolution of very poorly soluble drugs is inherently 
sustained. SR formulations of such drugs should aim at 
making their dissolution more uniform rather than reducing 
it. 
Extremely lipid soluble drugs might also demonstrate low 
flux into the tissues or rapid flux followed by accumulation 
in tissues 
Very highly soluble drugs are difficult to formulate 
Stable at biological pH range should not undergo degradation due to pH or enzymatic 
activity (at any given time point the concentration in the GI 
fluid is lower than that of an immediate release dosage 
form) 
MW below 500 D Drugs with MWs above 500 Da show very small diffusion 
coefficients 
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Table 1.4: Examples of some drugs unsuitable for oral SRMS dosage forms. 
Drug Characteristic(s) 
Diazepam and phenytoin Long biological half-lives (>12 h) 
Riboflavin and ferrous salts Poorly absorbed in the lower intestine at unpredictable rates 
Penicillin G and furosemide  Short biological half-lives (<1 h) 
Sulphonamides Large doses (>1 g) required for therapeutic activity  
Phenobarbital and digitoxin Low therapeutic indices 
Anticoagulants, cardiac glycosides Personalized dosage is required 
Griseofulvin Poorly soluble and thus inherently sustained 
 
1.6.1 Solubility 
Solubility is one of the most important physiochemical properties of a drug. This is 
because following oral administration, the bioavailability of a drug depends primarily on its 
solubility in the GIT and its permeability across the cell membranes. This is the basis on which 
the Biopharmaceutics Classification System (BCS) runs (Amidon et al., 1995) (Figure 1.4). 
Solubility according to the BCS framework is determined by obtaining the pH–solubility profile 
of the drug substance in question in an aqueous media of pH range 1 to 7.5 at an established 
temperature of 37 ºC ± 1 ºC. A drug substance is thus considered to be highly soluble when its 
highest dose strength proves to be soluble in 250 mL or less of an aqueous media over the pH 
range of 1.0 to 7.5 (Blume and Schug, 1999); FDA, 2017). BCS Class I compounds are thus 
those that have high solubility and high permeability. Class II compounds are those that exhibit 
high permeability but because of their low solubility they fail to meet the criterion for solubility 
across the physiological pH range 1 to 7.5. Most of the compounds or drug substances that fall in 
this category tend to have high solubilities in part of the pH ranges of 1 to 7.5 because they are 
either weak acids or weak bases. The Class III compounds are the compounds with high 
solubility but low permeability. In this case, the pH of the medium selected for the compound or 
product is not influenced by the compound’s solubility due to its high solubility (Grundy et al., 
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1997). Class IV drugs or compounds have low solubility and low permeability – the rate of in 
vivo absorption of those drugs therefore depends on the relative rate of the two plus whether the 
drug’s low permeability is a borderline or is because of metabolism (Amidon et al., 1995). 
Knowledge of the solubility of a drug is therefore important when direct administration into the 
bloodstream is desired because low aqueous solubility could either delay or limit drug absorption 
(Amidon et al., 1995). Drug solubility is thus one of the important parameters that should be 
taken into account in drug release studies on a case–bycase basis (Tahara et al., 1995). 
 
Figure 1.4: The Biopharmaceutics Classification System (BCS). 
 
Matrix technology allows successful formulation of insoluble and soluble drugs. In 
general, the more soluble a drug is the faster its release. For example, (Kim, 1998) (Figure 1.5) 
and (Li et al., 2008) showed the rate of various drugs from Polyox
TM
 matrix systems to reduce 
with the decrease in aqueous drug solubility.  
23 
 
 
  
Figure 1. 5: Effect of drug solubility on the release of drugs from PE04 tablets (39% loading): 
(○) diclofenac Na, (□, ∆) theophylline, (□, ■) salicylic acid, (●) sulfathiazole, and (▲) 
sulfapyridine. Reprinted with permission from (Kim 1998).  
For a soluble drug to be released from a matrix, the water (or biological fluids) should 
wet/infiltrate the matrix, after which the drug is dissolved and then diffused out of the matrix. 
Solubility often decides the mechanism of drug release because the drug usually occupies a 
substantial portion of the formulation. When matrix swelling and erosion reach equilibrium, the 
local volume fraction of a drug (γds, cm
3
drug/cm
3
gel) in the gel layer is a function of drug 
solubility and loading, as described by the following equation (Colombo et al., 1999a). 
𝜸𝒅𝒔 =  𝑪𝒔
𝜸𝒘
𝜺𝒅
 
        (1.2), 
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where Cs is the solubility of drug in water, γw is the volume fraction of water at that point, and εd 
is the density of drug.  
Drug solubility also affects the mechanism of drug release by affecting gel characteristics 
(Kim, 1999). In particular, drug solubility (and drug loading (Section 1.6.2) governs the place 
occupied by the diffusion front in the gel layer (Colombo et al., 1999b). This is because the 
amount of drug dissolved in the gel layer (along with polymer relaxation) affects the distance 
between the diffusion and erosion fronts, which is fundamental in the drug release mechanism 
(Colombo et al., 1999a; Colombo et al., 1999) (Figure 1.5). The polymer volume fraction will be 
high towards the swelling front whereas the volume fraction of water will be high towards the 
erosion front. 
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Figure 1.6: Physical situation and schematic illustration of different fronts position in a 
swellable-soluble matrix tablet during drug release. The three distinct moving fronts are 
indicated. At all times, the dissolved drug profile extends from the diffusion to the erosion front 
and the water profile from the swelling to the erosion front (i.e. the entire gel layer). Modified 
from (Kiil and Dam-Johansen, 2003). 
 
In theory, the effect of solubility on drug dissolution can be described using Fick’s first 
law (Martin et al., 1993). 
𝐉 =  −𝐃 
𝐝𝐂
𝐝𝐗
 
(1.3), 
where J is the mass flux (the amount of material flowing through a unit cross–section of a barrier 
in unit time), D is the diffusion coefficient (which is controlled by structural characteristics of the 
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drug), and dC/dx is the concentration gradient (which is dependent on water solubility). From 
Eq. 2, the diffusion coefficient (D) is controlled by structural characteristics of the drug. In the 
case of a poorly soluble drug, both dissolved and undissolved particles are present within the 
matrix, from which only the dissolved drug can diffuse into the dissolution media. 
In general, highly soluble drugs (e.g. Propranolol HCl and DTZ HCl) are primarily 
released from hydrophilic polymer matrices by diffusion of dissolved drug molecules through the 
gel layer, and to a lesser extent via erosion of the gel matrix. This is because highly soluble drugs 
promote swelling/hydration of the hydrophilic matrix (Zuleger and Lippold, 2001). In contrast to 
poorly soluble drugs, osmotic stress and acceleration of water permeation into the matrix occur 
with substances having high solubility. This causes a high degree of polymer swelling/hydration 
and the formation of more microcavities, and as such diffusion becomes the mechanism of drug 
release for highly soluble drugs (Caraballo, 2010). Additionally, the diffusivity of a solute 
depends on the chemical gradient across the dissolution medium, which is a function of solute 
solubility. Therefore, the mass transfer coefficient of various drugs (Cimetidine HCl, Diclofenac 
Na, and Diprophylline) has been shown to be a function of drug solubility (Harland et al., 1988), 
(Table 1.5). In some cases, highly soluble drugs could dissolve instantly after being exposed to a 
dissolution medium, causing a very rapid initial drug release even before the formation of a gel 
layer on the tablet surface, leading to the ‘burst effect’ Li et al., 2008; Huang and Brazel, 2001). 
This is because highly soluble drugs act as pore-formers, thus the gel structure becomes more 
porous resulting in faster drug release (Li et al., 2005). Such burst effect is not wanted in SR 
formulations because it may lead to producing concentrations of drug above the MTC (due to 
rapid absorption) or below the MEC (due to rapid metabolism) (Huang and Brazel, 2001). 
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Table1. 5:  Effect of drug solubility of the release mechanism (determined using the diffusion 
coefficient (Peppas, 1985) from Carbopol
®
 matrices. Solubility data were taken from 
(Yalkowsky and Dannenfelser, 1992) whereas diffusion coefficient data were taken from 
(Lubrizol, 2011). 
Drug BCS Solubility (mg/mL) Diffusion coefficient (n) Mechanism of drug release 
Theophylline Class IV 7.3 0.59 Anomalous diffusion 
Hydrochlorothiazide Class IV 0.722 1.11 Relaxation 
Ketoprofen Class II 0.051 1.48 Relaxation 
 
In contrast to highly soluble drugs, poorly soluble drugs have low dissolution rates 
because of their low diffusion rates and hence the drug release rate that tends to follow diffusion 
mechanism would be low. The release of poorly soluble drugs (e.g. indomethacin, diazepam and 
isosorbide dinitrate) from hydrophilic polymer matrices is dominantly by osmosis and polymer 
relaxation (Kim 1998; Bettini et al., 2001). For example, the in the case of Carbopol
®
 matrices, a 
highly soluble drug (THP, BCS Class IV) was released by diffusion, whereas poorly soluble 
drugs (e.g. carbamazepine, hydrochlorothiazide, and ketoprofen) tend to partition into the more 
hydrophobic domains of the system (such as the acrylic backbone of the Carbopol
®
 polymer), 
from where they showed an almost linear release profiles (Lubrizol, 2011) (Table 5). (Pérez-
Marcos et al., 1991), showed atenolol (a highly soluble drug, 26.5 mg/mL, BCS Class III) to be 
released from carbomer matrix systems via diffusion kinetics, whereas the release of furosemide 
(a poorly soluble drug, 0.073 mg/mL) followed zero–order profile. In another study, (Efentakis 
et al., 2000) showed the release of furosemide from Carbopol
®
 974P NF matrices to occur 
through polymer relaxation mechanism due to the hindered movement of drug molecules from 
the interior of the polymer mass towards the surface caused by strong entanglement of polymer 
molecules. Only after complete matrix hydration (i.e. complete matrix transformation into the 
rubbery state), the contribution of erosion to drug release increases as the solubility of the drug 
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decreases (Tahara et al., 1996; Ford et al., 1991). This explains the conflicting results obtained 
from few studies which showed faster drug release in the case of less soluble drugs due to the 
hindered gel formation (Mitchell et al., 1993a). This is because poorly soluble drugs are usually 
hydrophobic, thus a region of hydrophobicity is created upon their inclusion in a hydrophilic 
matrix. These hydrophobic substances also remain as solid particles for a longer period of time in 
the gel. The regions of hydrophobicity created to reduce the entanglement of the polymer chains 
and gel strength (i.e. hinders the expansion of the polymer), meaning that erosion becomes 
favourable as the mechanism by which drug release occurs after complete matrix hydration. 
Therefore, poorly soluble drugs tend to show a pulse release at the end of their release profile, 
attributable to the displacement of insoluble particles through the gel layer, pushing the particles 
through the gel layer and thereby increasing the exposure of the particles to water  (Bettini et al., 
2001) (Figure 1.7). Due to their poor solubility (<0.01 mg/mL) and dissolution rate, poorly 
soluble drugs could also show incomplete release. The solubility of such poorly soluble drugs in 
hydrophilic matrices has been improved using various strategies such as the use of hydrophilic 
carrier systems (Giunchedi et al., 1994), surfactants (Efentakis et al., 1991), drug-cyclodextrin 
inclusion complexes (Rao et al., 2011), and nanosized formulations (Kaialy and  Al Shafiee, 
2015). 
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Figure 1.7: Pictures of the base of HPMC matrices containing nitrofurantoin (BCS Class II) 
taken after 1 h (left) and 24 h (right). Reprinted with permission from (Bettini et al., 2001). 
 
Finally, it should be kept in mind that aqueous solubility of a drug depends on its 
chemical structure, stereochemical configuration, and polymorphic form, all of the latter 
properties could affect drug release properties by altering drug solubility. The pH of the 
dissolution medium and polymer–related variables (Section 1.7) could also interact with the 
effect of drug solubility on drug release from SRMS. Some examples are given below.  
1.6.2 Loading 
In general, providing that drug solubility is not high enough, drug release rate increases 
with increasing drug loading, attributable to higher chemical gradient at the diffusion front as 
well as greater channel formation in the swollen matrix. For example, (Lapidus and Lordi, 1966) 
showed the increase in chlorpheniramine maleate loading to cause an increase in drug release 
rate from methylcellulose matrix systems (Figure 1.8). In the same line, increasing the loading of 
U-78875 (Tahara et al., 1995) and prednisolone (Rao et al., 2011) have been reported to lead to 
an increase in the percentage of drug release from hypromellose matrix systems. 
A rationally SR profile is usually obtained if the gel structure is formed within the first 5 
minutes of contact of the matrix tablet with dissolution medium. If such formation of a gel 
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structure failed, a premature drug release could be observed due to quick matrix erosion (Velasco 
et al., 1999; Nellore, 1998). Some authors reported a burst effect in the case of SR formulations 
containing a high loading of highly soluble drugs (Velasco et al., 1999) because of the presence 
of few areas on the matrix surface not covered by polymer. Producing burst effect from SR 
formulations also depends on other variables such as polymer particle size (Section 1.7.6) as 
discussed later. 
The loading level of a drug is fundamental to explaining its drug release behaviour from 
inert matrices, drug loading showed relatively less influence on the drug release behaviour from 
hydrophilic matrices. This is because water enters the system through the hydrophilic polymer 
and through the pores that arise through the swelling process, thus the need of a cluster of soluble 
substances at the onset of the drug release process is not a necessity (Miranda et al., 2007; 
Fuertes et al., 2010). 
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Figure 1.8: Drug release profiles for tablets containing 150 mg (A), 100 mg (B), 75 mg (C), 50 
mg (D), and 25 mg (E) of chlorpheniramine maleate. Reprinted with permission from (Lapidus 
and Lordi, 1966). 
1.6.3 Molecular weight, size and shape 
According to Higuchi’s model (Higuchi,  1963), (Eq. 1), solute MW is one of the 
variables (along with the diameter of the solute molecule and the viscosity of the diffusion 
medium) that determines the diffusion coefficient, of which the release rate from matrix-based 
SR dosage form systems is proportional to the square root. The release of drugs having MWs 
above 500 Da is likely to be constrained by interaction with the aqueous gel network leading to 
poor diffusivity in hydrophilic matrices (Flynn et al., 1974). (Baveja et al., 1987) reported that 
molecular size and shape are important variables that affect the release rate of structurally related 
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water–soluble bronchodilators (namely ephedrine HCl, salbutamol sulphate, terbutaline sulphate, 
aminophylline, and reproterol HCl) from hypromellose matrix systems. This conclusion was 
supported by another research group, who showed the mean dissolution time of drugs having 
various MWs to decrease for drugs having lower MW (Talukdar et al., 1996). In another study, 
(Fyfe et al., 2000) showed that the release rate of triflupromazine HCl was slower than that of 5-
fluorouracil due to its smaller molecular size and higher MW. Such results can be explained as 
drug diffusion through the gel layer tends to be easier as the drug MW and size decrease (Figure 
1.9). 
 
 
                    
       Figure 1.9: Self-diffusion coefficients of water (open squares), triflupromazine–HCl (open 
triangles) and 5-fluorouracil (filled circles) in selected hypromellose mixtures. Reprinted with 
permission from (Fyfe et al., 2000). 
33 
 
1.6.4 Particle size and shape 
Particles having varied sizes and shapes usually show different intrinsic in vitro 
dissolution profiles, attributable to differences in particle surface area (Blagden et al., 2007), or 
increased abundance of polar groups (Kaialy et al., 2014), potentially leading to different release 
rates from SRMS. For example, rod-shaped dipyridamole particles demonstrated considerable 
enhanced in vitro dissolution rate with potential improved bioavailability in comparison to 
rectangular needle-shaped particles (Adhiyaman and Basu, 2006). 
In theory, drug particle size alters the tortuosity of the hydrated gel layer and thus can 
affect drug diffusion through the gel layer, leading to altered drug release rate, as described by 
Lapidus and Lordi equation (Lapidus and Lordi, 1966). 
𝑫∗ =  
𝑫
𝒕
 
(1.4), 
where D* is the apparent diffusion coefficient of the drug in the gel layer, D is the real diffusion 
coefficient of the drug in the dissolution medium, and τ represents the tortuosity of the gel. It is 
known that drug diffusion through the gel layer decreases with increasing tortuosity leading to a 
decrease in drug release rate. 
Apparently conflicting results were however reported on the effect of drug particle size 
on drug release rate from matrix systems. Some studies showed larger drug particle sizes to lead 
to faster drug release rates for both highly soluble (e.g. DTZ) (Li et al., 2008), and poorly soluble 
drugs (e.g. rifampicin) (Hiremath and Saha, 2008). In the case of highly soluble drugs, the larger 
the particle size of the drug the larger the size of the channels (pores) that cross the gel layer. 
Such increased porosity of the swollen matrix system leads to facilitated complete release (Kim 
1999). Additionally, the greater surface area of highly soluble drug particles present on the 
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surface of the matrix (in the case of drug particles having smaller size distributions) lead to a 
quicker formation of gel layer. In the case of poorly soluble drugs, the faster drug release from 
the matrix systems in the case of drug particles having larger particle size is due to a greater 
degree of erosion of the matrix (Ford et al., 1987). Such release behaviour could also provide a 
probable mechanism for dose dumping from this type of matrix tablets. In contrast, (Velasco et 
al., 1999), showed the decrease in particle size of diclofenac Na (a moderately soluble drug) to 
increase in the dissolution rate of that drug in the external media via a diffusion-controlled 
release mechanism. These findings were in accordance with other studies who showed the 
decrease in the particle size of oxazepam (de Llarduya et al., 1997), and propranolol HCl (Ford 
et al., 1985), to cause an increase in drug dissolution rate from hypromellose K100M (de 
Llarduya et al., 1997), and hypromellose K15M (Ford et al., 1985), matrices. In another study, 
(Salomon et al., 1979), reported the use of two particle sizes of potassium chloride particles (63 
µm to 100 µm and 315 µm to 400 µm) to lack significant effect on the release rate of potassium 
chloride from hypromellose matrices. Such seemingly conflicting results is because the effect of 
drug particle size on drug release rate from matrix systems depends on other variables such as 
drug solubility (Section 1.6.1), polymer level (Section 1.6.7), and pH of the dissolution medium, 
particularly in the case of moderately soluble drugs (Vazquez et al., 1992). 
 Drug solubility and polymer level 
Some studies showed the effect of drug particle size on drug release rate is only 
important (or more important) in the case of matrices containing low polymer level (since such 
matrices have inherently high porosity/low tortuosity characteristics (Velasco et al., 1999; 
Campos-Aldrete and Villafuerte-Robles, 1997; Ford et al., 1985; Mitchell et al., 1993b), and 
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poorly soluble drugs (since those drugs are predominantly released via an erosion mechanism) 
(Ford et al., 1985a; Ford et al., 1985c; Ford et al., 1985d). 
 Polymer-related variables 1.7
Polymers are high MW long chain molecules formed from smaller molecules called 
monomers with unique size and 3D arrangement bound covalently to one another. Polymeric 
materials are widely used for controlling drug release. Hydrophilic soluble polymers have been 
used in controlled release systems via the oral route, whereas biodegradable polymers based on 
polylactic acid or polyanhydrides have been used to control drug release from implants and other 
drug delivery systems. The release rate from matrix systems is governed by polymer internal 
structure, which depends on its chemical structure, solubility/hydrophilicity, MW, substitution 
degree and cross-linking. The effect of some polymer-related variables on drug release from 
SRMS is discussed below. 
1.7.1 Type 
Since polymers have different structural, physicochemical and mechanical characteristics, 
the type of polymer is a key factor that can affect the mechanism of drug release from matrix 
systems (Alderman, 1984; Mitchell et al., 1993c). A range of natural hydrophilic polymers, 
cellulosic or non-cellulosic, hydrophilic (soluble and swell in water) or hydrogels (insoluble but 
swell in water), alone or in mixtures have been used to modulate drug release from SRMS, 
including starch derivatives, alginates, xanthan gum, polyethylene oxides, carrageenan, and 
remarkably derivatives of cellulose, which are the most commonly used groups of polymers in 
SRMS (Ravi et al., 2008), (Table 1.6).  
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Table1.6: Some polymers commonly used in SRMS. 
Cellulosic 
Hydrophilic 
Methylcellulose 
Hydroxypropylmethylcellulose (hypromellose) 
Hydroxyethylcellulose 
Ethylhydroxyethylcellulose (E-HEC) 
Sodium carboxymethyl cellulose 
Hydroxypropylcellulose 
Hydrogel 
Ethylcellulose 
Hypromellose acetate succinate  
Cellulose acetate  
Cellulose acetate propionate  
Non-Cellulosic 
Hydrophilic 
Carrageenan 
Carbomer 
Xanthan gum 
Sodium alginate  
Chitosan 
Guar gum  
Pectin 
Crosslinked high amylose starch 
Poly-(ethyleneoxides) 
Hydrogels 
Polymethacrylates 
Polyvinyl acetate 
 
Except for cellulose esters and ethylcellulose (EC), cellulose have a derivatives of certain 
degree of hydrophilia of all the hydrophilic polysaccharides, hypromellose is the most commonly 
used polymer used to retard drug release from hydrophilic matrix systems, due to its water 
solubility, non-ionic nature, and stability at biological pH range from 3.0 to 11.0 (Kaialy et al., 
2014; Asare-Addo et al., 2013a; Asare-Addo et al., 2013b). In contrast to hypromellose which 
usually lead to type–I or diffusion drug release kinetics, xanthan gum has been shown to elicit 
zero-order (or at least time-independent) kinetics from matrix systems (Talukdar and Kinget, 
1995), attributable to its faster hydration rate compared to hypromellose (Talukdar et al., 1996). 
Sucrose esters (SE) have been shown to sustain the release of highly soluble drugs via gelation as 
well as enhancing the mechanical properties of matrix systems, making them promising 
excipients for the preparation of directly compressed tablets (Chansanroj and Betz, 2010). (Sinha 
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Roy and Rohera, 2002), showed hydroxyethylcellulose (HEC) and hydroxypropylcellulose 
(HPC) matrices to elicit different release mechanisms. The release of chlorpheniramine maleate 
from HEC matrices followed non-Fickian mechanism (in which drug diffusion as well as 
polymer swelling and erosion is involved), whereas the release of drug from HPC matrices 
followed Fickian mechanism (in which only drug diffusion as is involved). Polymer crosslinker 
levels also affect the rate of hydration/swelling of the polymer hydrogel and thereby affect drug 
release from matrix systems. In general, highly crosslinked polymers tend to be less efficient in 
controlling drug release than lightly crosslinked polymers. For example, at 10% polymer level, 
Carbopol
®
 971P NF polymer (lightly crosslinked) produced slower release rates of THP than 
Carbopol
®
 974P NF polymer (highly crosslinked) (Lubrizol, 2011) (Figure 1.10). 
         
Figure 1.10: Effect of Carbopol
®
 polymer type on the release rate of theophylline release (USP 
apparatus 2, pH 6.8 buffer) from wet granulated tablets (Lubrizol, 2011). 
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1.7.2 Solubility  
Swellable polymers can be broadly classified into hydrophilic polymers and hydrogels 
(Ebube et al., 1997), (Table 1.6).  
In general, hydrophilic polymers elicit faster drug release rates than hydrogels (Reza et al., 
2003). Dissolution of a polymer includes absorption/adsorption of water in more accessible 
place, rupture of polymer-polymer linking with the simultaneous forming of water-polymer 
linkage, separation of polymeric chain, swelling, and finally dispersion of polymeric chain in the 
dissolution medium (Figure 1.6). Polymer hydrophilicity is known to influence the kinetics of 
drug release from matrix systems. Hydrophilic matrix systems typically release drug through 
diffusion across the hydrated gel layer, whereas hydrophobic matrix systems release drug 
through aqueous pores formed in the drug depletion zone. This is because polar polymers can 
produce adequate energy to disperse polymer chains from the glassy state via interaction with an 
aqueous dissolution medium. Hydrophilic polymers, particularly cellulose ethers (Salsa et al., 
1997), are therefore usually preferred in the formulation of SRMS because they have good 
swelling properties that lead to a rapid formation of the external gel layer through which the drug 
is released via diffusion, and additionally they often give good compression characteristics even 
when compressed directly.  
Freely soluble drugs (e.g. metoprolol succinate) may require a large quantity of polymer 
to attain a desirable retarded release of drug, which ultimately results in large tablets that are 
difficult to swallow. The use of water–insoluble polymers can often resolve this problem. 
Therefore, water–insoluble (e.g. EC and acrylic resins) and pH–dependent soluble polymers (e.g. 
hypromellose acetate succinate) have also been used to sustain drug release from matrix systems. 
For example, Eudragit
®
 RS and RL have been used in LS formulations to allow for better 
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prolongation of the release of a highly soluble drug (propranolol HCl) compared to conventional 
formulations due to better encapsulation of drug particles within the hydrophobic polymers 
(Javadzadeh et al., 2008). The combination of hydrophilic and hydrophobic polymers has also 
been shown to effectively control the release of freely water–soluble drugs from SR formulations 
(Gade and Murthy, 2014). 
1.7.3 Molecular weight and radius of gyration 
Polymer MW determines gel strength and thus water penetration through the gel layer 
during swelling (Brady et al., 2009). Radius of gyration (Rg) is a parameter directly related to 
polymer MW. It refers to the statistical average of the molecular length and is used to describe 
the dimensions of the polymer side-chain (Beignon et al., 1998). With increasing polymer MW, 
the degree of polymer swelling increases whereas the polymer’s ability to erode decreases. Some 
studies showed that at low Polyox
TM
 MW (WSRN 1105 and WSR 303), DTZ (Maggi et al., 
2002) and metronidazole (Kiss et al., 2008), were released primarily by erosion and diffusion of 
the Polyox
TM
, whereas at high MW of Polyox
TM
 the drugs were released through the swelling of 
the polymer and the diffusion of the drug across the hydrogel layer. In an attempt to provide 
better understanding of the effect of polymer MW and Rg on the mechanism of drug release 
from SRMS, (Viridén et al., 2009), evaluated the drug release rates from matrices containing 
polymers having similar MWs. Different drug release rates were obtained from polymers having 
similar MW and Rg, namely hypromellose 60SH50, 65SH50, 90SH100 and 90SH100SR, 
indicating that predicting drug release rates from polymer MW or Rg alone is not possible. 
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1.7.4 Particle size and shape 
Numerous studies showed polymer particle size to play an important role in moderating 
drug release from SRMS due to its effect on polymer disintegration/hydration/erosion rate (Heng 
et al., 2001; Miranda et al., 2007; Caraballo, 2010; Velasco et al., 1999; Mitchell et al., 1993d). 
Different commercial grades of a polymer may also have different particle shape distributions. 
For example, in one study, fibrous-shaped interlocking particles have been shown to produce 
stronger matrices that could potentially modify the swelling characteristics of the matrix, leading 
to reduced burst effect along with decreased drug release rates (Bonferoni et al., 1996). 
In general, polymer particle size affects the availability of contact points as well as the 
porosity/tortuosity of the matrix. The change in matrix porosity in turn changes the resistance for 
water penetration and the diffusibility of the drug through the hydrated gel layer of the polymer, 
potentially leading to a meaningful change in the drug release rate (Mulye and Turco, 1996). The 
decrease in particle size of both water-soluble (e.g. hypromellose (Heng et al., 2001) and 
Polyox
TM
 (Shojaee et al., 2015) and water–insoluble (e.g. Eudragit® RS–PM and Ethocel® 100) 
(Sánchez-Lafuente et al., 2002) polymers have been shown to elicit slower drug release rates 
from matrix systems. For example, (Alderman, 1984) showed a premature drug release from 
matrices containing coarse particles of K chemistry–hypromellose. Other studies showed that the 
release rate of propranolol HCl (Mitchell et al., 1993b) and metronidazole (Campos-Aldrete and 
Villafuerte-Robles, 1997) from hypromellose matrices to decrease as the particle size of 
hypromellose decreased. In another study, (Parojĉić et al., 2004) attributed the differences in the 
release rates of paracetamol (BCS Class IV) between matrices containing Carbopol
®
 71G NF 
polymer (granular polymer) and Carbopol
®
 971P NF polymer to their varied sizes. The 
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Carbopol
®
 71G NF polymer allowed a quicker penetration of the dissolution medium into the 
matrix, leading to faster drug release compared to Carbopol
®
 971P NF. 
Polymer particle size can affect drug release rate because coarse polymer particles 
(typically > 200 µm) need more time to capture water and to swell to form a stable gel barrier 
(i.e. hydrate too slowly), resulting in a faster drug release by disintegration rather than by 
diffusion (Colombo et al., 2000; Mitchell et al., 1993a; Campos-Aldrete and Villafuerte-Robles, 
1997; Alderman, 1984). For example, coarse (> 355 μm) hypromellose K15M particles produced 
larger pore sizes when a gel layer is obtained, resulting in a decrease in the stability of the gel 
structure and thus rapid drug release. In contrast, the polymer grade having smaller particle size 
(< 150 µm) prompted the development of gel layer, sealed the pores on the surface of matrix 
systems, and thereby prevented disintegration of the system (Dow, 2006). (Velasco et al., 1999), 
showed the particle size of hypromellose to affect lag time and release mechanism. Larger 
particle size fractions of hypromellose showed less lag period, indicating a degree of burst effect 
occurred during the initial stages before the formation of the gel layer. In another study, (Heng et 
al., 2001) showed large (> 180 µm), medium (113 µm to 180 µm) and fine (<113 µm) size 
fractions of hypromellose to release aspirin (BCS Class IV) from matrix systems via 
disintegration, diffusion, and a combination of diffusion and erosion respectively. Similar 
observations were obtained in the case of hydrogels. For example, small-size fractions (< 125 
µm) of EC produced a slower release rate of propranolol HCl compared to larger size fractions 
(385 µm to 420 µm), which facilitated water penetration into matrices (Dabbagh et al., 1996). 
Additionally, from a physical viewpoint, polymers having small particle sizes can produce 
stronger tablets compared to those having larger particle sizes, attributable to their higher bulk 
(packing) density and thereby increased interparticle average contact points leading to better 
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interparticle bonding (Velasco et al., 1999). Therefore, micronized hydrophilic polymers are 
today available in small particle sizes to ensure quick and consistent polymer hydration and 
thereby prevent prompt tablet disintegration, and to allow for the preparation of controlled 
release tablets via direct compression (Colombo et al., 2000). 
Finally, it should be kept in mind that the effect of polymer particle size on drug release 
from matrix systems depends on other variables such as drug solubility (Section 1.6.1) and 
polymer level (Section 1.7.7). 
 polymer level 
Several authors reported that polymer particle size is only important in the case of 
formulation matrices containing relatively low levels of polymer (Zuleger and Lippold, 2001; 
Campos-Aldrete and Villafuerte-Robles, 1997; Heng et al., 2001; Velasco et al., 1999). For 
example, (Mitchell et al., 1993d) showed that the effect of hypromellose particle size on the 
release rate of propranolol HCl decreased with decreasing polymer level. This was because at 
low polymer levels, there will be a lack of polymer particles in particular areas of matrices 
leading to a burst effect. (Campos-Aldrete and Villafuerte-Robles, 1997) showed that the effect 
of reducing hypromellose particle size on retarding metronidazole release from a matrix system 
could only be observed when hypromellose (Demacol
®
) levels were below 20% (w/w). Likewise, 
(Heng et al., 2001) showed that changes in particle size of hypromellose K15M did not affect the 
mechanism of aspirin release when the hypromellose levels were higher than 20% (w/w). The 
behaviours reported by the latter studies (Campos-Aldrete and Villafuerte-Robles, 1997; Heng et 
al., 2001; Mitchell et al., 1993d) could be explained by the so-called percolation threshold of 
polymer. Historically, percolation theory was first introduced into the pharmaceutical field by 
(Leuenberger et al., 1987). According to this theory, a cluster is defined as a group of 
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neighbouring particles of the same component. A cluster could be considered finite or infinite. In 
general, the percolation threshold corresponds to the concentration of one component for which 
there is a maximum probability of appearance of an infinite or percolating cluster of this 
component (Caraballo, 2010). The percolation threshold of a polymer corresponds to the volume 
fractions of the polymer that is needed to produce a robust matrix system (Miranda et al., 2006). 
In general, polymer particle size does not affect drug release when polymer level is above the 
threshold due to a consistent formation of gel layer, whereas polymer particle size does affect 
drug release when polymer level is below the threshold due to a heterogeneous formation of gel 
layer (Miranda et al., 2007). 
1.7.5 Level 
Since hydration plays a key role in the choice of polymer selected for SR systems, the 
presence of a sufficient amount of polymer is important to form a uniform barrier that protects 
the incorporated drug from inconstant release and initial burst effect upon contact with water 
(Mandal et al., 2007). Polymer level is therefore one of the most important drug release 
controlling factors in hydrophilic matrices (Velasco et al., 1999; Nellore, 1998; Ford et al., 1985; 
Ford et al., 1985b; Mitchell et al., 1993e). 
In theory, a linear relationship can be obtained when plotting the release rates (RH, log % 
min
1/2
) against the reciprocal of the mucilage concentration at which they were obtained, as 
described by equation 1.7 (Ford et al., 1985a). 
logRH = M (1/W) + C (1.5), 
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where M (% min
−1/2
 mg
−1
) is the slope of derived straight line, W (mg) is polymer weight, and C 
(% min
−1/2
) is a constant. This confirms that formulators could obtain desirable release profiles 
by changing polymer level in the matrix formulation. Although the above relationship (Eq. 1.6) 
could be used to estimate the release rate at a range of polymer content, it cannot be used in the 
case of very low polymer content (particularity low-viscosity grades of polymers such as 
hypromellose K100LV) which could promote burst release of drug and thereby deviation from 
Higuchi’s equation. 
In general, the level of polymer in SR matrix formulations typically ranges between 20% 
and 50% (w/w), depending on drug–related variables (Section 1.6), co–excipients (Section 1.8), 
processing parameters, and the anticipated release pattern. In the case of matrix systems 
containing highly soluble drugs, polymer levels ≥30% (w/w) in the matrix system are 
recommended to obtain a robust formulation that eliminates the effect of minor variations in 
manufacturing method or raw materials (Tiwari et al., 2003; Ford et al., 1985). 
Previous studies showed drug release rate from hydrophilic matrix systems to decrease 
with increasing polymer level regardless of polymer physicochemical characteristics (Reza et al., 
2003). For example, (Ebube et al., 1997) showed increasing the levels of cellulose ether 
polymers (from 3.5% to 19.2%) to decrease the release rates of paracetamol from 
hypromellose/polyvinylpyrrolidone mixture matrices. Other studies showed the increase in 
hypromellose level to result in slower release rate of THP (Figure 1.11), tetracycline HCl (Ford 
et al., 1987b), Metoprolol tartrate (Nellore, 1998) and Atenolol (Vázquez et al., 1996) from 
matrix tablets. Similar conclusions were attained in the case of insoluble polymers. For example, 
increasing the level of carbomer 934 has been shown to lead to a decrease in the release rate of 
atenolol (Perez-Marcos et al., 1996). In another study, increasing the level of Carbopol
®
 974P 
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NF has been shown to decrease and linearize the release rate of ibuprofen (BCS Class II) along 
with shifting the release mechanism from anomalous type towards a swelling-controlled, a 
phenomenon caused by the closing of micropores and a reduction in regions of low 
microviscosity in the swollen tablets (Khan and Jiabi, 1998). Increasing the level of both 
Carbopol
®
 71G NF (from 15% to 30%) and Carbopol
®
 971P (from 2.5% to 20%) polymers led 
to a slower and more linear release profiles for a soluble (THP) and a poorly soluble (ketoprofen) 
drug respectively (Lubrizol, 2011) (Figure 1.12). 
In general, increasing the content of hydrophilic polymers (e.g. hypromellose) in a matrix 
formulation increases the strength/viscosity of the gelatinous diffusion gel layer around the 
tablets, thus retarding the penetration of water into the dry glassy core and increasing the 
length/tortuosity of the diffusional path (due to fewer interstitial spaces between the microgels) 
(Mitchell et al., 1993a; Alderman, 1984; Dabbagh et al., 1996; Klančar et al., 2015). This results 
in a decrease in the effective diffusional coefficient of both soluble and insoluble solutes, leading 
to a reduction in drug release rate (Campos-Aldrete and Villafuerte-Robles, 1997; Ford et al., 
1985a; Ford et al., 1985d; Alderman, 1984; Dabbagh et al., 1996; Mitchell et al., 1993d; 
Lotfipour et al., 2004), although the slow hydration of the polymer is preferred for insoluble or 
poorly soluble drugs to minimise or limit the thickness of the gel layer.  
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Figure 1.11: The effect of hypromellose K15M content (■ 45 mg, ○ 60 mg, ▼ 90 mg,  180 
mg, and □ 270 mg) on the release profiles of theophylline from matrix tablets. Reprinted with 
permission from (Ford et al., 1987b). 
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Figure 1.12: Effect of Carbopol
®
 71G NF polymer level on theophylline release (a) and effect of 
Carbopol
®
 971P NF polymer level on ketoprofen release (b) from roller compacted tablets 
(Lubrizol, 2011). 
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In contrast to the foregoing studies, few authors reported that the increased levels of 
polymer did not significantly affect (Tiwari et al., 2003) or promoted (Gade and Murthy, 2014) 
drug release from matrix systems. (Tiwari et al., 2003), reported that changes in the 
hypromellose level failed to significantly affect the release rate of a highly soluble drug 
(tramadol). (Gade and Murthy, 2014), showed the increased concentrations of an insoluble 
polymer (ethyl cellulose) in matrix formulation to lead to faster release rate of metoprolol 
succinate the drug due to erosion of the matrix. This could be because there is an optimum 
concentration (i.e. a threshold level, e.g. 20% for Demacol
®
 (Campos-Aldrete and Villafuerte-
Robles, 1997) and between 20.76% and 26.41% for hypromellose K4M (Fuertes et al., 2006), of 
hydrophilic polymer that is needed to be incorporated into matrix formulation to make a gel 
structure around the matrix to control the release of highly soluble drugs, after which further 
increase in polymer level might not lead to slower drug release rate. Additionally, above a 
particular polymer level, the effect of polymer content dominates over the effect of polymer 
viscosity and particle size on the effect on drug release from matrix systems. Therefore, at 
hypromellose level of 30% to 40%, different grades of hypromellose (hypromellose 2208, 2906, 
and 2910) showed similar drug release profiles (Nellore, 1998; Ford et al., 1985b). In another 
study, formulations containing hypromellose level of 30% to 40% showed similar release 
profiles of THP regardless of the diluent used (Vargas et al., 1999).  
Finally, it should be kept in mind that polymer level in a formulation may not always 
affect drug release in the same way as expected due to possible interactions between 
drug/polymer/co–excipient (Sections 1.8.4 and 1.8.5). For example, ionic polymers such as 
sodium carboxymethylcellulose (NaCMC) and chitosan have been reported to show pH-
dependent drug release. The release rate from chitosan matrix systems has also been shown to be 
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influenced by the interaction between chitosan and anionic drugs (Kristmundsdottir et al., 1995). 
Such chemical interactions of some polymers with different classes of drugs complicate the 
mechanism and kinetics of drug release from matrix tablets. 
1.7.6 Mixture of polymer 
    For decades polymers have been one of the most broadly applied alternatives for the 
formulation of sustained release mixtures to modulating the release profiles of drugs 
competently, and in this situation, it is obvious to find mixtures of various kinds of polymer 
(Tiwari et al., 2003). One combination that has been broadly examined is that of ethylcellulose (a 
cellulose derivative related Hypromellose but water insoluble) and Hypromellose (Sankalia et 
al., 2008). In investigations made with Tramadol in Hypromellose matrices, without and with 
ethylcellulose, it was noted that this latter acted as a retardant of Tramadol release; this was 
attached to the decreased approach of solvent into the matrix due to the appearance of the 
hydrophobic matrix (Quinten et al., 2009). Traconis et al., 1997 noted that the addition of 
ethylcellulose (EC) to Hypromellose matrices of Metronidazole decreased the dissolution rate of 
the drug although did not alter its release pattern. Release rate of the drug reduced linearly by the 
percentage increase of ethylcellulose when EC rate was below a threshold. Over this threshold, 
the dissolution rate improved with increasing concentration of EC. Other writers have studied the 
chance of formulating with mixtures of Carbopol and Hypromellose both polymers being 
generally employed in the field of modified release (Samani et al., 2003). In this case, the 
synergies established among the two polymers afford excellent results as regards to the release 
properties of drug because the enable the fluctuations characteristic of Carbopol to be reduced, 
this compound first gives slow release rates in the initial phases, after which they improve to a 
large extent (Perez-Marcos et al., 1996). Perez-Marcos et al., 1996), examined the same mixture 
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of polymers, but in this situation with Propranolol HCl, to investigate the impact of pH on drug 
release. While the pH enhanced, Carbopol was more ionized leading to the formation of an 
insoluble drug–polymer complex holding its release to the dissolution. Likewise, the authors 
concluded that the influence of the Hypromellose /Carbopol ratio in the drug release rate 
improved with pH. 
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Table 1.7: Polymers mixture investigated to retard the dissolution profiles of drugs. 
Mixture of polymers Drug used Results Reference  
Ethylcellulose (EC) + Hypromellose Tramadol 
 
A retardant of Tramadol release was observed 
 
Sankalia et al., 2008 
 
Carbopol+ Hypromellose Propranolol Hcl The influence of the Hypromellose /Carbopol ratio in the drug 
release rate improved with Ph. 
Perez-Marcos et al., 
1996 
Hypromellose +Na–CMC 
  
Metronidazole The dissolution rate decreased when  Na CMC increased 
in the polymer blend and resulting in zero-order kinetics 
Traconis et al.,1997 
Atenolol The results showed that both diffusion and erosion controlled 
drug release, 
Lotfipour et al., 2004 
Captopril The dissolution retard drug release from tablet matrices Nokhodchi et al., 2008 
Ketoprofen Sustained release was achieved Chopra et al., 2007 
Naproxen Na The dissolution retard drug release from tablet matrices Rao et al., 1990 
Zidovudine It shows slower drug release  
Hypromellose C+HPC Acetaminophen Sustained release was achieved Ebube and jones, 2004 
Hypromellose +Polyethyloxazoline 
(PEOX) 
Dyphylline Controlled release was observed in the combination of the 
mixed polymer 
Shenouda et al., 1990 
EC+Xanthan gum Ibuprofen The results showed that drug release was controlled by both 
diffusion and erosion, 
Verhoeven et al., 2006 
Metoprolol 
tartrate 
Sustained release was seen in Metoprolol tartrate with two 
polymer mixture 
Verhoeven et al., 2008 
Hypromellose /hydroxypropyl cellulose Caffeine Drug release rate with higher polymer levels leading to slower 
drug release 
Hardy et al., 2007 
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 Co-excipients 1.8
It is necessary to add co-excipients to drug-polymer SR powder formulations to improve 
their mechanical properties (i.e. flowability and compressibility). Similar to drug (Section 1.6) 
and polymer (Section 1.7), the physicochemical properties of the co–excipient(s) present can 
affect the rate and mechanism of drug release from SRMS (Williams et al., 2002).  
1.8.1 Diluents 
Diluents are fillers that can be used to make up the required bulk of a tablet formulation. 
They can also be used to improve the mechanical (i.e. flow and tableting) and/or modify the rate 
of drug release. Diluents added to matrix formulations can be soluble (e.g. lactose), insoluble 
(e.g. DCP), or partially soluble (e.g. partially pregelatinized starch). In general, the incorporation 
of fillers in matrix formulations usually increases drug release rate regardless of diluent and/or 
drug solubility (Ford et al., 1987a; Khan and Jiabi, 1998; Lotfipour et al., 2004).  
Increasing the amount of diluent agents has also been shown to increase drug release rate 
(Lotfipour et al., 2004). In general, more soluble excipients (e.g. lactose) cause the drug to be 
released at a relatively faster rate and to a greater extent than insoluble (e.g. dibasic calcium 
phosphate (DCP) and microcrystalline cellulose), or less soluble, excipients (Williams et al., 
2002). For example, (Rekhi et al., 1999) showed lactose to afford faster release rates of 
metoprolol tartrate than that of dicalcium phosphate from hypromellose matrices. Soluble fillers 
increase drug dissolution rate by enhancing the wettability, and increasing the porosity of the 
path of the drug by encouraging water penetration and thereby the formation of channels within 
the matrix (Levina and Rajabi-Siahboomi, 2004). This leads to the creation of more permeable 
(i.e. weaker) hydrated gel layer than that for insoluble excipients, leading to faster drug diffusion 
and increased erosion rate (Ford et al., 1987b).  
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Finally, it should be acknowledged that the magnitude at which diluents manipulate the 
drug release from matrix formulations depends on the concentration at which they were 
incorporated as well as drug solubility 
 Diluent concentration 
Insoluble (but weakly swellable) diluents at a high level (above 20%, w/w) can remain 
within the gel structure, thus decreasing matrix wettability and retard the penetration of 
dissolution medium leading to reduced drug release via diffusion (Vidyadhara et al., 2013). 
However, some studies found evidence that the incorporation of a small amount of insoluble 
filler may increase drug release rate by preventing the quick formation of a homogeneous gel 
layer and disturbing uniform swelling due to erosion of its particles (Zuleger and Lippold, 2001; 
Ford et al., 1987a; Williams et al., 2002; Rekhi et al., 1999). For example, in one study, 
(Alderman, 1984), showed that only 10% of Methocel
TM
 K4M (a non-swelling insoluble filler) 
may disturb the integrity of the gel layer leading to premature disintegration of a matrix tablet. In 
another study (Levina and Rajabi-Siahboomi, 2004), lactose has been shown to afford slower 
release rates of two drugs having different solubilities (chlorpheniramine maleate and THP, at 
30% loading) compared to pre-gelatinized maize starch (Starch 1500™) from hypromellose 
matrices. This is because starch has a swelling nature when it is exposed to the dissolution 
medium, thus it can become integrated into the structure of the gel layer, making it denser. 
1.8.2 Surfactants 
Surfactants are usually classified based on the nature of hydrophilic groups as follows: 
anionic surfactants (e.g. carboxylates, sulphates and phosphates), cationic surfactants (e.g. 
quaternary ammonium compounds), amphoteric surfactants (e.g. lecithin and betains) and non-
ionic surfactants (e.g. spans and tweens).  
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Numerous studies showed the incorporation of surfactants, particularly those of high 
hydrophilic-lipophilic balance (HLB), in controlled release dosage forms to promote faster drug 
release by acting as wetting agents (leading to facilitated fluid entrance into the dosage form), 
reducing interparticle adhesion in the wetted tablet, and reducing the interracial tension between 
the gel layer and the dissolution fluid leading to enhanced drug diffusion rate (Efentakis et al., 
1991; Baveja et al., 1987). 
In contrast, other studies showed the incorporation of some surfactants to result in slow 
drug release from matrix formulations via forming insoluble drug-surfactant complexes with 
subsequent precipitation, providing less porous matrix through which the dissolved drug could 
diffuse (Wells and Parrott, 1992). For example, the release rate of propranolol HCl (cationic 
drug) was shown to reduce with increasing the concentration of sodium lauryl sulphate (SLS, 
anionic surfactant) due to the formation of propranolol–SLS complex which is less soluble in 
water than propranolol HCl (Nokhodchi et al., 2002). A slower release pattern of quinine 
sulphate was also observed from the matrix containing SLS compared to that containing 
polyoxyl 40 stearate (Choulis and Papadopoulos, 1975). Surfactants have also been shown to 
modify drug release rate from matrix systems by forming interactions with polymeric materials 
and thereby altering their swelling properties (Vlachou et al., 2000). For example, anionic 
surfactants can bind to non-ionic polymers and thereby increase their viscosity, leading to slower 
drug release rates. Therefore, the incorporation of sodium dodecyl sulphate (an anionic 
surfactant) in hypromellose matrices has been shown to decrease the release rate of propranolol 
HCl, whereas the incorporation of cetrimide (quaternary ammonium) has been shown to afford 
an opposite effect (Ford et al., 1991). Likewise, the incorporation of SLS (an anionic surfactant) 
has been shown to reduce the release rate of chlorpheniramine maleate from hypromellose 
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matrices (Feely and Davis, 1988). In another study, the incorporation of diocetyl sodium 
sulphosuccinate (an anionic surfactant) has been shown to retard the release of ascorbic acid 
from cellulose-based controlled system during the first hour (Gaylord and Schor, 1989).  
In conclusion, depending on their structure, the incorporation of surfactants could lead to 
either faster or slower release from matrix formulations (Baveja et al., 1987; Wells and Parrott, 
1992; Vlachou et al., 2000; Feely and Davis, 1988; Gaylord and Schor, 1989). For example, in 
contrast to anionic surfactants which could bind to the non-ionic cellulose ethers to form a strong 
gel network leading to slow drug release, cetyl trimethylammonium bromide (CTAB, cationic 
surfactant) could hardly bind to cellulose ethers leading to scarcely modified drug release 
process (Walderhaug et al., 1995). Finally, it has to be kept in mind that although the 
incorporation of anionic surfactants with cationic drug form insoluble drug-surfactant 
complexes, the dissolution rate of such drug-surfactant complexes could increase significantly by 
the formation of micelles if the surfactant was present at concentrations above its critical micelle 
concentration (Wells and Parrott, 1992). 
1.8.3 Binding agents  
Binding agents can coat drug particles, thus change the rheology of the gel layer resulting 
in slow drug release rates. For example, when incorporated in hypromellose matrices, 
polyvinylpyrrolidone has been shown to afford zero–order release profiles of anhydrous caffeine 
instead of bimodal profiles (Hardy et al., 2007).  
More investigations are needed in the future to deliver better understanding of the 
mechanism of drug release from sustained release matrix systems in vivo. To this end, more 
techniques are required in the future to characterise drugs and polymers used in matrix systems 
in a non-invasive manner. More systematic studies based on Design of Experiment approach are 
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also needed in the future to evaluate the influence of drug-, polymer-, and co-excipient related 
variables on drug release and thus evolve predictive approach(es) to develop such systems. This 
will allow the creation of desired sustained release formulations based on a robust Quality by 
design approach. 
1.8.4 Co-solvents in liquisolid systems 
             The liquisolid (LS) technique refer to the conversion liquid medications prepared using 
non–volatile organic solvents into powder mixtures by mixing a liquid medication with a solid 
phase containing carriers and coating materials (Spireas, 1998). Although LS systems were 
initially designed to improve the solubility and dissolution rate of poorly soluble drugs, they 
have recently been employed to sustain the release of highly soluble drugs using polymeric 
carriers such as hypromellose, Eudragit
® 
(Spireas and Bolton, 1998) and Polyox
TM
 (Kaialy et al., 
2016).  
The type of LS vehicle (i.e. non-volatile solvent) incorporated in LS formulations has 
recently been shown to have a major influence on the drug release from LS tablets. In a recent 
study, (Kaialy et al., 2016), showed polysorbate 80 to cause greater retardation of the release of a 
highly soluble drug (DTZ) as compared to Propylene glycol (PG) and polyethylene glycol 
(Figure 1.13). The retardation effect was shown to increase with increasing polysorbate content 
within LS formulations. It was suggested that the solvent capability for retaining the release of 
drug molecules from LS matrix increases with increasing the solubility of the drug in the solvent 
used. 
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Figure 1.13: Release profiles (mean ± SD, n = 4) of diltiazem HCl from physical mixture (PM) 
and liquisolid (LS) formulations prepared using polysorbate 80 (PS 80), propylene glycol (PG) 
and polyethylene glycol (PEG–200 and PEG–600). Reprinted with permission from (Kaialy et 
al., 2016). 
 Preparation and optimization of LS systems 1.9
The LS technique can be employed to form liquid medications (i.e., liquid drugs and drug 
solutions, drug suspensions or emulsions of poorly soluble solid drugs provided in non-volatile 
liquid vehicles) into powders proper for tableting or encapsulation. A simple blending of such 
liquid medications with calculated amounts of a powder substrate consisting of specific 
excipients such as the carrier and coating powder materials can produce dry looking, non-
adherent, free-flowing and easily compressible powders (Spireas and Bolton 1999). The liquid 
part, which can be a liquid drug, a drug suspension or a drug solution in proper non-volatile 
liquid vehicles, is dispersed into the acceptable carrier material. Once the carrier is soaked with 
liquid, a liquid layer is developed on the particle surface which is immediately absorbed by the 
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fine coating material particles. The coating material renders the conversion from a wet to a dry 
surface and provides the LS system with excellent flow properties (Figure 1.14).                                    
 
 
 
 
 
 
 
 
 
Figure 1.14: Schematic representations of the LS systems 
 Spireas et al., (1998) were pioneers in formulating LS tablets, where the dissolutions of 
pridinsolone and hydrocortisone were improved by using the LS technique. Since then, many 
research articles were performed using the same approach to improve dissolution of many drugs 
(Hentzschel et al., 2012). The improved drug dissolution by LS method could be attributed to 
increased surface area, increased aqueous solubility, and improved wettability of drug particles 
(Javadzadeh et al., 2007). By the proper design of the LS formulation, a powder mixture of good 
flow and compaction properties could be obtained. Therefore, this technique is industrially 
applicable due to simplicity and comparatively low cost (Hentzschel et al., 2012). Moreover, 
stability issues are of no major concern as it was reported that these compacts are not greatly 
affected by different storage conditions (Sheth and Jarowski, 1990). Several excipients such as 
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drug solution or  
drug suspension 
Carrier saturated 
with liquid (wet 
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Coating particles 
   (dry surface) 
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disintegrants, (immediate release) and lubricants or matrix forming materials (sustained release) 
may be added to the LS system to produce LS compacts. 
 
 
 
  Blending  
 
 
 Addition excipients  
  
                                                                               Tabletting 
Figure 1.15: Schematic outline of the steps in the preparation of LS compacts  
LS compact of Poorly water-soluble drugs carrying a drug suspension or drug solution in 
a solubilising vehicle that show enhanced drug release due to an improved surface area of drug 
available for release, an improved wettability of the drug particles and an increased aqueous 
solubility of the drug, (Nokhodchi et al., 2011). Accordingly, such improved drug release may 
occur in higher drug digestion in the GIT and, therefore, enhanced oral bioavailability may occur 
(El-Houssieny, et al., 2010). The mechanism of release prolongation is possible to be a more 
effective encapsulation of drug particles by the hydrophobic polymers. The appearance of 
nonvolatile solvent lessens the glass change temperature (Tg) of allows flexibility and polymers. 
As a result, reducing of Tg of the polymer might be the cause for the release prolongation of LS 
tablets. In the above temperature the Tg, a better coalescence of the polymer particles, transpires 
that forms a fine matrix and a network with a higher tortuosity and lower porosity. In this way, 
the drug is entangled and surrounded by the polymer network, resulting in the limited leaching of 
Solid drug + liquid 
vehicle 
Drug solution, 
drug suspension 
Liquid drug 
Liquid 
Carrier material & 
coating material 
 
Liquisolid system 
Tablet formulation Liquisolid compact 
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the drug, therefore, sustaining the release of drug from LS matrices. LS technique has been 
suggested to have the potential to be optimized for the reduction of drug dissolution rate and 
thereby product of sustained release systems. According to Javadzadeh et al., 2008, propranolol 
HCl was separated in polysorbate 80 as the liquid vehicle. The liquid vehicle chose by least 
solubility of liquid vehicle, and then a binary mixture of carrier–coating materials (Silica as the 
coating material and Eudragit
®
 RL or RS as the carrier) was added to the liquid medication under 
constant mixing in a mortar. The effect of drug concentration, thermal treating, loading factor 
and growing on the release profile of propranolol HCl from LS compacts was examined at two 
pH values (1.2 and 6.8). LS technique prepared tablets showed greater retardation properties in 
comparison with conventional matrix tablets. This result also showed that wet granulation had an 
exceptional impact on release rate of propranolol HCl from LS compacts, reducing the release 
rate of drug from LS compacts. The kinetics studies showed that most of the LS formulations 
resulted to the zero-order release pattern (Javadzadeh et al., 2008).  
1.9.1 Advantages of liquisolid system 
A great number of slightly water–soluble and efficiently water-insoluble liquid and solid 
drugs such as Prednisolone, Digitoxin and Hydrocortisone can be formed into LS systems the 
new formulation–mathematical model. Excellent availability of an orally administered water-
insoluble drug is obtained when the drug is in solution form. Despite the drug is in an 
encapsulated or tabletted dosage form, it is held in a solubilized liquid state, which consequently 
provides to improved drug wetting properties, thereby enhancing drug dissolution. Optimized 
rapid-release LS tablets or capsules of water-insoluble drugs show improved in-vitro and in-vivo 
drug release as compared to their commercial counterparts. Optimized sustained–release LS 
tablets or capsules of water-insoluble drugs show surprisingly steady dissolution rates (zero–
61 
 
order release) comparable only to valuable commercial preparations that combine laser–drilled 
tablets and osmotic pump technology.  
1.9.2 Disadvantages of Liquisolid system 
Limitations of LS include the demand of high solubility of the drug in non-volatile liquid 
vehicles if drug solutions are employed (Singh et al., (2012). The main disadvantage of LS is the 
uncertain formulation of a high dose of poorly water-soluble drugs (e.g. flutamide, 
carbamazepine). These drugs need a large number of liquid vehicles and also carrier and coating 
material to provide a dry powder with proper flowability and compressibility. This could 
improve the mass of each tablet above the limit for easy use (Gavali et al., 2011). 
Although, its has been confirmed that it is likely to load a large amount of drug into a LS 
system applying additives (such as hypromellose, Polyvinylpyrrolidone, and polyethylene glycol 
35000), which can be combined with the drug in liquid state to decrease the amount of carrier 
and coating material (Javadzadeh et al., 2007).  Singh et al., (2012), have revealed that higher 
viscosity of the additives leads to smaller quantities of carrier and coating material required to 
provide a flowable powder. The use of advanced carriers and coating materials with a large 
particular surface area and high absorption volume (e.g., Neusilin®) is another way of inclusion 
of higher doses of water-insoluble drugs into LS systems. 
1.9.3 Application of liquisolid systems 
Dosage forms with improved bioavailability and enhanced release rates. Sustained 
release of water-soluble drugs (propranolol HCl) can be achieved. LS technique can be strongly 
applied in formulation of orodispersible tablets (Nagabandi et al., 2011). 
Various LS formulations, which were investigated in vivo, have previously been reported 
in findings. For example, El-Houssieny et al., (2010) studied the influence of LS compacts 
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comprising repaglinide on glucose tolerance in rabbits. They confirmed that the bioavailability of 
repaglinide was increased significantly if it was applied orally in the form of LS compacts in 
comparison to commercially prepared tablets. In vivo the behaviour of LS tablets with 
hydrochlorothiazide in beagle dogs was evaluated (Khaled et al., 2001). LS tablets exhibited 
higher values of AUCμ, AUCt, Cmax and F parameters than commercial hydrochlorothiazide 
tablets. The mean values of total bioavailability of hydrochlorothiazide from LS tablets were 
raised by~15 % in compared with commercially available tablets. When in vivo evaluation of 
carbamazepine LS tablets, it was seen by Chen et al., (2013) that complete bioavailability of 
carbamazepine was raised by 82 % when compared with commercially available tablets. 
Evaluation of LS tablets carrying famotidine exhibited a higher dissolution rate compared the 
conventional, directly compressed tablets. LS formulation released 78 % of famotidine in the 
first 10 min, which is 39 % more than the release from directly compressed tablets (Fahmy and 
Kassem, 2008). 
1.9.4 Rationale of liquisolid system 
The oral route remains the most favoured route of drug administration due to its good 
patient compliance, convenience and low drug production costs. The poorly soluble hydrophobic 
drugs bioavailability (class II in BCS) is restrained by their dissolution pattern, solubility and for 
a drug to be absorbed into the systemic circulation resulting oral administration; the drug must be 
dispersed in the gastric fluids. The dissolution pattern of these drugs can be increased by or 
improving the surface area, decreasing crystallinity and decreasing particle size. Various studies 
have been investigated to increase the dissolution behaviour of drugs by decreasing the particle 
size, by creating nanoparticles and microparticles (Spireas, 2002). 
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1.9.5 Excipients for liquisolid systems 
 Non-volatile solvents. 
 Different high-boiling point, non-volatile, preferably water-miscible and not highly 
viscous solvents are employed for the formulation of LS systems. The solvent had a significant 
effect on drug release from LS systems as shown in various studies (Nokhodchi et al., 2010). For 
improved drug release from LS preparations, a liquid vehicle in which the active component is 
most soluble is usually chosen. In the case of formulating LS systems with limited release, 
solvents with a low capability to solubilize the drug are employed. 
PG is usually applied in the pharmaceutical industry as a stabilizer for vitamins and co–
solvent in ointments for medicinal purposes. The main role of PG is to solubilize and give 
homogeneous dispersion of the active component in the formulation (Hassan et al., 2007). 
According to Gubbi and Jarag, (2009) discovered that LS compacts with bromhexine HCl 
provided using PG exhibited a higher dissolution rate compared to bromhexine HCl with PEG 
400. The slower release of bromhexine HCl from PEG 400 LS compacts can be attached to 
lower solubility of bromhexine HCl in PEG 400. Liquid PEG 200-600 are applied as solvents 
and solubilizing agents for active substances and excipients in liquid and semi-solid preparations 
(Daher et al., 2003).  
Mahajan et al., (2011) studied the influence of the type of non-volatile solvent on the dissolution 
profile of glipizide of LS tablets. PG, PEG 200 and PEG 400 were employed to prepare LS 
formulations in that research. It was seen that all three liquid vehicles were able to improve the 
dissolution rate of glipizide from LS tablets when compared to their commercial counterparts. LS 
tablets carrying PEG 400 as liquid vehicle revealed higher dissolution rates in comparison to LS 
tablets containing PG and PEG 200 as liquid vehicles. Polyoxyethylene sorbitan fatty acid esters 
(Tween, Polysorbate) are broadly used in pharmaceutical and cosmetic industry as dispersants, 
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emulsifiers or stabilizers because of their effectiveness at low toxicity and relatively low 
concentrations and (Tatsuishi et al., 2005). Also, Polysorbate is fit with the majority of active 
ingredients (Wang et al., 2008). The most commonly employed polysorbate in LS systems is 
Polysorbate 80. Polysorbate 80 was successfully employed to dissolve the drug in different LS 
systems containing carbamazepine (Tayel et al., 2008), indomethacin (Saeedi et al., 2010a), 
propranolol HCL (Javadzadeh et al., 2008), piroxicam (Javadzadeh et al., 2005), etc. 
 Carrier materials 
Carrier material refers to a preferably porous material possessing sufficient absorption 
properties, such as microcrystalline and amorphous cellulose, which contributes in liquid 
absorption. In the LS preparation technique, carrier materials play the main function in getting 
the dry form of powder from the drug in liquid state. Each carrier has its unique features, but 
each should be a porous material maintaining adequate absorption capacity for liquids (Gavali et 
al., 2011). It was seen that the particular surface area (SSA) (Table 1.8) of the carrier is a major 
factor in the formulation of LS systems (Karmarkar et al., 2010). Carrier choice depends on its 
liquid binding size, flowability of powders and compressibility (Kavitha et al., 2011). Carriers 
can be classified into four classes based on their chemical structure, (Table 1.8). MCC, Avicel
®
, 
Ceolus
®
, Vivapur
®
, Emcocel
®
) is the most regularly used carrier in LS formulations based on its 
long-term use in the pharmaceutical industry, its availability and stability. It was used to 
formulate LS system comprising Nifedipine (Gubbi and Jarag, 2009), Tramadol HCl (Gonjari et 
al., 2009), furosemide (Akinlade et al., 2010), etc. 
It was seen in previous investigations that carriers other than MCC (such as lactose, starch or 
sorbitol) were needed in larger amounts for conversion of liquid preparations to the dry, non-
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adherent, free-flowing powder form. This was attached to the larger particular SSA of MCC 
(Table 1.8) (Karmarkar et al., 2010). 
 
Table 1.8: Classification of carrier material into four categories and their SSA 
Carrier category Carrier    SSA[m
2
/g] 
   
Cellulose and cellulose 
Derivatives   
Microcrystalline cellulose 
Hypromellose 
 ~1.18 
------------- 
Saccharides Lactose 
Sorbitol 
~0.35 
~0.37 
Silicates Magnesium aluminometasilicate 
Kaolin 
Diosmectite 
Ordered mesoporous silicates 
110–300 
~24 
---------- 
up to 1500 
Others Anhydrous dibasic calcium phosphate 
Polymethacrylates 
Starch   
Magnesium carbonates   
 30 
---- 
~0.60 
~10 
a 
Carrier material for LSS with controlled drug delivery 
 
 Coating materials 
Coating material refers to a material maintaining fine and highly adsorptive particles, 
such as several types of silica, which provides in covering the wet carrier particles and displaying 
a dry looking powder by adsorbing any excess liquid (Spireas, 2002).Coating material should be 
a material maintaining fine (0.01–5 μm in diameter) and highly absorptive particles, which 
provide to coating the wet carrier particles and illustrating a dry powder by adsorbing surplus 
liquid to assure good flowability of the produced blend (Kulkarni et al., 2010). In LS system 
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formulations, this function is performed by materials with a large particular surface area and 
absorption capacity, which cannot be utilized as carriers due to their poor flowing or 
compressing properties. Nowadays, the most commonly employed coating material in LS 
formulations is colloidal silicon dioxide (Aerosil
®
, Cab-O-Sil
®
 M5). It was strongly used with 
Tramadol HCl (Gonjari et al., 2009), Trimetazidine Dihydrochloride (Pavani et al., 2013), 
propranolol HCl (Javadzadeh et al., 2008), etc. 
Pre–formulation studies are required to attain a powder mixture with adequate powder 
flow and LS formulations that provide all conditions generally required on capsules, granules 
and tablets. These investigations are closely relevant to selection of the best non-volatile solvent 
to calculate the appropriate amount of powder excipients–carrier and coating material and to 
solubilize drugs (El–Say et al., 2010). 
Solubility studies are carried out by preparing a saturated solution of the drug by 
combining an excess of drug into non–volatile solvents and allowing it stay to gain the 
equilibrium state (e.g. by stirring, shaking). At the end of this step, the amount of drug diffused 
in a specific solvent is estimated analytically (Gavali et al., 2011). Solvents with higher ability to 
solubilize the drug are chosen for the formulation of LS systems for enhanced release 
(Karmarkar et al., 2010). Measurement of the angle of slide (q) is used to estimate the flow 
property of powder excipients (Tiong and Elkordy, 2009). Spireas et al., (1992), required that the 
angle of slide is the preferred approach to ascertain the flowability of powders by particles 
smaller than 150 μm. The needed amount of carrier is placed and weighed on one end of a metal 
plate with a polished surface. This end is constantly increased until the plate produces an angle 
with the plane surface at which powder is about to slide. This angle is called the angle of slide. 
The angle of slide of 33° is considered as optimal flow behaviour for the following processing 
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from LS system admixtures (compressing into tablets and filling into capsules) (Karmarkar et al., 
2009). 
 Additives 
The disintegration of solid dosage forms certainly affects drug release. Hence, 
disintegrants are normally introduced in LS compacts to enable a fast disintegration. Some 
generally employed disintegrants in LS system comprise croscarmellose sodium, low substituted 
hydroxypropyl cellulose and sodium starch glycolate (Yadav and Yadav, 2009). 
Polyvinylpyrrolidone (PVP) is another encouraging additive, which has the potential to combine 
high amount of drug into LS systems and therefore decrease the compact weight (Javadzadeh et 
al., 2007). Also, due to the crystal growth inhibition influence of PVP, LS compacts carrying 
PVP show an enhancement of dissolution rate (Singh et al., 2012). LS system has another 
additive - Hypromellose, which normally performs as a release retarding agent to prolong drug 
release (Karmarkar et al., 2010). 
 
1.9.6 Liquisolid technique as a tool to minimize the influence of pH 
variation on drug release 
The weak acids and bases solubility depend on the pH of the local environment and 
ionization constant (pKa) of the compound. Hence, the bioavailability and dissolution of these 
drugs are considerably affected by the pH of GI fluids. This further leads to a high degree of 
intravariability and intervariability in therapeutic effects and drug bioavailability (Badawy et al., 
2016). El-Hammadi et al., (2012) first investigated the feasibility of using LS technique to 
reduce the impact of pH variation on the release of loratadine. Various LS formulations were 
prepared using MCC as a carrier, silica as a coating material and PG as a liquid vehicle. The 
dissolution rate of the prepared LS compacts was studied in three different buffered media with 
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pH values of 1.2, 2.5, and 5, respectively. In comparison between the directly compressed tablets 
and marketed tablets (Clarityn
®
), the results indicate that the dissolution profiles of LS compacts 
were significantly higher and less influenced by pH variation. These results also suggested that 
LS technique is a promising and encouraging method to minimize the influence of pH variation 
on the dissolution profile of poorly water-soluble drugs. Similar result were also published by 
Chella et al., 2014, whereas an optimized LS formulation was achieved with a significant 
enhancement in dissolution rate and a less pH–dependent release profile compared to its 
commercial formulation or drug alone. Badawy et al., (2016) described the robustness of 
mosapride citrate (a poorly soluble weak base) LS compacts that minimize the influence of pH 
variation on drug release along the GIT with bio–relevant media. 
1.9.7 Sustained release with liquisolid formulations 
Accordingly, with LS compacts the coalescence of the polymer particles occurs at lower 
temperatures than with conventional matrix tablets. This more pronounced coalescence of 
polymer particles of LS compact leads to a matrix with lower porosity and higher tortuosity. 
Consequently, the drug is surrounded by a fine network of the hydrophobic polymer resulting in 
a sustained release of the drug (Azarmi et al., 2005). Moreover, it has been shown that the 
addition of Hypromellose increases the retardation effect of LS compacts (Spireas, 2002). 
Hypromellose is commonly used for the preparation of hydrophilic matrix systems. Depending 
on its MW the polymer either swells in contact with water or forms a hydrated matrix layer 
through which the drug has to diffuse or erodes resulting in a zero order drug release kinetic 
(Shoaib et al., 2010). In the case of Hypromellose it was also found that a stronger retardation 
effect was observed with LS compacts as compared to directly compressed tablets (conventional 
formulation) (Gonjari et al., 2009) 
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LS tablets were prepared by mixing liquid medication with silica–Eudragit® RL or RS followed 
by the compaction. The effect of Hypromellose and co–solvent on THP release was determined. 
The sustained release was improved in LS compacts by Hypromellose (Nokhodchi et al., 2010) 
(Table 1.9). Similar conclusions obtained from Khanfar et al., (2014), where LS formulation 
containing venlafaxine HCl tablets showed greater retardation properties in comparison to the 
directly compressed tablets. The type of liquid vehicle was seen to influence drug release 
significantly (Table 1.9). Other major factors involved drug concentration in the excipients ratio 
(R) and liquid medication. Specifically, dissolution rate from LS tablets could be decreased with 
the increase of drug concentration. A reduction of dissolution rate was seen in LS tablets with 
higher R value. This was because the volume of carrier and swelling agents (Hypromellose) was 
improved in these formulations, which lead to slow diffusion of drug within the porous carrier 
and the gel layer made by Hypromellose. The studies further concluded that prolonged 
venlafaxine HCl release behaviour was taken from LS tablets containing Tween 80 as a non-
volatile solvent with suitable carrier and coating material. 
According to Javadzadeh et al., 2007, liquid medications containing the drug were 
adsorbed on the surface of carrier materials during the preparation of LS compacts. When this 
method is shown to dissolution medium, the drug on the surface of the compact dissolves quickly 
and spread into the dissolution medium. These can be considered to be the cause of the burst 
release effect perceived. The concentration of drug in liquid medication is an essential aspect as 
it affects drug release. As these were also shown in previous studies, an increase in drug 
concentration in liquid medication leads to a lower drug release rate. These happen, when drug 
tends to precipitate within silica (Aerosil 200) pores at a higher drug concentration. Propranolol 
tablets prepared by LS technique showed excellent retardation properties in comparison with 
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conventional matrix tablets. For example, LS compact carrying 30% liquid medication with a 
loading factor of 0.225 delivered only 80% of drug in 8 h but this amount of release in its 
counterpart, the conventional matrix tablet, was achieved within 3 h. This suggested that LS 
systems showed much retardation in comparison with conventional matrix system. The outcomes 
also showed that wet granulation had a remarkable influence on the release rate of propranolol 
from LS compacts, lessening the release rate or drug from LS compacts. The kinetics studies 
reported that most of the LS formulations followed the zero-order release pattern. X-ray 
crystallography and DSC ruled out any variations in crystallinity or complex formation during 
the production process of LS formulations (Nokhodchi et al., 2007). It was also shown that by 
replacing the type of liquid medication a good release profile is obtainable and sustained release 
action of Hypromellose in LS formulations is increased. These results suggested that zero-order 
release can be realized with LS formulations (Nokhodchi et al., 2010). 
71 
 
Table1.9: Liquisolid formulation with sustained drug release. 
 
Drug Non-volatile 
solvent 
Carrier and coating 
material 
Polymer Result Reference 
Propranolol 
HCl 
 
Polysorbate 80 Eudragit
®
 RL or 
RS and Colloidal silica 
Hypromellose 
(K4M) 
The results showed that wet granulation had a remarkable impact 
on release rate of propranolol HCl from LS compacts, reducing 
the release rate of drug from LS 
Javadzadeh et al., 2008 
Tramadol 
HCl 
PG Avicel PH 102 and 
AEROSIL
®
 200 
 
Hypromellose 
(K4M) 
The prepared LS compacts are new dosage forms showing more 
sustained release behaviour as compared to marketed sustained 
formulations 
Gonjari  et al., 2009 
Theophylline Polysorbate 80 Silica–Eudragit RL or RS Hypromellose LS compacts have a potential to produce zero–order release 
kinetics for less water-soluble drugs 
Nokhodchi et al., 2010 
Nifedipine PEG 400 MCC and Colloidal Silica Hypromellose Sustained release was achieved Gubbi and Jarag, 2009 
Tramadol 
HCl 
 MCC and Colloidal Silica Hypromellose Sustained release was achieved Gonjari et al., 2009 
Trimetazidine 
Dihydrochlori
de 
polysorbate 80 Eudragit
®
 L–100 and 
RS–100and AEROSIL® 
Ethyl cellulose 
(EC) 
Drug release profiles on model fitting follow Peppas model as 
the best fit model, which indicates TZH released from this tablet 
follows sustained release profile. 
Pavani et al., 2013 
Diltiazem 
HCl 
 (PEG 200 and 
400) 
Eudragit
®
 RS and RL Hypromellose 
(K4M) 
The optimized new technique can be used in the preparation of 
sustained release formulations of water-soluble drugs. 
Adibkia et al., 2014 
72 
 
Diltiazem 
HCl 
Polysorbate 80 AEROSIL
®
 X50 and 
Lactose 
Polyox
TM
 The dissolution behaviours of DTZ release from both LS and 
conventional tablets showed retardation properties at high MW 
of Polyox
TM
. 
Kaialy et al., 2016 
Venlafaxine 
HCl  
 
PG, PEG 400, 
polysorbate 80 
Eudragit
®
 RS PO and 
Colloidal Silica 
Hypromellose LS formulations have shown better retardation properties in 
comparison to conventional tablets. The type of liquid vehicle 
was to found to influence the drug release significantly 
Khanfar et al., 2014 
Eudragit® RL: Acrylic resin RL polymer, Eudragit® RL PO: A copolymer of ethyl acrylate, methyl methacrylate and a low content of 
methacrylic acid ester with quaternary ammonium groups, Eudragit® RS: Acrylic resin RS polymer, Eudragit® S-100: Anionic copolymer 
based on methacrylic acid and methyl methacrylate, Hypromellose: Hydroxypropylmethyl cellulose, Sodium CMC: Sodium carboxymethyl 
cellulose 
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This study aims to retard the release of highly water–soluble drugs, such as DTZ, from LS 
matrix tablets. The influence of several formulation factors, i.e., the Polyox
TM
 grade 
(WSRN10, WSRN80, WSRN750, WSRN1105, WSR301 and WSR303) at
 
different MWs, 
polyox
TM
 particle size and ratio, the coating material (e.g. AEROSIL
®
 X50, 130, R812 and 
200 at
 
different surface area), the use of diluents (including lactose, mannitol, sorbitol, 
compressol
SM
 and hydrogenated vegetable oil),  polymer type (e.g. Polyox
TM
, hypromellose, 
psyllium Eudragit RL and Eudragit RS), and the drug type (e.g. DTZ, THP and ZNM) on the 
retardation properties of drug LS tablets will be investigated. LS formulation powders will be 
prepared and characterized in terms of solid–state (powder X–ray diffractometery and 
thermogravimetric analysis), size (laser diffraction), shape (scanning electron microscopy), 
density and flowability. LS compacts will be prepared and evaluated in terms of physical 
prosperities e.g., hardness and in vitro drug release profiles. Independent models including 
dissolution efficiency, mean dissolution time and mean dissolution rate will be calculated to 
quantify the drug release profiles from different LS tablets in comparison to conventional 
tablets. 
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 Materials  2.1
Diltiazem, Theophylline and Zonisamide were obtained from TCI, USA. Poly (ethylene) 
Oxide with several grades, i.e., WSRN10 (MW =100,000), WSRN80 (MW = 200,000), 
WSRN750 (MW = 300,000), WSRN1105 (MW = 900,000), WSR301 (MW = 3,000,000) and 
WSR303 (MW = 7,000,000) were obtained from Colorcon Dartford, Kent, Polysorbate 80 
(PS 80, Sigma Aldrich, Kosher, USA) are used. Hypromellose was obtained from Sigma 
Aldrich, USA. Psyllium Husk, Oxford Vitality, UK. Eudragit RLPO, RSPO were obtained 
from Evonik, Germany. Colloidal silicon dioxide (AEROSIL
®
 X50, AEROSIL
®
 130, 
AEROSIL
®
 200 and AEROSIL
®
 R812) was obtained from Evonik, Germany. Lactose was 
obtained DFE Pharma, UK. Mannitol mannogem granular was obtained from SPI Pharma, 
UK. Compressol
SM
 from SPI Pharma, UK. Hydrogenated Vegetable oil was obtained from 
JRS Pharma, Germany. Sorbitol was obtained from TCI, USA. 
 UV calibration curve of DTZ in aqueous media 2.2
A stock solution of DTZ, THP and ZNM reference standard was prepared by transferring 4.9 
mg of each drug into a 100 ml of volumetric flask and diluting with water. From this stock 
solution, seven various concentrations (0.049, 0.25, 0.49, 0.75, 0.98, 1.47 and 4.9 mg/ml) of 
each solution were transferred to 100 ml volumetric flasks and diluted with distilled water. 
The UV absorbance readings of these solutions were measured at 240 nm (DTZ) 271 nm 
(THP) and 251 (ZNM) using UV/Visible spectrophotometer (UV–160, Shimadzu, Japan). 
Distilled water was used as a reference. Then, the absorbance versus concentration of 
solutions was plotted to obtain the calibration curve which resulted in a very good R–square 
value (Figure 2.1, 2.2 and 2.3).  
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Figure 2. 1: UV absorption calibration curve of DTZ reference standard in aqueous media at 
240 nm 
 
Figure 2. 2: UV absorption calibration curve of THP reference standard in aqueous media at 
271 nm. 
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Figure 2. 3: UV absorption calibration curve of ZNM reference standard in aqueous media at 
251 nm. 
 Particle Size Fractions of Polyethylene Oxides 2.3
To study the effect of particle size on drug release, Polyox
TM
 WSR303 particles with various 
size fractions were obtained using mechanical sieving via mechanical shaker (an Endecott 
sieve shaker) with different sieve meshes (<63, 63–150, 150–180 and >180 μm). A stack of 
sieves with cover and collection pan were prepared in the following order from top to 
bottom: >180 μm, 150–180 μm, 63–150 μm and <63 μm. The bulk PolyoxTM powder was 
poured onto the top sieve (>180), and the mechanical shaker was tightened closely and 
operated for 30 min, in which the respected size fractions of Polyox
TM
 were collected and 
kept in sealed glass vials until used. 
 General Preparation of LS and physical PM formulations 2.4
A calculated quantity of DTZ, THP and ZNM was separately dispersed in a non-volatile 
water-miscible solvent, i.e., PS 80 used as liquid vehicles to form liquid medication phase. A 
fixed drug:solvent ratio of 1:1 (w:w) was used. An accurately weighed Polymer in (g) was 
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separately mixed with coating material at a constant carrier: AEROSIL
®
 ratio of 10:1. This 
blending was performed in a plastic container in a Turbula
TM
 blender (Basel, 
Maschinenfabrik, Switzerland) at a fixed speed of 100 rpm for 10 min. The resulting mixture 
of carrier:coating material (g) was introduced in a mortar, then the liquid medication phase 
(drug:solvent) from the beaker was slowly incorporated to the solid phase under continuous 
and thorough mixing using the pestle repeatedly until the liquid medication phase was 
absorbed onto the solid phase. Finally, a dry–looking mixture with apparent uniformity was 
achieved. For comparison purpose, conventional PM formulations (without a solvent) were 
also produced. Each PM formulation contained a solid phase as mention above. The mixing 
was performed using a V−shape powder mixer (GHP72, Zhejiang wisely machinery, Jiangsu, 
China) at a rotation speed of 100 rpm (ten rotations clockwise followed by ten rotation 
anticlockwise repetitively) for 5 minutes in laboratory conditions (22ºC, RH = 50%). All 
formulations prepared in this thesis were stored in sealed glass vials for at least 7 days in 
laboratory conditions (22ºC, RH = 50%) before further investigation. Different PM and LS 
formulations were prepared accordingly. 
 Laser diffraction 2.5
Volume-weighted particle size analysis of LS and PM formulation powders were conducted 
using a Malvern Mastersizer 2000 (Malvern Instruments Ltd, Germany) laser diffraction 
particle size analyser equipped with a dry sampling system (Aero S, Malvern Instruments, 
UK) as the particle size range covered by this laser diffractometer is from 0.1 μm to 3500 μm. 
Before measurement, a background reading was taken. The dispersion of air pressure was 
adjusted to 2.0–bar and a feed rate of 30% was applied. The measurement time was 5 s. The 
particle sizes at 10% (d10%), 50% (d50%, median diameter) and 90% (d90%) of the volume 
distribution, and the volume mean diameter (VMD, the average diameter based on the unit 
volume of a particle) was calculated automatically using the Malvern Software (Version 
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2.20). The span (calculated using Eq. 2.1) of the volume distribution was used as a measure 
of the width of the distribution of size relative to the median diameter. 
Span = 
𝒅𝟗𝟎%−𝒅𝟏𝟎%
𝒅𝟓𝟎%
                                                                                                               (2.1) 
Three samples were measured for each formulation and results were averaged. 
 Characterization of powder density and flowability 2.6
All the formulation samples in this study were gently poured into a 100 mL measuring 
cylinder using a glass funnel and weighed accurately. The bulk volume of each powder was 
recorded, and then the cylinder was tapped 200 times using a tapping machine (JV 1000, 
Copley Scientific, UK) under laboratory conditions (20 °C, 50% RH) and the tapped volume 
after each tapping of each powder was recorded. The experiments showed that the 200 taps 
were adequate to reach the maximum reduction in the volume of the powder beds. Tap 
density was calculated as powder weight over powder tap volume.  
Compressibility is one factor contributing to flow. The Carr’s compressibility index (CI, Eq. 
2.2) was calculated as the percentage change in the volume of constant mass of powder as a 
result of tapping. 
CI = (
Tap density
 –
 Bulk density
  Tap density
) × 100                                                                               (Eq. 2.2). 
 Scanning electron microscopy (SEM) 2.7
Scanning electron microscopy (SEM) makes use of electrons to form an image. A focused 
beam of energy high energy electron produced at the top of the microscope is used to 
generate a variety of signals at the surface of solid specimens. The accelerated electrons then 
discharge their energy as a variety of signals produced by the electron-sample interactions 
when the incident electrons are decelerated in the solid sample. These signals together with 
the secondary electrons produce SEM image. All samples during this research were analysed 
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using a Zeiss EV050–EP scanning electron microscope with EM scope of (Sc 500) (Polaron 
equipment, Watford, UK), operated using beam current of 10µA at an accelerated voltage of 
10 KV; the samples preparation was done by sticking few milligrams of each formulation on 
a separate aluminium stub using an adhesive carbon tab then sputter coating them with gold, 
The SEM images were obtained at different magnitudes with the aim to ascertain their 
representativeness (Mcconville et al., 2015) 
 Electrostatic charging analysis 2.8
The charge properties of commercial DTZ, PM and LS formulation powders were analysed 
using a recent novel instrument developed in our laboratory, as described in detail elsewhere 
(Hassan et al., 2016). The experimental apparatus consists of a single non-contact 
electrostatic inductive sensor (probe), a charge amplifier unit, national instrument data 
acquisition equipment and a personal computer for data recording and processing. An 
example of processed charge signal obtained from pure DTZ particles moving through the 
sensor using a vibratory orifice feeder under gravity. This novel method allows the detection 
and measurement of charge distribution on the charge sign basis in a population of particles. 
The positive charge is the sum of all positive charges whereas the negative charge is the sum 
of all negative charges. The netcharge is the sum of positive and negative charges. The 
charge-to-mass ratio (CMR or charge density) is the charge (negative charge for N–CMR, 
positive charge for P–CMR, netcharge for net–CMR) per unit mass, in nC/g. 
 Fourier Transform Infrared (FT–IR) 2.9
Infrared spectra of DTZ HCl were obtained using (Bruka Alpha UK) FT–IR equipped with a 
single bounce attenuated total reflectance (ATR) accessory; using micro spatula, a few 
milligrams of each drug/polymer samples were placed on the middle of the sample stage after 
cleaning with acetone, the knob was then slowly rotated clockwise, so that is above the 
sample and was then compressed by rotating the screw on the top of the arm to fixate the 
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sample and then start button was pressed on the monitor until green bar appears; a scanning 
range between 400 to 4000 cm
-1
 with resolution of 4cm
-1
was employed and the spectra 
obtained were the results of averaging 16 scans. 
 Powder X-ray diffractometry 2.10
This is an analytical technique used in the identification of crystalline phase by the diffraction 
patterns for the characterisation of crystallinity index. This was carried out at the University 
of Wolverhampton. Powder PXRD patterns of LS and PM formulations were collected on a 
Empyrean PANalytical powder diffractometer (Philips: PW1770 UK). The tube voltage and 
amperage were set at 40 kV and 40 mA, respectively. The monochromator slit was set at 20 
mm sample size. Each sample was scanned between 5° and 45° in 2Ɵ with a step size of 
0.01° at 1 step/s. The sample stage was spun at 30 rpm. The instrument was calibrated before 
use using a silicon standard. 
 Preparation of compacts 2.11
Accurately weighed samples of each LS–formulation and PM–formulation were separately 
weighed and then compressed on 8 mm punch and die using a manual tabletting machine 
(Globpharma, USA) at a fixed pressure of 2000 psi. Each tablet contained 60 mg of DTZ. 
Before direct compression of compacts, 1% w:w magnesium stearate (Acrõs Organics, New 
Jersey, USA) in acetone (Fisher Scientific, UK) was applied to the die and punch as a 
lubricant to aid ejection. 
 In vitro dissolution studies 2.12
Dissolution testing was performed to give a reasonable prediction of the product’s in-vitro 
dissolution and the rate at which the drug is released from its tablet dosage form. A USP 
dissolution apparatus 2 (paddle method) was used with a rotational speed of 75 rpm. The 
dissolution testing system comprised of a VK7010 dissolution apparatus (Varian, USA) and 
an automated sampling manifold (Varian, UK). The dissolution test was performed according 
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to the British Pharmacopoeia (2011), conditions for DTZ dissolution. The dissolution media 
consisted of 900 mL of distilled water equilibrated to 37 ºC ± 0.5 ºC. Samples were 
withdrawn from the dissolution flask using a peristaltic pump at different time intervals for 
up to 8 h (every 15 min for the first 2 h and then every 30 min up to 8 h). The absorbances 
were recorded using a UV spectrophotometer (UV–160, Shimadzu, Japan) at 240 nm. Three 
compacts were tested for each formulation.  
 
o For effect of various drugs, drug release study (n=3) was performed in a paddle 
apparatus 2 (paddle method) at a rotational speed of 75 rpm. The dissolution media 
consisted of 900 mL of distilled water equilibrated to 37 ºC ± 0.5 ºC. Each tablet was 
inserted in a stainless steel basket and samples were withdrawn from the dissolution 
flask using a peristaltic pump at different time intervals for up to 8 h (every 15 min 
for the first 2 h and then every 30 min up to 8 h). Drug release was measured using a 
UV–spectrophotometer at 240, 271 and 250 nm for DTZ, THP and ZNM respectively.  
o For effect of rotational speed, drug release study (n=3) was performed in a paddle 
apparatus 2 (paddle method) at a rotational speed of 25, 50 75 and 100 rpm using 900 
ml of distilled water. A UV spectrophotometer determined the amount of drug 
released at a wavelength of 240 nm for DTZ. The samples were withdrawn from the 
dissolution flask using a peristaltic pump for 8hrs as seen in the previous method. 
o For effect of pH, Drug release behaviour of the PolyoxTM and PolyoxTM:Psyllium was 
investigated in a series of buffer solutions that simulated the stomach and intestinal 
conditions with the pH values of 1.2, 2.2, 5.8, 6.8, 7.2 and 7.5 using 900 ml. The 
dissolution was conducted for 8hrs for all formulations using a UV–
spectrophotometer at a wavelength of 240 nm for DTZ. The same withdrawal 
procedure was used as seen in the previous method. 
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 Dissolution parameters 2.13
Independent models including dissolution efficiency (DE, Eq. 2.3) (Khan, 1975), mean 
dissolution time (MDT, Eq. 2.4) and mean dissolution rate (MDR, Eq. 2.5) were employed to 
quantify the drug release profiles from different LS tablets in comparison to conventional 
tablets. Such mathematical analyses enable the statistical comparison between different 
formulations and evaluate how each formulation factor affects the dissolution rate of DTZ. 
The DE is the area under the dissolution curve produced up to a certain time, t, expressed as 
the percentage of the area of the rectangle. 
𝐃𝐄𝐭 =
∫ 𝐲 × 
𝐭
𝟎 𝐝𝐭
𝐲𝟏𝟎𝟎 × 𝐭
× 𝟏𝟎𝟎                                                                                        (Eq. 2.3), 
where t is the total time of drug release, y is the percentage of drug release at time t and Y100 
is a 100% drug release.  
MDT is a model–independent method that is suitable for dosage forms having different 
mechanisms of drug release. MDT the time at which 50% of the drug is dissolved from its 
solid state under dissolution conditions, whereas MDR is the percent release of the drug 
every min.  
𝐌𝐃𝐓 =
∑ 𝐭𝐣
𝐧
𝐣=𝟏 ∆𝐌𝐣
∑ ∆𝐌𝐣
𝐧
𝐣=𝟏
                                                                                                    (Eq. 2.4) 
𝐌𝐃𝐑 =
∑ ∆𝐌𝐣
𝐧
𝐣=𝟏 /∆𝐭
𝐧
                                                                                                   (Eq. 2.5), 
where j is the sample number, n is the number of dissolution samples, t or tj is the time at 
the midpoint between t and t-
1
 (which can be calculated using (t + (t-
1
) /2), and Mj is the 
additional amount of drug dissolved between t and t-
1
. 
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 Similarity factor 2.14
A similarity factor (f2, Eq. 2.6) (Moore and Flanner, 1996) was used to compare the in vitro 
release profiles of LS tablets and conventional tablets. 
f
2
= 50 × Log {[1+
1
n
∑ (Rt-Tt)
2n
t=1 ]}
-0.5
×100                                                               (Eq. 2.6), 
Where: n is the number of test points for the samples; Rt is the reference assay at time point t, 
and Tt is the test assay at time point t. An f2 value between 50 and 100 suggests a similarity 
between the two release profiles and the closer the value is to 100 the more similar or 
identical the profiles are. Also dissimilarity occurs with decreasing values less than 50 
(Moore and Flanner, 1996). 
 Release Kinetics   2.15
In addition to dissolution parameters, the kinetics of drug release from all formulations under 
investigation was determined to obtain information on the mechanism of drug release from 
the LS matrix tablets.  
The release data obtained were analysed using the Power law proposed by Peppas and 
Korsemeyer and known as the Peppas model (Korsemeyer and Peppas, 1983). In this method, 
the log cumulative percentage of the drug release is plotted against the log of time. As this 
model assumes a uniform distribution of drug through a polymeric matrix (diffusion model), 
the release kinetics are evaluated by using drug release from 5 % to 60 % and fitting it into 
equation 2.7 as proposed by Ritger and Peppas (Ritger and Peppas, 1987). 
Q = ktt
n 
                                                                                                                          (Eq. 2.7),
 
where Q is the percentage of drug released at time t, k is the release constant and n is the 
diffusional release exponent indicative of the operating release mechanism. 
The value of n characterises the release mechanism of drug in this model. Since the tablet 
matrices prepared in this investigation had a cylindrical shape, Fickian diffusion is suggested 
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for n values up to 0.45, whereas Case-II transport is suggested when values are above 0.89. 
Values of n between these two suggest anomalous transport occurring (Siepmann and Peppas, 
2001). 
 Swelling behaviour 2.16
To evaluate the effect of Polyox
TM
 dissolution on DTZ release kinetics, Polyox
TM
 tablets 
were separately weighed (W0) and then placed in small containers with a metal mesh 
underneath them. Another mesh was placed on the top of each container to make sure the 
tablets are held inside the chamber. To simulate the in vitro dissolution conditions, the small 
containers carrying the tablets were placed in the bottom of dissolution vessels containing 
distilled water equilibrated to 37 ºC ± 0.5 ºC. Paddles were used to stir the dissolution 
medium at a rate of 75 rpm at 37 °C ± 0.5 ºC. At various time intervals (0, 2, 5, 15 and 30 
min), the tablets were withdrawn using a small basket, soaked on a tissue paper (to remove 
excess water). The percentage increase in weight of each tablet due to water uptake was 
calculated using the following equation.   
% swelling = 
𝑴𝒕−𝑴𝟎
𝑴𝟎
× 𝟏𝟎𝟎                                                                       (Eq. 1.8),   
 where Mt is the weight of tablet at time ‘t’ and M0 is the weight of tablet at time 0. The 
experiments were performed in triplicate for each time point. Fresh samples were used for 
each time point.      
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 Introduction 3.1
Diltiazem HCL (DTZ) is a calcium channel blocker employed in the treatment of angina 
pectoris and hypertension. DTZ is largely metabolized by the liver and excreted by the 
kidney. Although DTZ is absorbed up to about 80%, it is subjected to an entire bioavailability 
of ~ 40% due to an extended first–effect (Chaffman and Brogden, 1985). Additionally, the 
plasma elimination half-life resulting from single or multiple administrations is relatively 
short (~ 3 to 5 hrs). Therefore, DTZ is a good candidate for a sustained release dosage form 
(Lachman et al., 1990), which is useful to patients to maintain sustainable levels in the blood 
plasma (Piepho et al., 1982). The main goals of designing a sustained release form is to 
achieve a steady state blood level of drug that is nontoxic and therapeutically effective for an 
extended time to reduce dosing frequency and fluctuations of drug levels in the blood (Putney 
and Burke, 1998). Polymers are long chain molecules formed from smaller molecules called 
monomers. Numerous studies reported the influence of various factors associated with 
hypromellose polymers, such as MW (Krögel and Bodmeier, 1999), concentration (Mitchell 
et al., 1993), particle size distribution (PSD) (Velasco et al., 1999), on drug release. 
However, there is a shortage of data on the influence of factors associated with polyethene 
oxide (Polyox
TM
). Polyox
TM
 is an attractive hydrophilic polymer for the use in the preparation 
of pharmaceutical formulations because of its nontoxicity, ease of production, high water–
solubility, high swellability, and insensitivity to the pH of the biological medium (Shojaee et 
al., 2014). LS systems were initially designed to improve the solubility and dissolution rate of 
poorly soluble drugs (Nokhodchi et al., 2016). Recently, it has been employed to sustain the 
release of highly soluble drugs. The influence of Polyox
TM
 MW on the physicochemical and 
pharmaceutical properties of LS formulations was not reported previously. To this end, LS 
formulations containing various grades of Polyox
TM
 having MWs ranging from 1 × 10
5
 to 70 
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× 10
5
 were prepared and studied for their physicochemical and drug release properties in 
comparison to their PM counterparts. 
 Formulation 3.2
DTZ powder (2.4 g) was dissolved in 2.4 g of polysorbate 80 (PS 80) (60 ºC, 200 rpm), a 
non–volatile water-miscible solvent used as a liquid vehicle to form liquid medication phase 
at a fixed drug:solvent ratio of 1:1 (w:w). Each grade of Polyox
TM
 powder under investigation 
(3.6 g, solid phase) was introduced to a mortar, and the mixing process was carried out as 
described earlier (Section 2.5). For comparison purpose, PM formulation contained a mixture 
of DTZ (2.4 g) and Polyox
TM
 (3.6 g). The mixing was performed as described in Section 2.5. 
Accurately weighed samples of each liquisolid (300 mg) and PM (240 mg) formulation were 
separately weighed and then compressed on 8 mm punch and die using a manual tableting 
machine at a fixed pressure of 2000 psi. 
 Results and discussion 3.3
3.3.1 Solid state 
Polymorphic change of drug is one of the main features that may affect the drug dissolution 
rate and bioavailability (Abdou, 1989). Therefore, it is vital to study the polymorphic changes 
of DTZ in the prepared LS tablets. No polymorphs have been reported for DTZ to date 
(Mazzo et al., 1994). The PXRD patterns and FT–IR spectra of commercial DTZ, LS 
formulations and PM formulations are shown in Figure 3.1 and Figure 3.2. DTZ displayed 
sharp peaks at 8.10°, 10.12°, 18.30°, 19.53°, 20.10°, 21.66°, 24.77°, 28.10°, 30.01°, 32.10°, 
40.23° and 42.10° 2θ, suggesting a typical crystalline pattern (Mazzo et al., 1994). It can be 
observed that, LS formulations and PM formulations showed two prominent peaks with the 
highest intensity at 2θ of 18.33° and 23.57°. This indicate the presence of PolyoxTM in both 
the PM and LS formulations (Figure 3.1). No significant changes were also observed in the 
FT–IR spectra of LS formulations in comparison to their PM counterparts. The characteristic 
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bands at 2931.90 cm
-1
 (O‒CH3 and C‒H stretching), 2387.93 cm
-1 (amine HCl, N‒H 
stretching), 1741.78 cm
-1
 (acetate C=O stretch), 1678.13 cm
-1
 (lactam C=O stretch), 831.33 
cm
-1
 (O‒substituted aromatic C‒H out of plane deformation), and 673.48 cm-1 (P‒substituted 
aromatic C‒H out of plane) were present in all samples. Such observations confirmed that 
there was no significant change in the solid state of the drug during the preparation of LS 
formulations. The results also ruled out the existence of significant drug-excipient interaction 
within both LS and PM formulations. 
Figure 3.1: PXRD patterns of physical mixture (PM) and LS (LS) formulations containing 
various grades or Polyox
TM
 (a) Pure DTZ, (b) Pure Polyox
TM
 (c) DTZ-WSR 10, (d) DTZ-
WSR 80, (e) DTZ-WSR 750, (f) DTZ-WSR 1105, (g) DTZ-WSR 301 and (h) DTZ-WSR 
303. 
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Figure 3.2: FTIR patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various grades or Polyox
TM
 (a) Pure DTZ, (b) DTZ-WSR 10, (c) DTZ-WSR 80, 
(d) DTZ-WSR 750, (e) DTZ-WSR 1105, (f) DTZ-WSR 301 and (g) DTZ-WSR 303. 
3.3.2 Particle size distributions 
LS formulations showed larger PSDs compared to their PM counterparts, although such 
increase in particle size was not statistically different (VMD, P> 0.05) in the case of 
Polyox
TM
 grades with MW >9 x 10
5
 (Table 3.1). This could be attributed to increased particle 
aggregation for LS formulations (Figure 3.3). Different degrees of aggregation were observed 
in LS formulations. Smaller DTZ particles were generally not presented as distinct particles 
in the case of LS formulations but as aggregates due to strong DTZ–PolyoxTM cohesion 
(Figure 3.3). All formulations showed a span value higher than unity, donating broad PSDs 
(Table 3.1). Nevertheless, LS formulations showed relatively narrower size distributions 
compared to their PM counterparts as indicated by their lower span values (Table 3.1). The 
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significant reduction of fine particulates content recorded for LS formulations compared to 
their PM counterparts, as indicated by the higher d10% values (Table 3.1), could account for 
their improved size homogeneity. This could be attributed to the adhesion of such fines on the 
surfaces of larger particles in the case of LS formulations as confirmed by SEM observations 
(Figure 3.3). Additionally, the striking morphological differences in the blend structures 
between LS and PM formulation mixtures support the higher span values obtained for LS 
formulations compared to PM formulations (Figure 3.3). Two different populations of 
particles could be observed in the PMs accounting for morphologies of both DTZ (slabby) 
and Polyox
TM
 (botryoidal) particles, whereas no distinct DTZ or Polyox
TM
 particles were 
observed in LS formulations (Figure 3.3). The improved mass distribution for LS 
formulations is of great importance because it relates directly to dose uniformity. In contrast 
to LS formulations, the different sized particles in the case of PM formulations will lead to a 
different amount of drug per unit mass. When the various sized particles segregate (e.g. by 
percolation segregation), drug-rich areas may result where the small particles congregate 
(Kaialy, 2016–a), as confirmed by SEM observations for PM formulations (Figure 3.3). 
 
 
 
92 
 
 
Table3 1: Particle size distribution (i.e. particle size at 10% (d10%), 50% (d50%), 90% (d90%), volume mean diameter (VMD), and span; mean ± 
SD, n = 3) of DTZ–PolyoxTM liquisolid (LS) formulation powders and their physical mixture (PM) counterparts. 
 
 
 
 
Formulation Polyox
TM
 
MW (× 10
5
) 
d10% (μm) d50% (μm)  d90% (μm) VMD (μm) Span 
DTZ (alone)  8.2 ± 0.  1 29.2 ± 0.3 147.3 ± 8.0 1 67.0 ± 4.5 4.0 ± 1.5 
  PM              LS PM                       LS               PM                         LS               PM                   LS PM LS PM LS 
DTZ–WSRN10 1 23.0 ± 4.7   59.5 ± 0.0 119.0 ± 9.2 163.1 ± 0.1 337.0 ± 49.0 486.0 ± 0.0 167.7 ± 38.1    273.0 ± 0.0 2.6 ± 0.2 2.5± 0.0 
DTZ–WSR 80 2 21.2 ± 0.3   52.8 ± 0.4 114.7 ± 9.3 143.2 ± 1.1 346.3 ± 44.8 343.7 ± 5.0 156.3 ± 19.1   174.3 ± 1.5 2.8 ± 0.2 2.0 ± 0.0 
DTZ–WSR 750 3 27.7 ± 3.5  56.6 ± 0.6 144.3 ± 20.8 159.0 ± 4.6 387.7 ± 42.8 421.0 ± 5.1 188.0 ± 18.1  230.7 ± 38.0 2.5 ± 0.1  2.3± 0.2 
DTZ–WSR 1105 9 24.9 ± 2.6   60.0 ± 0.4 139.7 ± 20.6 155.0 ± 0.6 389.3 ± 47.5 378.7 ± 9.0 184.7 ± 26.6   195.3 ± 8.5 2.6 ± 0.1 2.1 ± 0.0 
DTZ–WSR 301 40 36.1 ± 3.5   58.0 ± 0.3 167.7 ± 9.3 166.1 ± 1.7 439.3 ± 19.6 439.7 ± 11.5 211.7 ± 10.0  218.3 ± 9.2 2.4 ± 0.1 2.3 ± 0.0 
DTZ–WSR 303 70 35.0 ± 1.1   51.6 ± 13.4 152.0 ± 11.3 163.2 ± 1.2 390.5 ± 31.8 395.7 ± 1.1 190.0 ± 14.1  199.7 ± 2.3 2.3 ± 0.0 2.1 ± 0.1 
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3.3.3 Powder density 
LS formulations showed significantly (P< 0.05) lower bulk densities compared to PM 
formulations (Table 3.2), indicating that there are fewer average points of physical contact 
between particles within LS powders compared to PM powders. The wider polydispersity of 
particle size for PM formulations compared to LS formulations (Table 3.1) could account for 
their higher bulk and tapped densities because polydispersed particles pack more efficiently 
(i.e. smaller particles filling in the interstices created by the large particles). LS powders 
showed poorer flow properties compared to PM powders as indicated by their higher CI 
values (Table 3.2). Undoubtedly, the nature and extent of interparticle forces provide a major 
influence in powder flowability. The poorer flow properties of LS powders in comparison to 
PM powders (Table 3.2), despite their lower content of fine particulates (Table 3.1), is due to 
the high viscosity of PS 80, which increases the cohesive properties of the LS powders. SEM 
photographs showed LS powders to be composed of irregular, deformed particles with 
rough/uneven surfaces and increased particle aggregation due to increased interparticle 
cohesion (Figure 3.3). Therefore, LS powders will have a higher propensity to geometrical 
interlocking upon packing (i.e. increased frictional forces) resulting in poorer flow properties 
as compared to PM powders. The tap density and CI of both LS and PM formulations showed 
generally decreasing trends with increasing the MW of Polyox
TM
 (Table 3.2), indicating that 
powders containing Polyox
TM
 grades with higher MWs have better flow properties. 
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Figure 3. 3: Representative scanning electron microscopy (SEM) photographs of commercial 
diltiazem HCl (DTZ) and LS formulations containing DTZ drug and formulated with 
Polyox
TM
 WSRN10 or Polyox
TM
 WSR303 in comparison to their physical mixture (PM) 
counterparts. 
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Table 3 2: Bulk density, tap density and Carr’s index (CI) (mean ± SD, n = 5) for DTZ–PolyoxTM liquisolid (LS) formulation powders and their 
physical mixture (PM) counterparts. 
 
 
Formulation Polyox
TM
 MW (× 10
5
) Bulk density (g/cm
3
) Tap density (g/cm
3
) CI (%) 
  PM LS PM LS PM LS 
DTZ–WSRN10 1 0.42 ± 0.01 0.35 ± 0.01 0.57 ± 0.00 0.55 ± 0.01 25.7 ± 0.9 36.5 ± 1.2 
DTZ–WSR 80 2 0.41 ± 0.01 0.34 ± 0.01 0.54 ± 0.01 0.52 ± 0.02 23.7 ± 1.1 34.1 ± 2.8 
DTZ–WSR 750 3 0.36 ± 0.01 0.33 ± 0.01 0.50 ± 0.01 0.49 ± 0.03 23.0 ± 0.4 33.3 ± 3.1 
DTZ–WSR 1105 9 0.40 ± 0.01 0.34 ± 0.01 0.52 ± 0.02 0.50 ± 0.02 23.0 ± 1.2 32.1 ± 5.4 
DTZ–WSR 301 40 0.38 ± 0.01 0.34 ± 0.01 0.48 ± 0.01 0.50 ± 0.01 20.0 ± 1.3 31.7 ± 1.7 
DTZ–WSR 303 70 0.40 ± 0.01 0.36 ± 0.02 0.51 ± 0.00 0.51 ± 0.03 21.4 ± 1.5 30.0 ± 1.0 
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3.3.4 Drug release 
The release profiles of DTZ from various PM and LS formulations under investigation are 
shown in Figure 3.4. No tablet exhibited any initial burst drug release (Figure 3.4). This is 
because Polyox
TM 
forms a viscous gel layer when it is exposed to aqueous media, allowing 
the retardation of the release of highly water-soluble drugs (Shojaee et al., 2015). The 
dissolution rate of DTZ from both LS and PM tablets decreased as the MW of Polyox
TM
 
increased (Figure 3.4). This was confirmed by dissolution parameters analyses that showed 
both LS and PM tablets containing Polyox
TM
 grades with higher MWs to produce lower DEs, 
higher MDTs and lower MDRs compared to those containing lower MWs (Table 3.3). The 
delayed DTZ release could be related to the rate and extent of hydrogel formation on the 
tablet surface. Soluble drugs such as DTZ are predominately released by diffusion 
mechanism through the gel layer. Upon immersion in an aqueous medium, the hydrophilic 
Polyox
TM
 matrix physically swells to form a hydrogel layer around the tablet. The quick 
formation of such gel layer is vital as it contributes to retaining structural integrity, slows 
down water entering the interior of the matrix tablet and prevents tablet disintegration (Khan 
et al., 1995). It could be assumed that the solvent penetrates the free spaces between the 
macromolecular chains of Polyox
TM
, and the Polyox
TM
 chains become flexible, enhancing the 
thickness of the gel layer and allowing drug release through the gels outer surface (Colombo 
et al., 1995). This could also be described as water plasticising the Polyox
TM
 and 
transforming it from glassy state to rubbery state. When it is highly hydrated, the outer layer 
ultimately reaches a dilution point leading to Polyox
TM 
disentanglement from the surface of 
the matrix. The gel layer is then constantly replaced with the hydrated Polyox
TM
 from inside 
the core. In comparison to matrices containing a Polyox
TM 
grade with a lower MW, matrices 
containing a Polyox
TM 
grade with a higher MW could produce more coherent (thicker of 
more viscous) hydrogel layers, acting as a barrier against release of drug and thus resulting in 
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a slower drug release since it takes time for DTZ molecules to travel across the gel layer and 
reach the dissolution medium. In contrast, Polyox
TM 
grades with low MWs are more 
susceptible to erosion due to the formation of thinner (softer) hydrogel layers (Wu et al., 
2005). It can also be argued that Polyox
TM
 grades with higher MWs produce slower drug 
release due to higher viscosity and thus higher energy required for pulling longer chains of 
the polymer off the matrix (Hiremath and Saha, 2008).  
 
 
Figure 3.4: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from physical 
mixture (PM) and liquisolid (LS) formulations containing various grades or Polyox
TM 
(WSRN10, WSRN80, WSRN750, WSRN1105, WSR301 and WSR303). 
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Figure 3.5: Percent swelling of physical mixture (PM) and liquisolid (LS) formulation tablets 
containing various grades or PolyoxTM (WSRN10, WSRN80, WSRN750, WSRN1105, 
WSR301 and WSR303), and the effect of MW on % swelling (mean ± SD, n = 3). 
 
This was confirmed by swellability studies which showed the water uptake of both LS and 
PM tablets to increase as the MW of Polyox
TM
 increased (Figure 3.5). Similar findings were 
reported in the case of hypromellose by (Wan et al., 1993), where an increase in gel layer 
thickness after 30 min of swelling was reported for matrix tablets containing hypromellose 
grades with higher MWs. LS tablets showed lower swellabilities than their PM counterparts 
tablets (Figure 3.5). Such differences could be attributed to the differential expansion of the 
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glassy core of the matrix. In general, LS tablets showed slower release patterns compared to 
PM tablets, although whether such decrease in drug release rate is statistically different was 
dependant on Polyox
TM 
MW (Table 3.3). Statistical analysis confirmed that DTZ release 
profiles from LS tablets containing Polyox
TM
 grades with MWs below 9 × 10
5
 (i.e. WSRN10, 
WSRN80 and WSRN750) was not significantly different (f2> 50, Table 3.3) in comparison to 
their PM counterparts (Figure 3.4). In contrast, better retardation properties were observed for 
LS tablets containing Polyoxes with MWs ≥9 × 105 (i.e. WSR1105, 351 WSR301 and 
WRS303) in comparison to the conventional tablets (Figure 3.4), as substantiated by f2 values 
below 50 (Table 3.3). Similar conclusions could, in general, be obtained when considering 
MDT and MDR results.  
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Table 3 3: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR), similarity factor (f2) and in vitro release 
kinetic parameters (r
2
, correlation coefficient squared; n value, and MPE, mean percentage error based on Korsemeyer-Peppas equation, Q = kttn 
(Eq. 8) of diltiazem HCl obtained for liquisolid (LS) formulations containing various grades or Polyox
TM
 (WSRN10, WSRN80, WSRN750, 
WSRN1105, WSR301 and WSR303) in comparison to their physical mixture (PM) counterparts. The counterpart physical mixture was chosen 
as the standard for each liquisolid formulation when calculating f2 values. The results are expressed as the mean ± SD, n = 3 (*indicates a 
significant difference, P< 0.05). 
Formulation Polyox
TM
 MW 
(× 10
5
) 
DE (%)  MDT (min) MDR (min
-1
) f2 r
2
 n MPE (%) 
  PM              LS PM                       LS               PM                         LS               PM                   LS  LS vs 
PM 
 
   LS PM LS PM PM 
DTZ–WSRN10 1 90.6 ± 2.4 91.6 ± 1.2 31.5 ± 10.0 34.0 ±4.5 0.60 ± 0.01 0.59 ± 0.01 62.7 0.997 0.931 1.301 0.871 3.51 9.63 
DTZ–WSR 80 2 90.3 ± 1.3  89.0 ± 0.9 48.4 ± 6.6 57.8 ± 5.7* 0.49 ± 0.02* 0.48 ± 0.01* 70.2 0.989 0.975 1.150 0.812 6.98 7.72 
DTZ–WSR 750 3 86.7 ± 3.0 82.3 ± 1.4* 79.9 ± 12.2* 93.5 ± 3.5* 0.37 ± 0.02* 0.34 ± 0.01* 64.0 0.989 0.952 1.169 0.771 10.11 11.69 
DTZ–WSR 1105 9 87.9 ± 0.4 78.4 ± 2.1* 72.7 ± 2.4* 101.4 ± 16.0* 0.38 ± 0.01* 0.38 ± 0.05* 43.7 0.972 0.990 1.239 0.828 16.82 5.51 
DTZ–WSR 301 40 74.4 ± 2.5* 64.4 ± 0.7* 109.4 ± 6.2* 136.5 ± 0.4* 0.32 ± 0.01* 0.27 ± 0.01* 49.0 0.989 0.987 0.726 0.650 5.39 5.96 
DTZ–WSR 303 70 69.4 ± 8.7* 58.0 ± 2.5* 131.3 ± 24.4* 119.4 ± 5.9* 0.35 ± 0.05* 0.25 ± 0.01* 47.5 0.994 0.998 0.712 0.580 4.84 5.10 
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For example, The DEs obtained from LS and PM tablets were statistically similar (P> 0.05) 
in the case of Polyoxes with MWs below 9 × 10
5
, whereas LS tablets produced lower DEs 
than conventional tablets in the case of Polyoxes with MWs ≥ 9 × 105 (Table 3.3). An 
interesting trend was obtained when plotting the difference in the dissolution efficiency of 
DTZ obtained from PM and LS formulations (ΔDE = DEPM – DELS) against the MW of 
Polyox
TM. ΔDE increased with increasing PolyoxTM MW (Figure 3.6). This indicates that 
only polyox
TM
 with higher MW to produce more sustained drug release from LS tablets in 
comparison to their PM compact. The dissolution data were fitted into Eq. 8 and the in vitro 
release kinetic parameters are listed in Table 3.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Difference in dissolution efficiency (ΔDE, %) of diltiazem HCl (DTZ) between 
liquisolid (LS) and (PM) formulations in relation to Polyox
TM
 molecular weight (MW). 
 
All profiles were well fitted as indicated by the excellent r
2 
values obtained. In comparison to 
PM formulations, all LS formulations showed higher n values regardless of Polyox
TM 
MW 
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(Table 3.3), indicating a higher contribution of macromolecular relaxation and erosion 
mechanisms and near zero–order release. The release of DTZ from all PM formulations 
followed the anomalous transport mechanism (0.45> n> 0.89) regardless of Polyox
TM 
MW 
(Table 3.3). In contrast, the mechanism by which DTZ was released from LS formulations 
was dependent on polyox
TM 
MW. LS formulations containing Polyoxes with MWs above 9 × 
10
5
 released the drug via anomalous transport (or non-fickian diffusion) mechanism (0.45> 
n> 0.89) whereas LS formulations containing Polyoxes with MW ≤ 9 × 105 released the drug 
via case–II transport mechanism (n> 0.89) (Table 3.3). This indicated that only PolyoxTM 
grades with MWs ≥ 9 × 105 (WSR301 and WSR 303) are better candidates to produce more 
sustained drug release from LS tablets in comparison to PM tablets. More efficient 
encapsulation of the drug particles by the Polyox
TM
 particles could be a mechanism of drug 
release prolongation in the case of LS tablets. The solvent incorporated in LS formulations 
could exert a plasticising effect within the membrane of Polyox
TM
 after the swelling and 
diffusion processes (Gruetzmann and Wagner, 2005). Polysorbate was shown to reduce the 
Tg of polymers such as Polyox
TM
 (Javadzadeh et al., 2008) and thus it could slow the release 
rate of DTZ from LS tablets compared to the PM tablets through affecting the intermolecular 
bonds between Polyox
TM
 chains. 
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3.3.5 Electrostatic charge 
Triboelectrostatic charging is a multifaceted complex phenomenon that depends on several 
factors such as contact surface resistivity, particle surface roughness, PSD, particle surface 
resistivity, and environmental relative humidity. The charge sign of a group of particles 
depends on their relative electron-donor or -acceptor properties and work functions (Kaialy, 
2016–b). Commercial DTZ, LS and PM formulation powders showed strong bipolar charging 
behaviours (Figure 3.7), a phenomenon that has been particularly recognised in polydispersed 
powder mixtures having similar or dissimilar chemical compositions (Kaialy, 2016–b). 
Commercial DTZ showed an electronegative net–CMR (netcharge) (Figure 3.7). In general, 
the P–CMRs and net–CMRs of both LS and PM formulation powders showed increasing 
trends with increasing the MW of Polyox
TM
 (Figure 3.7). Compared to their PM counterparts, 
LS formulations containing Poylox
TM
 grades with MWs below 9 × 10
5 
showed higher 
netcharges, whereas the reverse trend could be observed for LS formulations containing 
Poylox
TM
 grades with MWs ≥ 9 × 105 (Figure 3.7). This suggested that LS formulation 
containing high MW Polyox
TM
 provide improved handling compared to their PM 
counterparts. The differences in electrostatic behaviour between LS and PM powders are 
because particles can roll, slide, and collide with each other during the preparation of LS 
formulations, all the foregoing actions can induce electrostatic charge development at the 
level of the particle surfaces. It should also be noted that although PM formulations 
containing Polyoxes with MWs below 9 × 10
5
 showed negligible absolute magnitude of 
netcharge (≤ 0.3 nC/g), these formulations showed considerable levels of both positive 
charging and negative charging (Figure 3.7). This suggests that measuring only the netcharge 
(i.e. the sum of electrostatic charges carried by a powder sample) for powders exhibiting 
bipolar charge behaviour is not a good indicator of charging behaviour as it can produce 
erroneous conclusions. Thus, it is necessary to characterise particulate materials for their 
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bipolar electrical characteristics to recognise the underlying phenomenon of tribocharging so 
that a corrective action can be taken. 
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Figure 3.7: Positive–charge-to-mass ratio (P–CMR), negative–charge-to-mass ratio (N–
CMR) and net–charge-to-mass ratio (net–CMR) (mean ± SD, n = 3) for commercial diltiazem 
HCl (DTZ), liquisolid (LS) formulations containing various grades or PolyoxTM (WSRN10, 
WSRN80, WSRN750, WSRN1105, WSR301 and WSR303) in comparison to their physical 
mixture (PM) counterparts. 
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 Conclusion 3.4
Polyox
TM–based LS tablets have a potential to produce zero-order release kinetics for a highly 
water–soluble drug, DTZ, although a careful selection of PolyoxTM grade is nevertheless vital 
to producing slower release pattern of LS tablets in comparison to PM tablets. Only when the 
MW of Polyox
TM
 was sufficiently high (i.e. ≥ 9× 105) was the rate and extent of drug release 
lower for LS tablets in comparison to conventional tablets. Being simple and easily scaled up, 
the LS method should have general applicability to many highly water-soluble drug entities. 
Further work is therefore required to comprehensively explore LS technique as a robust and 
reliable method of retarding the release rate of highly soluble drugs. This will aid in the 
design and development of improved ER delivery systems in the future. 
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 CHAPTER 4: EFFECT OF POLYETHYLENE OXIDE PARTICLE 4
SIZE AND LEVEL 
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 Introduction 4.1
LS technique is a relatively new concept in which a liquid lipophilic medication or a water–
insoluble solid drug is dissolved in a suitable non–volatile solvent (to form a solution or a 
suspension), and then this liquid medication is converted to into a free–flowing, non–adhering 
and dry–looking compactable powder mixtures with a use of carrier and coating material 
(Gubbi and Jarag, 2009). The advantages of LS techniques include the low cost, suitability for 
industrial production and simplicity of the process needed to produce the formulation (i.e. less 
time–consuming than other methods) (Nokhodchi et al., 2011). Sustained release dosage 
forms are designed to release the drug at a decided rate by controlling a constant drug release 
for a particular period of time, leading to less side effects, better efficacy, improved patient 
compliance and higher safety. Many researchers have investigated the influence of polymer 
particle size on drug release from sustained release dosage forms. Mitchell et al., (1993) 
investigated the effect of particle size of hypromellose on the release rate of propranolol HCl 
from tablet matrices. The findings showed that the dissolution rate generally decreased as the 
particle size distribution decreased from 350 μm to 150 μm. (Campos-Aldrete and Villafuete-
Robles, 1997) also observed that hypromellose with smaller particle size distributions 
produced slower release rates of metronidazole when a higher concentration of drug:Polymer 
is used. In the same line, Novak et al., (2012), reported that when the smallest particle size 
distribution (< 75 μm) of hypromellose is used, slower dissolution rates were observed for 
diclofenac Na. In another study, (Crowley et al., 2004) showed that the compacts containing 
ethylcellulose with a smaller particle size 80 μm to 30 μm released guaifenesin, a model 
water-soluble drug, more slowly as compared to the ones having larger particles 325 μm to 80 
μm. A mean particle size of hypromellose K15M smaller than 113 μm was shown to lead to 
the release of Aspirin from tablet matrices through a combination of erosion and diffusion 
mechanisms, whereas matrix tablets containing hypromellose with mean particle size larger 
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than 113 μm produced fast Aspirin release behaviour through an erosion-based mechanism 
(Heng et al., 2001). Miranda et al., (2007) showed that the larger hypromellose K4M particle 
sizes were less effective in the formation of a homogeneous gel layer. To my knowledge, the 
influence of Polyox
TM
 particle size and concentration on the physicochemical and 
pharmaceutical properties of LS formulations was not investigated recently. To this end, LS 
formulations containing various particle size and concentration of Polyox
TM
 containing 70 × 
10
5
 were prepared and studied for their physicochemical and drug release properties in 
comparison to their PM counterparts. 
 Formulation  4.2
DTZ powder (1.2 g) was dissolved in 1.2 g of polysorbate 80 (PS 80) (60 ºC, 200 rpm), a 
non–volatile water–miscible solvent used as a liquid vehicle to form liquid medication phase 
at a fixed drug:solvent ratio of 1:1 (w:w). An accurately weighed 3.6 g of each Polyox
TM
 
particle size and 3.6 g (1:3), 4.8 g (1:4) and 6 g (1:5) drug: Polyox
TM
 ratio was separately 
mixed with 4.24 g (1:3), 5.12 g (1:4) and 6 g (1:5) of lactochem as a carrier and  0.36 g (1:3), 
0.48 g (1:4) and 0.6 g (1:5) of the AEROSIL
®
 coating material at a constant carrier: coating 
material ratio of 10:1. Detailed of formulation process was given in (section 2.5). For 
comparison purpose, conventional PM formulations were also produced. PM formulation 
contained a mixture of DTZ (1.2 g), 3.6 g Polyox
TM
 and AEROSIL
®
 as seen above with 3.44 
g (1:3), 4.32 g (1:4) and 5.2 g (1:5) of lactochem as a carrier. The mixing was performed as 
described earlier in section 2.5  
Accurately weighed samples of each liquisolid 530 mg (1:3), 640 mg (1:4) and 7:50 mg (1:5) 
and PM 430 mg (1:3), 540 mg (1:4) and 650 mg (1:5) formulation were separately weighed 
and then compressed on 8 mm punch and die using a manual tableting machine at a fixed 
pressure of 2000 psi. 
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 Results and discussion 4.3
4.3.1 Solid state 
If the drug interacts with the excipients and the liquid vehicle, the peaks consistent to the 
functional groups in the drug FT–IR will shift to various wavenumbers compared to spectra of 
the pure drug and pure excipients (Silverstein et al., 2014). This study was carried out to 
investigate if there was any chemical interaction between pure DTZ and different size fraction 
and drug:Polyox
TM
 ratio within both the LS formulations and their counterpart PM. From 
Figure 4.1, it can be observed that, LS formulations and PM formulations showed a 
remarkable change compared to that of commercial drug, DTZ, where a band at 2393 cm
-1 
was completely disappeared. This confirmed the interaction between dimethylamino group of 
the DTZ and oxygen of Polyox
TM
 (Figure 4.1). These results agreed with the findings of (Abd 
et al., 2012), where DTZ HCl – carbopol formulation showed a complete disappearance of the 
band at 2393 cm
-1 
when compared to the commercial DTZ. This confirmed the interaction 
between dimethylamino group of DTZ and carboxylate group of the polymer. The PXRD 
patterns of commercial DTZ, LS formulations and PM powders are shown in (Figure 4.2). 
The diffraction pattern of the commercial DTZ demonstrates that it has a very crystalline solid 
state in nature, with sharp intensive peaks throughout its pattern. In comparison to the pure 
drug diltiazem, both the LS formulations and PM powders showed less intensity peaks at 
8.10°, 10.12°, 18.30° and 28.10° with the highest intensity at 2θ of 18.33° and 23.57° 
regardless of their concentration and particle sizes fractions used (Figure 4.2).   
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Figure 4.1: FTIR patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various grades of Polyox
TM
 (a) Pure DTZ, (b) Polyox
TM
, (c) Polysorbate 80, (d) 
DTZ-WSR303 >180 (1:3), (e) DTZ–WSR303 150-180 (1:3), (f) DTZ–WSR303 63-150 (1:3), 
(g) DTZ–WSR303 <63 (1:3), (h) DTZ–WSR303 >180 (1:4), (i) DTZ–WSR303 150–180 
(1:4), (j) DTZ–WSR303 63-150 (1:4), (k) DTZ–WSR303 <63 (1:4), (l) DTZ–WSR303 >180 
(1:5), (m) DTZ–WSR303 150–180 (1:5), (m) DTZ–WSR303 63–150 (1:5), (o) DTZ–
WSR303 <63 (1:5). 
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Figure 4.2: PXRD patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various grades or Polyox
TM 
(a) Pure DTZ, (b) DTZ–WSR303 >180 (1:3), (c) DTZ-
WSR303 150–180 (1:3), (d) DTZ–WSR303 63–150 (1:3), (e) DTZ–WSR303 <63 (1:3), (f) 
DTZ–WSR303 >180 (1:4), (g) DTZ–WSR303 150–180 (1:4), (h) DTZ–WSR303 63–150 
(1:4), (i) DTZ–WSR303 <63 (1:4), (j) DTZ–WSR303 >180 (1:5),  (k) DTZ–WSR303 150–
180 (1:5), (l) DTZ–WSR303 63–150 (1:5) and (m) DTZ–WSR303 <63 (1:5).  
4.3.2 Particle size distribution  
The LS formulations and their counterpart PM powders showed the larger particle size 
fraction (>180 μm) had the widest particle size distribution, whereas smaller particles 
fractions (<63 μm) had the narrowest distribution i.e., the VMD has increased with increasing 
the particle size faction ranging from (<63 μm to >180 μm) irrespective of their 
drug:Polyox
TM
 ratio used (Table 4.2). This indicates that both the LS formulations and their 
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counterparts PMs powders fell between the nominal sieve sizes, suggesting that the applied 
sieving process was satisfactorily efficient. On the other hand, the mean particle size of both 
the LS formulation was found to be decreasing with an increase in the concentration of 
drug:Polyox
TM
 ratio in the case of smaller particle fraction (<63 μm) (Table 4.2).  
4.3.3 Powder bulk properties 
The bulk densities and tapped densities of both PM and LS formulation powders showed 
increasing trends with increasing particles size fraction regardless of drug:Polyox
TM
 ratio 
(Table 4.1). This indicated that the cohesivity of both PM and LS formulation powders 
increased with decreasing Polyox
TM
 particle size fraction. The CI values obtained for both PM 
powders and LS formulation also showed decreasing trends with decreasing particles size 
fraction (Table 4.1), indicating better flow properties for the formulations containing smaller 
particle size distribution than those formulations containing larger particle size distribution in 
the case of higher concentration. Even though all formulations had CI value higher than 25% 
confirming to have poor flow properties as indicated in (Table 4.1). Certainly, the major 
influence in powder flowability is possibly due to the nature and extent of interparticle forces. 
The high viscosity of non–volatile solvent (PS 80) could be responsible for poorer flow 
properties of LS formulations when compared to their PMs powders which increases the 
cohesive properties of the LS powders. The CI value of LS formulations at smaller particles 
size of Polyox
TM
 decreased as the Polyox
TM
 concentration increased (Table 4.1). This 
indicates that powders containing (1:5) higher concentration have better flow properties than 
those formulations with lower concentration (1:3 and 1:4). The same trend is demonstrated 
using PMs Powders. 
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Table 4.1: Bulk density, tap density and Carr’s index (CI) (mean ± SD, n = 5) for DTZ–
Polyox
TM
 liquisolid (LS) formulation powders and their physical mixture (PM) counterparts. 
 
 
4.3.4 Hardness 
The hardness of both PM and LS tablets showed increasing trends with both decreasing 
Polyox
TM
 particle size and increasing drug:Polyox
TM
 ratio (Figure 4.3a and 4.3b). For 
example, the hardness of LS tablet containing DTZ:Polyox
TM
 at a ratio of 1 : 5 (w:w) 
increased from 14.2 N to 31.6 N when the mean particle size of Polyox
TM
 decreased from 245 
μm to 84.7 μm (Table 4.2). The results are in agreement with those published by (Shojaee et 
al., 2015) for THP matrices. The hardness of THP‒PolyoxTM matrices decreased from 52.0 N 
to 45.0 N as the Polyox
TM
 particle size fraction increased from (20 to 45) μm to (180 to 425) 
μm. This could be due to a difference in the surface area of particles available for bonding. 
Smaller particles show a higher ratio of surface/volume compared to larger particles, resulting 
Product Particle size Bulk density (g/cm
3
) 
      PM                    LS 
Tapped density (g/cm
3
) 
     PM                    LS 
CI (%) 
      PM                   LS 
DTZ-WSR303 (1:3)   <63 0.36 ± 0.00 0.36 ± 0.01 0.53 ± 0.03 0.49 ± 0.01 32.0 ± 4.5 31.8 ± 1.6 
DTZ-WSR303 (1:3)  63–150 0.41 ± 0.00 0.42 ± 0.00 0.60 ± 0.01 0.56 ± 0.01 31.8 ± 0.4 23.8 ± 0.7 
DTZ-WSR303 (1:3)  150–180 0.44 ± 0.01 0.44 ± 0.00 0.61 ± 0.01 0.64 ± 0.00 29.0 ± 1.0 31.4 ± 0.5 
DTZ-WSR303 (1:3)  >180 0.48 ± 0.01 0.48 ± 0.00 0.64 ± 0.00 0.67 ± 0.00 25.0 ± 1.0 25.2 ± 1.1 
DTZ-WSR303 (1:4)  <63 0.37 ± 0.00 0.36 ± 0.01 0.52 ± 0.00 0.49 ± 0.01 30.4 ± 1.3 29.8 ± 3.7 
DTZ-WSR303 (1:4)  63–150 0.42 ± 0.01 0.41 ± 0.00 0.57 ± 0.01 0.55 ± 0.01 26.8 ± 0.8 25.4 ± 1.3 
DTZ-WSR303 (1:4)  150–180 0.44 ± 0.00 0.45 ± 0.00 0.62 ± 0.01 0.62 ± 0.00 29.8 ± 1.1 28.4 ± 0.9 
DTZ-WSR303 (1:4)  >180 0.47 ± 0.01 0.47 ± 0.01 0.64 ± 0.01 0.63 ± 0.01 26.8 ± 0.8 25.4 ± 1.6 
DTZ-WSR303 (1:5)  <63 0.44 ± 0.00 0.37 ± 0.00 0.62 ± 0.00 0.52 ± 0.00 29.7 ± 0.5 28.0 ± 0.02 
DTZ-WSR303 (1:5)  63–150 0.46 ± 0.01 0.41 ± 0.00 0.59 ± 0.01 0.57 ± 0.01 30.8 ± 1.1 30.0 ± 1.8 
DTZ-WSR303 (1:5)  150–180 0.47 ± 0.01 0.45 ± 0.00 0.66 ± 0.01 0.63 ± 0.01 32.2 ± 1.8 31.8 ± 1.6 
DTZ-WSR303 (1:5)  >180 0.49 ± 0.00 0.47 ± 0.02 0.70 ± 0.00 0.68 ± 0.03 34.8 ± 0.8 33.2 ± 1.1 
115 
 
in an increase in the number of contact points between particles and thus better bounding. PM 
tablets recorded higher hardness values in comparison to their LS formulation. This was due 
to the presence of the polysorbate 80 in the LS tablets which hinder the formation of the 
interparticle bonds that are the main reason for the higher hardness obtained in PM tablets. 
Khanfar et al., 2014, also reported similar conclusion, where all LS tablets showed weaker 
hardness than their counterpart conventional tablets. A trend of reasonably increasing 
hardness was also observed from 1:3 to 1:5 DTZ:Polyox
TM
 ratio of the resultant tablets 
(Figure 4.3a and 4.3b). For example, in the case of Polyox
TM
 with the smallest particle size 
fraction (<63 μm), the hardness of LS tablets increased from 10.1N to 30.6N with increasing 
DTZ:Polyox
TM
 ratio from 1:3 to 1:5 (Figure 4.3b). This could be attributed to a relatively 
higher concentration of Polyox
TM
, and therefore less DTZ particles, in the formulations that 
give more available bonding place beside physically combined polymer chains. In comparison 
to their PM formulation tablets, LS tablets also demonstrated lower hardness regardless their 
drug to polyox
TM
 ratio used.  
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Figure 4. 3: Hardness of DTZ from (a) physical mixture (PM) and (b) liquisolid (LS) matrix 
tablets containing various particle size distributions and ratio of Polyox
TM
. 
 Drug release studies 4.4
4.4.1.1 Effect of PolyoxTM particle size faction 
The effect of four different particle size fractions of Polyox
TM
 on the release rate of DTZ from 
both LS and PM tablets matrices were investigated. The results showed that all formulations 
enabled prolonged drug release irrespective of the Polyox
TM
 particle size fraction used 
(Figures 4.4a–4.4f). The release of DTZ from LS tablets showed mostly decreasing trends 
with decreasing Polyox
TM
 particle size distribution. This can be explained as, for the same 
quantity of polymer, a decrease of polymer particle size statistically increased the number of 
particles and therefore increased the number of contact points available for binding of the 
swelling particle. This would support the structure of a continuous gel layer that would delay 
drug release, as well as hinder more water penetrating into the tablet core. Additionally, a 
smaller polymer particle size distribution would provide a lower pressure differential 
expansion on swelling when related to a larger particle. Therefore, the smaller polymer 
particles were less liable to cause disintegration of the matrix tablets compared to larger 
particles. The above effects explain the lower release rate with decreasing Polyox
TM
 particle 
size. This was in complete agreement with the findings obtained by (Velasco et al., 1999; 
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Campos-Aldrete and Villafuete-Robles, 1997 and Mitchell et al., 1993). They reported that 
the effect of particle size on the release rate of a drug from tablet matrices showed that the 
dissolution rate generally decreased as the particle size distribution decreased from larger 
particle to smaller ones. The tablets containing smaller particle size fractions have greater 
surface area related to similar weights of fractions with a larger particle size fraction. This 
larger surface area enables for better polymer–water contact thereby improving the overall 
rate by which absolute polymer hydration occur (Cahyadi et al., 2011). At 1:3 and 1:4 
drug:Polyox
TM
 (w:w) ratios, and regardless of Polyox
TM
 particle size distribution, LS 
formulations produced statistically similar release profiles compared to conventional 
formulation tablets (Figure 4.4a–4.4e). From the above findings, particle size faction is known 
as an important variable. Decreasing Polyox
TM
 ratio to 1:3 and 1:4, exert similarities for all 
Polyox
TM
 particle size faction on DTZ release profile. This was supported by similarity factor 
results where f2 values for Polyox
TM
 particle size are greater than 50 which indicate that the 
dissolution profiles were similar. The influence of Polyox
TM
 particle size was significantly 
reduced when the Polyox
TM
 ratio increased to 1:5. The release profiles shown in Figure 4.4 
can be correlated with the hardness (Figure 4.3). Comparing Figure 4.4 and Figure 4.3 shows 
that there should be a direct relationship between the hardness and drug release. However, LS 
formulation tablets produced significantly slower release profiles compared to conventional 
formulation tablets in the case of higher concentration of drug:Polyox
TM
 ratio 1:5 (w:w) 
(f2<50). This indicated that the performance of Polyox
TM
 as a retardant agent in LS tablets is 
better than it is in the PM compacts. The results were also supported by the dissolution 
parameters that showed LS compacts to have lower DEs. For instance, the DE value of 
fractions from (<63 μm to >180 μm) was (19.4% ± 3.4 to 36.2% ± 0.2) compared to the PM 
compacts (DE = 27.0% ± 1.4 to 39.0% ± 0.5). Similar conclusions could be drawn when 
considering MDT values (Table 4.2). An interesting trend was obtained when plotting the DE 
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of DTZ obtained from PM and LS formulations against the Polyox
TM 
particle size faction. DE 
increased with increasing Polyox
TM 
particle size faction regardless of the drug to Polyox
TM
 
ratio used (Figure 4.5). This trend indicated that the ability of PM and LS formulations to 
produce slower drug release with decreasing Polyox
TM
 particle size faction.  
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Figure 4.4: Physical mixture (PM) and liquisolid (LS) matrix containing Polyoxes at different 
DTZ:Polyox
TM
 concentration, i.e. (a and b) 1:3, (c and d) 1:4, (e and f) 1:5 (w:w).  
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Figure 4.5: Dissolution efficiency (DE, %) of diltiazem HCl (DTZ) of liquisolid (LS) and 
(PM) formulations in relation to Polyox
TM 
particle size fraction. 
 
4.4.1.2 Effect of PolyoxTM concentration 
Four various particle size fractions of Polyox
TM
 were chosen to investigate the influence of 
Polyox
TM
 concentration (1:3, 1:4 and 1:5 w:w) on DTZ release. The results obtained from 
both LS formulations and PM tablets showed the release rate of DTZ became slower with 
increasing the concentration of drug:Polyox
TM
 ratio (from 1:3 to 1:5 w:w) i.e., the dissolution 
rate of DTZ to decrease with increasing the concentration of drug:Polyox
TM
 ratio, regardless 
of their Polyox
TM
 particle size fractions used, which can be attributed to the greater binding of 
the drug with the Polyox
TM
 in the case of higher concentration (Figure 4.6). This may be 
explained as the concentration of the polymer increased, tablet matrix resulted in rapid 
hydration and formation of a stable gel–like structure of high viscosity and low–swelling 
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degree that acted as a barrier for the penetration medium hence retarding the diffusion of DTZ 
from the swollen Polyox
TM
. This was in complete agreement to the findings obtained by 
(Ebube et al., 1997; Ford et al., 1987b; Nellore, 1998; Perez-Marcos et al., 1995). Such 
decrease in drug release rate is not statistically different in the case of (>180 µm and 150 µm 
– 180 µm) larger PolyoxTM particle size faction (Figure 4.6a–4.6f). Statistical analysis 
confirmed that DTZ release profiles obtained from LS and PM tablets containing (1:3 to 1:5 
w/w) drug:Polyox
TM
 ratio was significantly different (f2<50), in the case of (<63 μm) smaller 
particle size fraction. The swelling studies (i.e. water uptake) of both LS and PM tablets 
decrease as the concentration (from 1:3 to 1:5 w:w) of drug (DTZ) to Polyox
TM
 ratio increased 
when smaller particle size was used (Figure 4.7). This may be attributed to the slow erosion of 
the gelled layer from the tablets containing higher ratio (1:5) Polyox
TM
. In general, slower 
drug releases were obtained in LS tablets in comparison to the PMs tablets (Figure 4.6a–4.6h).  
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Figure 4.6: Physical mixture (PM) and liquisolid (LS) matrix containing Polyoxes 
concentration at different Polyox
TM
 particles size distribution, i.e. (a and b) >180μm; (c and d) 
150 to180 μm; (e and f) 63 to150 μm and  (g and h) < 63μm respectively. 
123 
 
When plotting the DE of DTZ from both the LS and PM formulation tablets against their 
Polyox
TM 
ratio, the DE decreased as the drug to Polyox
TM 
ratio increased regardless of their 
Polyox
TM
 particle size faction used. These indicate the ability of Polyox
TM
 with higher ratio to 
produce slower drug release than those matrices containing Polyox
TM
 with lower ratio (Figure 
4.8). For instance, at smaller particle size (<63), the DE value of 1.3 DTZ:Polyox
TM
 ratio was 
(36.2 ± 0.90) whereas this value decreased to (19.4 ± 3.40) for matrices with DTZ:Polyox
TM
 
ratio (1:5 w:w). Similar consideration was obtained as seen with the PM tablets (Table 4.2). 
DEs value is consistent with dissolution behaviours confirming that the drug release rate from 
all the particle size used is slower in LS formulation tablets than their counterparts PM tablets 
(Figure 4.8).  Polyox
TM
 ratio was known to be very useful due to its effect on the influences of 
Polyox
TM
 particle size distribution. It was found that retaining Polyox
TM
 ratio 1:5 was helpful 
in developing a robust ER matrices system. 
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Table 4.2: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR), VMD and in vitro release kinetic 
parameters; n value of diltiazem HCl obtained for liquisolid (LS) formulations containing various particle size and ratio in comparison to their 
physical mixture (PM) counterparts. The results are expressed as the mean ± SD. 
Formulation (s) Particle 
size 
DE (%) 
      PM          LS 
MDT (min
-1
) 
     PM                LS 
MDR (min
-1
) 
      PM       LS 
VMD (μm) 
       PM          LS 
n value 
  PM         LS 
DTZ–WSR303 (1:3) <63 42.9 ± 1.10 36.2 ± 0.90 170 ± 12.0 185 ± 1.63 0.17 ± 0.01 0.17 ± 0.00 61.3 ± 25.0 99.7 ± 11.3 0.633 0.634 
DTZ–WSR303 (1:3) 63–150 43.4 ± 3.42 38.8 ± 1.39 174 ± 8.17 165 ± 15.2 0.19 ± 0.01 0.20 ± 0.04 98.2 ± 6.52 110 ± 17.4 0.650 0.704 
DTZ–WSR303 (1:3) 150–180 50.1 ± 3.70 42.2 ± 0.03 158 ± 40.6 178 ± 1.83 0.20 ± 0.03 0.18 ± 0.01 113 ± 2.31 145 ± 3.46 0.735 0.709 
DTZ–WSR303 (1:3) >180 53.8 ± 0.57 44.1 ± 2.45 125 ± 2.91 166 ± 10.1 0.25 ± 0.00 0.24 ± 0.01 189 ± 4.62 253 ± 4.73 0.779 0.581 
DTZ–WSR303 (1:4) <63 33.2 ± 0.66 27.7 ± 0.92 188 ± 4.13 189 ± 6.14 0.14 ± 0.01 0.11± 0.00 95.8 ± 9.99 90.6 ± 4.37 0.635 0.658 
DTZ–WSR303 (1:4) 63–150 39.2 ± 1.40 29.2 ± 2.10 190 ± 17.7 183 ± 0.23 0.13 ± 0.06 0.12 ± 0.01 85.1 ± 3.34 121 ± 5.57 0.747 0.646 
DTZ–WSR303 (1:4) 150–180 41.1 ± 2.09 31.5 ± 0.50 191 ± 0.60 176 ± 7.50 0.14 ± 0.01 0.17 ± 0.02 169 ± 85.1 151 ± 0.58 0.696 0.670 
DTZ–WSR303 (1:4) >180 48.3 ±2.39 39.6 ± 0.23 176 ± 24.2 170 ± 0.78 0.18 ± 0.02 0.15 ± 0.00 204 ± 7.21 262 ± 29.6 0.686 0.648 
DTZ–WSR303 (1:5) <63 27.0 ± 1.39 19.4 ± 3.40 206 ± 1.58 197 ± 5.05 0.16 ± 0.01 0.12 ± 0.01 57.1 ± 2.04  84.7 ± 6.2 0.709 0.781 
DTZ–WSR303 (1:5) 63–150 33.1 ± 1.60 25.0 ± 0.33 195 ± 5.02 206 ± 23.6 0.14 ± 0.00 0.11 ± 0.02 89.7 ± 5.04 118 ± 5.13 0.703 0.780 
DTZ–WSR303 (1:5) 150–180 37.0 ± 0.48 28.2 ± 0.60 191 ± 0.45 183 ± 1.32 0.15 ± 0.00 0.14 ± 0.01 125 ± 0.58 147 ± 2.65 0.676 0.696 
DTZ–WSR303 (1:5) >180 39.0 ± 0.50 36.2 ± 0.22 193 ± 1.30 178 ± 2.14 0.16 ± 0.01 0.12 ± 0.01 187 ± 2.08 245 ± 4.36 0.735 0.635 
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Figure 4.7: Percent swelling of physical mixture (PM) and liquisolid (LS) formulation tablets 
containing Polyoxes concentration at different Polyox
TM
 particles size faction i.e. (a and b) 
>180 and (c and d) <63. 
 
 
 
 
 
 
126 
 
 
 
 
 
Figure 4.8: Dissolution efficiency (DE, %) of diltiazem HCl (DTZ) of liquisolid (LS) and 
(PM) formulations in relation to Polyox
TM
 concentration. 
 
The mechanism of drug release from the matrix tablets was analysed and the dissolution data 
were fitted to Korsmeyer-Peppas kinetic models (Table 4.2). In this study, the drug release 
from both the LS and their PMs tablet from various particle sizes were fitted into Korsmeyer-
Peppas equation which indicates the combined influence of diffusion and erosion mechanisms 
for drug release (Korsmeyer, et al., 1983). The n values from LS formulations varied between 
0.581 and 0.781, corresponding to an anomalous (non-Fickian) diffusion mechanism, which 
suggests that diffusion of the drug and erosion (polymer matrix relaxation) both contribute to 
the overall drug release mechanisms. It was also noticed that the n values obtained from LS 
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formulations increase from (0.635 to 0.781) as DTZ:Polyox
TM
 concentration increased from 
(1:3 to 1:5 w:w), indicating a trend of gradual drug release in the case of smaller Polyox
TM
 
particle size (<63). A similar conclusion was shown in the case of PM tablets. 
 Conclusion  4.5
The results in this study showed that LS formulation and their counterpart PM with smaller 
particle size fractions of Polyox
TM 
(<63 μm) had a slowest DTZ release behaviour than the 
larger particles fraction (150–180 μm). Decreasing PolyoxTM ratio to 1:3 and 1:4, exert 
similarities for all Polyox
TM
 particle size faction on DTZ release profile. The influence of 
Polyox
TM
 particle size was significantly reduced when the Polyox
TM
 ratio increased to 1:5. 
The results also showed significant retardation properties of drug release with high 
concentration of drug:Polyox
TM
 (1:5) when compared to lower concentration (1:3) in the case 
of small particles size faction used. The hardness of DTZ tablets from both the LS 
formulation and their counterpart PM were also shown an increasing trend with decreasing 
Polyox
TM 
particle size and increasing concentration. Therefore, smaller Polyox
TM 
particle size 
faction and higher concentration of DTZ:Polyox
TM
 is an important formulation factor that 
should be optimised to improve the desirability of sustained release formulations prepared 
using the LS technique. LS tablets with better mechanical and slower drug release properties 
can be produced using smaller size fractions of Polyox
TM
. In conclusion, concentration and 
particle size distribution of Polyox
TM
 are important variables in determining the release of a 
highly soluble drug from Polyox
TM–based LS formulations. 
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 Introduction 5.1
Colloidal silicon dioxide (AEROSIL
®
) is broadly used as glidants in the production of 
capsules, tablets and powders (Müller et al., 2008). As its agglomerates, as well as its primary 
particles, are very small, they are completely adsorbed at surfaces of larger particles, e.g., 
corn starch (Meyer and Zimmermann, 2004). Though, due to the very fine particles that 
possess a strong tendency to produce segregation, agglomerates following simple mixing with 
different excipients can also transpire because of variations in the density. Therefore, proper 
dispersion of the glidants is a very relevant concern for achieving flowability and uniform 
coating improvement (Yang et al., 2005). AEROSIL
®
 was introduced in both LS formulations 
and PM as a coating material to improve the flow of model drugs such as Ketoprofen (Deore 
et al., 2009) Due to its large surface area, high porosity, and unique adsorption properties, 
AEROSIL
®
 has also been successfully used as a dispersing agent to increase the dissolution 
rate of sparingly soluble drug, Polythiazide (Sheth and Jarowski, 1990). AEROSIL® is one 
of the commercially accessible coating material in pharmaceutical production which is formed 
by high–temperature hydrolysis of silicon tetrachloride in an oxygen gas flame. It consists 
completely of a highly amorphous, dispersed and submicroscopic silica whose features can be 
controlled by suitable reaction states and surface changes (Morefield and Seyer, 2003). These 
changes do not affect the silica content or amorphous form. However, surface areas, 
hydrophilic nature, particle size and densities are influenced. Siloxane and silanol groups are 
generally situated on the surface of AEROSIL
®
 particles and the latter is responsible for the 
hydrophilic behaviour unless they are bound to proper hydrophobic compounds. In particular, 
hydrophilic AEROSIL
®
  shown by a number which refers to the specific surface area (m
2
/g), 
for example, AEROSIL
®
 X50, AEROSIL
® 
130, AEROSIL
® 
150, AEROSIL
®
 200, etc. 
Nevertheless, the influence of SiO2 commercial grade on the mechanical and drug release 
properties of LS formulations has not been reported previously. The aim of this research was 
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therefore to investigate the influence of various AEROSIL
®
 grades, namely AEROSIL
®
 
OX50 (hydrophilic, 35–65 m2/g), AEROSIL® 130 (hydrophilic, 105–155 m2/g), AEROSIL® 
200 (hydrophilic, 175–225 m2/g), and AEROSIL®R812 (hydrophobic, 230–290 m2/g), on the 
mechanical and drug release properties of LS Polyox
TM–based formulations containing a 
model high soluble drug, DTZ, in comparison to their PM counterparts. 
 Formulation 5.2
The solid phase consisted of Polyox
TM
 powder (6 g), each grade of AEROSIL
® 
contain (0.6 
g), and lactose (5.2 g) in the case of PM formulations and 6.0 g in the case of LS 
formulations), whereas the liquid phase consisted of commercial DTZ powder dispersed in 
polysorbate 80 (PS 80) (60 ºC, 200 rpm) at a drug:solvent ratio of 1:1 (w:w). Detailed of 
formulation process was given in section 2.5. 
Accurately weighed samples of each liquisolid (750 mg) and PM (650 mg) formulation were 
separately weighed and then compressed on 8 mm punch and die using a manual tableting 
machine at a fixed pressure of 2000 psi. 
 Results and discussion 5.3
5.3.1 Solid state 
This study was carried out to investigate if there is any chemical interaction between pure 
DTZ and different AEROSIL
® 
surface area in both the LS formulations and PM powders. No 
significant changes were also observed in the FT–IR spectra of LS formulations in 
comparison to their PM counterparts (Figure 5.1). Such observations indicated that virtually 
complete recrystallization of DTZ occurred during the preparation of liquisolid formulations. 
The results also ruled out the existence of significant drug-excipient interaction within both 
LS and PM (Figure 5.1). The PXRD patterns of commercial DTZ, LS formulations and PM 
powders are shown in (Figure 5.2). The diffraction pattern of the commercial DTZ 
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demonstrates that it has a very crystalline solid state in nature, with sharp intensive peaks 
throughout its pattern. The XRD pattern of AEROSIL
®
 alone appears to be amorphous which 
tend to agree with Morefield and Seyer, 2003 as state in the introduction above. The same 
peaks were observed from both LS formulations and PM powders, regardless of their surface 
area (Figure 5.2).   
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Figure 5.1: FTIR patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various grades or surface area (i.e. (a) Pure DTZ, (b) Polysorbate 80, (c) Polyox
TM
, 
(d) Pure lactose, (e)Pure AEROSIL
®
OX50, (f) Pure AEROSIL
®
130, (g) Pure AEROSIL
®
 
200, (h) Pure AEROSIL
®
 R812), (i) AEROSIL
®
OX50, (j) AEROSIL
®
130, (k) AEROSIL
®
 
200, (l) AEROSIL
®
 R812). 
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Figure 5.2: PXRD patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various grades or Polyox
TM
 (a) Pure DTZ, (b)Pure AEROSIL
®
OX50, (c) Pure 
AEROSIL
®
130, (d) Pure AEROSIL
®
 R812, (e) Pure AEROSIL
®
200), (f) AEROSIL
® 
OX50, 
(g) AEROSIL
® 
130, (h) AEROSIL
® 
200), (i) AEROSIL
®
 R812. 
5.3.2 Particle size distribution 
The effect of four different AEROSIL
®
 surface areas on the PSD from both LS formulations 
and PM powders was investigated. The results showed an increase in the AEROSIL® grade 
containing different surface areas from (65 m
2
/g to 290 m
2
/g) generally leads to a reduction in 
PSD. The widening of the particle size distribution was regarded as an indication of particle 
breakdown. Formulations containing AEROSIL
®
 OX50 within both PM and LS formulations 
had the lowest VMD value than those formulations containing AEROSIL
®
 130, 200 and R812 
(Table 5.1).  This may be caused by the smaller particle size which possessed high cohesion 
force leading to aggregation. LS formulations produced significantly higher PSDs compared 
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to their PM counterparts. SEM depicted pictures showed less spherical and mostly irregular 
particles in PM powders which interlock with each other increasing the cohesive strength and 
hence friction, whereas the LS formulations have mostly spherical powders which generally 
flow better than PM powders (Figure 5.3). Spherical particles provide fewer contact points 
between neighbouring particles as compared to irregular particles, therefore, spherical 
particles cause less friction and hence assist in flow indicating that the flowability improves as 
the particles become more spherical. In general AEROSIL
® 
R812 (hydrophobic, 230–290 
m
2
/g) were found to be spherical in both the LS formulations and PM powders (Figure 5.3).  
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Table 5.1: Particle size distribution (i.e. particle size at 10% (d10%), 50% (d50%), 90% (d90%), volume mean diameter (VMD), and span; mean ± 
SD, n = 3) of DTZ–PolyoxTM containing various AEROSIL® surface area from liquisolid (LS) formulation powders in comparison to  their 
physical mixture (PM) counterparts. 
 
 
 
Product (s) Surface 
area (m
2
/g 
d10% d50% d90% VMD (μm) Span 
         PM            LS          PM             LS             PM             LS           PM             LS        PM                 LS 
AEROSIL
®
 50 
 
65 10.9 ± 0.2 56.1 ± 1.4 42.2 ± 0.9 40.0 ± 0.3 135.0 ± 8.8 94.5 ± 1.5 57.1 ± 2.0 84.7 ± 6.2 1.6 ± 0.2 2.2 ± 0.1 
AEROSIL
®
 130 
 
155 53.3 ± 6.1 393.0 ± 43.0 650.0 ± 39.5 
 
725.7 ± 0.3 
 
1126.7 ± 25.2 
 
1200.0 ± 96.4 
 
641.0 ± 24.2 
 
750.3 ± 65.2 
 
1.2 ± 0.0 
 
1.7 ± 0.1 
AEROSIL
®
 200 
 
225 40.8 ± 13.2 322.0 ± 21.1 577.3 ± 29.4 
 
639.3 ±  26.3 
 
1083.3 ±  37.9 
 
1083.3 ± 34.0 
 
560.7 ± 42.5 
 
664.7 ± 31.2 
 
1.1 ± 0.2 
 
1.6 ± 0.1 
AEROSIL
®
 R812 290 62.2 ± 12.7 51.4 ± 27.5 564.7 ± 24.9 
 
710.6 ± 59.5 
 
1069.7 ± 33.1 
 
1453.3 ± 43.0 
 
564.7 ± 46.3 
 
734.7 ± 90.2 
 
2.0 ± 0.1 
 
1.8 ± 0.0 
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5.3.3 Powder density 
The PM formulation tablets produced lower bulk properties and higher Carr’s Index (CI) 
values than LS powders (Table 5.1). These indicate that PM powders have fewer average 
points of physical interaction among particles compared to LS formulations. The reason for 
this behaviour could be due to mechanical interlocking between adjacent particles found in 
PM powders than LS formulations. The CI values from PM and LS formulations showed 
decreasing trend with an increase in their AEROSIL
®
 surface areas which indicate powders 
containing AEROSIL
®
 grade with higher surface area have better and free–flowing behaviour 
than those containing lower surface area whereas LS formulations produced less than 25 CI 
value (Table 5.1), indicating acceptable values. In comparison to the LS powders, PM 
formulations produced higher CI values which indicate they have poorer flow properties 
compared to LS formulations. Additionally, matrices containing AEROSIL
® 
R812 
(hydrophobic, 290 m
2
/g) also shown acceptable CI values in both the LS powder and PM 
formulations (Table 5.1).  
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Figure 5.3: SEM of diltiazem HCl (DTZ) from physical mixture (PM) and liquisolid (LS) 
formulations containing various grades or surface area (i.e. AEROSIL
® 
OX50, AEROSIL
® 
130, AEROSIL
®
 200 and AEROSIL
®
 R812). 
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Table 5.2: Bulk density, tap density, Carr’s index (CI) and tensile strength (mean ± SD, n = 5) for DTZ– AEROSIL® Surface area liquisolid 
(LS) formulation powders and their physical mixture (PM) counterparts. 
 
Product (s) Surface area 
(m2/g)  
Bulk density (g/cm
3
) Tap density (g/cm
3
) CI (%) Tensile strength (TS) 
  PM LS PM LS PM LS PM LS 
AEROSIL
®
50 65 0.44 ± 0.00 0.37 ± 0.00 0.62 ± 0.00 0.52 ± 0.00 29.7 ± 0.5 28.0 ± 0.02 8.95± 0.3 1.02 ± 0.1 
AEROSIL
®
130 155 0.32 ± 0.01 0.35 ± 0.00 0.45 ± 0.00 0.49 ± 0.01 28.5 ± 1.0 24.4 ± 0.57 10.3 ± 0.2 1.92 ± 0.1 
AEROSIL
®
200 225 0.26 ± 0.00 0.33 ± 0.00 0.40 ± 0.00 0.45 ± 0.01 24.6 ± 0.3 23.5 ± 1.00  13.0 ± 1.6  2.83 ± 0.1 
AEROSIL
®
R812 290 0.35 ± 0.01 0.36 ± 0.00 0.50 ± 0.00 0.47 ± 0.00 24.5 ± 0.6 24.0 ± 0.00   8.98 ± 0.5 2.34 ± 0.3 
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5.3.4 Tensile strength 
The TS values of tablets made by various surface area of AEROSIL
®
 in LS produced weaker 
tablets than those prepared by PM formulations (Table 5.2). This could also be because the 
solvent incorporated in LS formulations exerts a plasticizing effect on Polyox
TM
, thus 
decreases the intermolecular bonds between Polyox
TM
 chains. Interestingly, the TS of LS 
tablets and their counterparts PM formulations showed increasing trend with an increase in 
the AEROSIL
®
 surface area (ranging from 65 m
2
/g to 225 m
2
/g) (Table 5.2). For example, 
the TS of LS formulations increased from (1.02 MPa to 2.83 MPa), as the surface area of 
AEROSIL
®
 increased from (65 m
2
/g to 290 m
2
/g). The results obtained were attributed to an 
increase in contact points between particles with the increase in the surface area of the 
coating material resulting in an increased interparticle bounding. A grade of AEROSIL
®
 200 
shows a higher ratio of surface/volume compared to a lower surface area of AEROSIL
®
 grade 
(AEROSIL
®
 X50, AEROSIL
®
 130). Although AEROSIL
®
 R812 has higher surface areas 
than AEROSIL
®
 200 (Table 5.2), both the LS and PM tablets containing AEROSIL
®
R812 
(hydrophobic, 290 m
2
/g) showed lower TS values 2.34 MPa and 8.98 MPa than the TS values 
(2.83 MPa and 13.0 MPa) of AEROSIL
®
200 (hydrophilic, 225 m
2
/g). This could be due to 
the lubricating effect that AEROSIL
®
 R812 could exert due to its hydrophobic properties, 
thereby interrupting interparticulate bonding with hydrophilic DTZ, PS 80 and Polyox
TM
 
particles. It could also be explained that the affinity of hydrophobic grade of silica–DTZ is 
weaker compared to that of hydrophilic silica–DTZ. 
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5.3.5 Drug release studies 
To evaluate the effect of different AEROSIL
®
 surface area on the retardation of model highly 
soluble drug, DTZ, four different AEROSIL
®
 surface area (that is 65 m
2
/g), AEROSIL
®
130 
(hydrophilic, 155 m
2
/g), AEROSIL
®
200 (hydrophilic, 225 m
2
/g) and AEROSIL
®
R812 
(hydrophobic, 290 m
2
/g) were investigated. It can be seen that DTZ containing higher surface 
area (225 m
2
/g) showed slower release behaviour among the various grades used in both the 
LS and PM formulations, i.e. the dissolution pattern has decreased with increase in the 
surface area of AEROSIL
® 
powders from (65 m
2
/g to 290 m
2
/g). This could be due to the 
higher TS of the tablets containing AEROSIL
®
 particles with higher surface area compared to 
those prepared using AEROSIL
®
 particles having lower surface areas (Table 5.2). 
Additionally, AEROSIL
®
 particles with higher surface areas can afford higher viscosity and 
density of its gel–layer, acting as a barrier against drug release via diffusion due to its 
increased tortuosity from both the LS formulations and their counterpart PM tablets. 
However, the dissolution profiles of LS tablets containing (AEROSIL
® 
R812) showed 
different release behaviour than their PM tablets (Figure 5.4).  
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Figure 5.4: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from (a) physical 
mixture (PM) and (b) liquisolid (LS) formulations containing various grades or surface area 
(i.e. AEROSIL
® 
OX50, AEROSIL
® 
130, AEROSIL
® 
200 and AEROSIL
®
 R812,)  
 
This may be attributed to the decreased penetration of the dissolution media in the presence 
of the hydrophobic silica (AEROSIL
®
 R812), in the PM compact leading to reduced 
diffusion of the drug from the matrix. Drug release occurs by dissolution of the active 
ingredient through capillaries formed of interconnecting drug particle clusters and the pore 
network, when a matrix is composed of water–soluble drug and a water–insoluble polymer 
(Shimpi et al., 2004). This is supported by dissolution parameters that pointed out in both LS 
and PM tablets containing AEROSIL
® 
grades with higher surface area to give lower DEs 
higher MDTs and MDRs in comparison to those with lower surface area (Table 5.3).  
However, LS tablets showed slower release patterns compared to PM tablets regardless of the 
hydrophilic AEROSIL
®
 surface area used (Table 5.3). It could be assumed that the solvent 
penetrates the free spaces between the macromolecular chains of Polyox
TM
, and the Polyox
TM
 
chains become flexible, enhancing the thickness of the gel layer and allowing drug release 
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through the gels outer surface. This could also be described as water plasticising the 
Polyox
TM
 and transforming it from a glassy state to a rubbery state. 
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Table 5.3: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR) and in vitro release kinetic parameters; n 
value of diltiazem HCl obtained for liquisolid (LS) formulations containing various grades AEROSIL
®
 Surface area in comparison to their 
physical mixture (PM) counterparts. The results are expressed as the mean ± SD. 
Product (s) Surface area      DE (%) MDT (min
-1
) MDR (min
-1
) n value 
      PM              LS      PM         LS        PM          LS  PM           LS 
AEROSIL
® 
50 65 27.0 ± 1.39 19.4 ± 3.40 206 ± 1.58 197 ± 5.05 0.16 ± 0.01 0.12 ± 0.01 0.709 
 
0.781 
AEROSIL
® 
130 155 25.0 ± 0.14 16.3 ± 1.04 202 ± 0.02 
 
189 ± 4.68 
 
0.10 ± 0.05 
 
0.08 ± 0.02 
 
0.696 
 
0.724 
AEROSIL
® 
200 225 19.6 ± 0.07 14.4 ± 0.78 205 ± 4.64 
 
210 ± 4.87 
 
0.08 ± 0.01 
 
0.05 ± 0.01 
 
0.740 
 
0.821 
AEROSIL
®
 R812 290 21.5 ± 4.07 24.5 ± 1.01 203 ± 0.10 
 
201 ± 3.45 
 
0.08 ± 0.02 
 
0.09 ± 0.01 
 
0.705 
 
0.741 
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This is further supported by the dissolution parameters that confirmed the LS tablets 
containing all AEROSIL
®
 grade to produce lower DEs irrespective of their surface area used 
(Table 5.3). In order to investigate the mechanism of drug release from LS tablets and their 
PM tablets, all release data were fitted into Peppas equation (Table 5.3). Regardless of 
AEROSIL
®
 surface area, the n values obtained from LS tablets showed higher values than 
those from PM compacts (Table 5.3). The release rate of DTZ from all PM formulations and 
LS powders followed the anomalous transport mechanism (0.45> n> 0.89) regardless of their 
AEROSIL
®
 surface area (Table 5.3). 
 
 
Figure 5.5: Dissolution efficiency (DE, %) of diltiazem HCl (DTZ) of liquisolid (LS) and 
(PM) formulations in relation to surface area (m
2
/g). 
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 Conclusion  5.4
Based on this result, it could be concluded that AEROSIL
® 
200 (hydrophilic, 225 m
2
/g) 
satisfactorily decreased the drug release profile from both the LS and PM tablets. Among all 
the AEROSIL
® 
grades used in these formulations, AEROSIL
®
200 was found to be the best, at 
the same ratio compared to different AEROSIL
®
 surface area. As indicated by the release 
kinetics it could be concluded that the release method may transpire by diffusion and the 
mechanism of diffusion is anomalous. Polyox
TM–based LS tablets have a potential to produce 
zero–order release kinetics for a highly water–soluble drug, DTZ, although a careful selection 
of AEROSIL
®
 coating material grade is nevertheless vital to producing slower release pattern 
of LS tablets in comparison to conventional tablets. Being simple, the LS method should have 
general applicability to many highly water–soluble drug entities. Finally, AEROSIL® interacts 
with the other components of the formulations. Further work is therefore required to 
comprehensively explore LS technique as a robust and reliable method of retarding the release 
rate of highly soluble drugs. 
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 Introduction 6.1
Diluents can be applied in compact formulations to produce the desired optimum size when 
the drug produces a small percentage of the formula. The need of a compact to consolidate the 
drug and fillers is the need to improve the bulk volume and consequently the size of the 
compact in order to help the handling and administration of the compact formulation 
(Lotfipour et al., 2004). They can be used to change the rate of drug release and also increase 
the mechanical strength (i.e. flow and tabletting). Diluents should be non–hygroscopic, that 
have good biopharmaceutical properties (e.g., water-soluble or hydrophilic), cheap and have 
an acceptable taste (Turkoglu and Sakr, 2002). Soluble diluents (e.g. lactose), insoluble (e.g. 
DCP), or partially soluble diluents (e.g. partially pregelatinized starch) are usually attached to 
matrix formulations. In general, the inclusion of diluents in matrix formulations normally 
improves drug release rate regardless of drug solubility (Ford et al., 1987; Lotfipour et al., 
2004). Drug release rate is improved using soluble fillers by increasing the porosity of the 
path of the drug by stimulating water entrance and enhancing the wettability and through the 
formation of channels within the matrix (Miranda et al., 2007). This influences the production 
of more permeable (i.e. weaker) hydrated gel layer than that for insoluble excipients, leading 
to faster drug diffusion and enhanced erosion rate (Ford et al., 1987). Lactose is a common 
water-soluble diluent broadly applied in various sustained release formulations due to its 
versatility. Lactose is usually employed as filler in tablets and capsules and as a component in 
the dairy source products (Smyth and Hickey, 2005). The inclusion of lactose in most 
pharmaceutical formulations has been shown to result in faster drug release from Polyox
TM
. 
For example, El-Malah et al., (2006), showed the inclusion of lactose in the formulation to 
afford faster release rates of THP from Polyox
TM
. The incorporation of lactose has also been 
shown to increase the release rate of a poorly soluble drug, Methylparaben from hypromellose 
matrices (Tahara et al., 1995). Asaduzzaman et al., (2011), reported that addition of mannitol 
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in the formulation demonstrate slower dissolution rate of Ranolazine from Methocel K4M. 
Another investigation discovered evidence that the inclusion of mannitol in the release rate 
Ciprofloxacin HCl from hypromellose matrices shown to have retardation properties 
(Mortazavi et al., 2010).  
Mannitol is a white crystalline polyol commonly used in a pharmaceutical formulation that 
incorporated industrially by catalytic hydrogenation of glucose syrup or fructose. Mannitol is 
a non–hygroscopic ingredient, water–soluble and non-toxic which is widely employed in food 
and pharmaceutical preparations (Debord et al., 1987). They are generally recognized as safe 
registered ingredient and are applied in various dosage forms obtainable commercially. 
Mannitol has been used as an alternative carrier to lactose because due to its non–reducing 
effect, it has limited hygroscopic tendencies than some of the other fillers, provides a high 
sweet taste that proves that a dose has been successfully delivered, (Saint–Lorant et al., 2007). 
It has been reported that mannitol improves dissolution of carteolol HCl matrix from 
Eudragit
®
 RL as it forms pores within the dosage form matrix (Holgado et al., 1995). An 
investigation was carried by Jaipal et al., (2015), which shows the incorporation of mannitol 
from (HPMC 15K) retard the dissolution rate of Buspirone HCl. Hydrogenated vegetable oils 
(HVO) are achieved by catalytic hydrogenation of the unsaturated bonds with nickel. The 
method produces hydrophobic solids with a ‘waxy’ appearance, proper for controlled-release 
applications (Reitz and Kleinebudde, 2007). In this study, the incorporation of HVO has been 
shown to retard the release of highly soluble drug from calcium sulphate with a 4% drug 
loading within 24hrs (Martini et al., 2000). Sorbitol is also one of polyols commonly applied 
in the pharmaceutical formulation. Sorbitol has been used as a diluent in tablets because of its 
non–toxicity, cheap and has an acceptable taste (Ma et al., 2014). Enhanced release properties 
of sorbitol have been reported for dispersions of different drugs, including Nitrofurantoin (Ali 
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and Gorash, 1984), Prednisolone (Jachowicz, 1987) and Ofloxacin (Okonogi et al., 1997). In 
most of these cases, other carriers provided better effects. Interestingly, Nitrofurantoin gave 
better release from sorbitol than mannitol dispersions (the two sugars are isomers) (Ali and 
Gorash, 1984). Certainly, a dispersion of Prednisolone in sorbitol released the drug faster than 
all other carriers tested, including PEG, PVP, urea and mannitol (Jachowicz, 1987). However, 
the effects of diluent as a potential carrier in the release rate of a model soluble drug, DTZ, 
from LS matrices up to date have not been investigated. Although to best of our knowledge, 
there are no systematic studies to explore the influence of different diluent type used in LS 
matrix tablets to modulate drug release. Therefore, the influence of those diluents (i.e. 
sorbitol, mannitol, compressol
SM
, HVO and lactose) on the physicochemical, mechanical and 
drug release properties of LS Polyox
TM–based formulations containing a highly soluble model 
drug, DTZ, in comparison to their PM counterparts  were investigated. 
 Formulation 6.2
The solid phase consisted of Polyox
TM
 powder (6 g), AEROSIL
® 
OX contain (0.6 g), and 
each diluent type contain (5.2 g) in the case of PM formulations and 6.0 g in the case of LS 
formulations), whereas the liquid phase consisted of commercial DTZ powder dispersed in 
polysorbate 80 (PS 80) (60 ºC, 200 rpm) at a drug:solvent ratio of 1:1 (w:w). Details of the 
formulation process were given in section 2.5. Accurately weighed samples of each liquisolid 
(750 mg) and PM (650 mg) formulation were separately weighed and then compressed on 8 
mm punch and die using a manual tableting machine at a fixed pressure of 2000 psi. 
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 Results and discussion 6.3
6.3.1 Solid state 
The PXRD patterns and FT–IR spectra of LS formulations were investigated and compared to 
those obtained from the PM powders (Figure 6.1 and figure 6.2). LS formulations and PM 
powders indicated the absence of the characteristic band of the DTZ at 2387.93 cm
-1
 (amine 
HCl, N‒H stretching) (Figure 6.1). Such investigations proved that there was a notable 
disappearance in the solid state of the drug during the preparation of both LS and PM 
formulations. This was also reported by Abd et al., 2012 as seen in section 3.3.1. The XRD 
study revealed there is a slight reduction in the intensity of LS formulations in comparison to 
their PM powders as reported from previous Chapters.  
 
 
  
151 
 
 
 
Figure 6.1: FTIR patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing DTZ and various diluents (i.e. (a) Pure DTZ, (b) Pure Polyox
TM
, (c) Pure 
Polysorbate 80 (d) Pure Sorbitol, (d) Pure Mannitol, (e) Pure Compressol, (f) Pure HVO, (g) 
Pure Lactose, (h) Sorbitol, (i) Mannitol, (j) Compressol, (k) HVO and (i) Lactose. 
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Figure 6.2: PXRD patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various diluents (i.e. (a) Pure DTZ, (b) Pure Sorbitol, (c) Pure Mannitol, (d) Pure 
Compressol, (e) Pure HVO, (f) Pure Lactose, (g) Sorbitol, (h) Mannitol, (i) Compressol, (j) 
Lactose and (k) HVO 
6.3.2 Particle size distribution 
The particle size distribution from various diluent in both LS formulations and PM powders 
were measured and presented as depicted in Table 6.1. The calculated span values were 
highest for mannitol in both LS formulation and PM powder and lowest for compressol
SM 
in 
LS and HVO (1.9 ± 0.1) in PM (Table 6.1). Hence, mannitol demonstrated higher 
polydispersity than HVO, whose particle sizes were more closely centred on the median value 
of 123.7 μm, which was the highest median value obtained in the case of PM powder. LS 
formulations containing sorbitol showed higher VMDs than other formulations, whereas HVO 
demonstrated higher VMDs in the case of PM powders than the LS formulations (Table 6.1).  
All the LS formulations were found to have higher VMDs than their counterpart PM powders. 
For example, the VMD in LS formulations ranged from 84.7 ± 6.2 μm to 259.0 ± 2.6 μm 
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whereas the range for the PM powders was 57.1 ± 2.0 μm to 138.3 ± 1.2 μm due to the 
occurrence of aggregated particles. SEM images of various diluents particles exhibited 
crystalline particles in both the LS and PM and its morphological variations were seen 
between different diluents particles (Figure 6.3).  Compressol
SM
 displayed the normal 
angular–subangular shape. Representative SEM image of HVO demonstrated spherical 
(rounded–subrounded, orange–like) particles with nearly uniform (regular) shape, well 
curved–plane surfaces, and well-rounded corners and edges (Figure 6.3). No indication of 
particle needle-like was seen in case of matrices containing compressol
SM
 and HVO samples 
in both their LS formulation and PM powder as depicted in (Figure 6.3). SEM image of 
lactose exposed irregular–deformed particles with sharp edges and mostly elongated 
morphology (Figure 6.3). It was clear that, in comparison to compressol
SM
 and HVO, lactose 
particles are less consistent in terms of shape and size, since different morphologies could be 
identified (Figure 6.3).  
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Figure 6.3: SEM of diltiazem HCl (DTZ) from physical mixture (PM) and liquisolid (LS) 
formulations containing various diluents (i.e. DTZ–sorbitol, DTZ–Mannitol, DTZ–
Compressol
SM
 and DTZ–Lactose, DTZ–HVO). 
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Table 6. 1: Particle size distribution (i.e. particle size at 10% (d10%), 50% (d50%), 90% (d90%), volume mean diameter (VMD), and span; mean ± 
SD, n = 3) of DTZ with various diluent type from liquisolid (LS) formulation powders and their physical mixture (PM) counterparts. 
 
 
Product (s) d10% d50% d90% VMD (μm) Span 
        PM          LS         PM            LS                         PM            LS          PM            LS      PM                LS 
DTZ-Sorbitol   11.5 ± 64.3 82.1 ± 2.4 50.9 ± 2.5 237.0 ± 1.0 
 
282.7 ± 11.7 
 
469.3 ± 13.7 
 
97.8 ± 6.1 
 
259.0 ± 2.6 
 
5.3 ± 0.1 
 
1.6 ± 0.1 
 
DTZ-Mannitol  14.0 ± 0.3 22.5 ± 0.2 47.5 ± 0.7 
 
61.8 ± 1.1 
 
280.0 ± 9.8 
 
365.7 ± 11.9 
 
96.6 ± 3.8 
 
141.7 ± 4.0 
 
5.6 ± 0.6 
 
5.6 ± 0.1 
 
DTZ-Compressol
SM
  16.2 ± 0.8 51.1 ± 1.5 53.9 ± 1.1 
 
132.7 ±  0.6 
 
155.0 ±  3.0 
 
247.0 ± 2.6 
 
71.3 ± 1.3 
 
142.0 ± 1.0 
 
2.6 ± 0.0 
 
1.4 ± 0.0 
 
DTZ-HVO 29.2 ± 0.3 55.9 ± 0.3 123.7 ± 1.5 135.0 ± 1.0 266.3 ± 1.5 287.0 ± 1.0 138.3 ± 1.2 154.7 ± 0.8 1.9 ± 0.1 1.7 ± 0.0 
DTZ-Lactose  10.9 ± 0.2 56.1 ± 1.4 42.2 ± 0.9 
 
40.0 ± 0.3 
 
135.0 ± 8.8 
 
94.5 ± 1.5 
 
57.1 ± 2.0 
 
84.7 ± 6.2 
 
2.2 ± 0.1 
 
1.6 ± 0.1 
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6.3.3 Powder density 
The bulk and tap densities of LS formulations and PM powders were varied (Table 6.2). In 
comparison to PM powders, the formulations containing various diluent in LS powders 
demonstrated lower bulk density, lower tapped density and higher CI (Table 6.2) indicating a 
lower degree of interparticle cohesive forces (e.g. van der Waals forces). Although good flow 
properties were observed from both LS formulations and their PM powders as indicated by 
their CI values (Table 6.2). The formulation containing lactose showed a poorer flow 
property (CI: 29.7% ± 0.9, (PM) and CI: 28.0% ± 0.0, (LS) very poor flowability) in both LS 
and PM powders (Table 6.2). This is ascribed to the more irregular, deformed particles with 
rough/uneven surfaces which can cause interlocking between particles and hence leading to 
an increased internal friction between particles containing lactose from LS and PM particles 
and thereby leading to poor flow properties (Table 6.2). In contrast, the formulations 
containing sorbitol and mannitol particles have less angular edges in comparison to lactose 
formulations as shown in SEM image (Figure 6.3), resulting in less geometric interlocking 
among sorbitol or mannitol formulations and thus improved powder flowabilities (Table 6.2). 
Formulations containing compressol
SM
 and HVO also produced better flow properties 
indicating lower degree of cohesivity and adhesivity. This could be due to its morphology 
and the existence of the rounded shape of these particles.  
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Table 6.2: Bulk density, tap density, Hardness and Carr’s index (CI) (mean ± SD, n = 5) for DTZ–diluents liquisolid (LS) formulation powders 
and their physical mixture (PM) counterparts
Product Bulk density (g/cm
3
) 
       PM       LS 
Tapped density (g/cm
3
) 
      PM       LS 
Hardness (N) CI (%) 
      PM             LS     PM                LS 
DTZ–Sorbitol   0.49 ± 0.00 0.46 ± 0.00 0.59 ± 0.00 0.56 ± 0.00 134 ± 3.4 31.1 ± 1.7 16.8 ± 0.5 18.0 ± 0.0 
DTZ–Mannitol  0.41 ± 0.00 0.39 ± 0.00 0.51 ± 0.00 0.48 ± 0.00 169 ± 2.6 37.0 ± 0.5 18.8 ± 0.5 19.2 ± 0.5 
DTZ–CompressolSM  0.43 ± 0.00 0.40 ± 0.00 0.53 ± 0.00 0.49 ± 0.01 168 ± 3.3  39.2 ± 6.6 18.2 ± 0.5 18.8 ± 0.3 
DTZ–HVO  0.45 ± 0.00 0.33 ± 0.00 0.56 ± 0.01 0.42 ± 0.00 185 ± 2.7 57.8 ± 0.8 19.0 ± 1.2 21.3 ± 0.5 
DTZ–Lactose 0.44 ± 0.00 0.37 ± 0.00 0.62 ± 0.00 0.52 ± 0.00 278 ± 2.4 31.6 ±1.4 29.7 ± 0.5 28.0 ± 0.0 
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6.3.4 Hardness 
Hardness of tablets made from various diluents was investigated in both the LS formulations 
and PM formulations. Matrices containing HVO recorded higher hardness tablets values in 
comparison to those matrices containing other diluents. The hardness was in the following 
rank order of HVO > compressol
SM
 > mannitol > lactose > sorbitol. In contrast, the tablets 
containing lactose showed higher hardness (or breaking force) among the various diluent 
used in the case of PM (Table 6.2). This could be due to the plastically deforming material of 
formulation containing lactose tablets which render it harder among diluents used in the PM 
tablets. In comparison to LS tablets, PM compacts produced a considerable higher hardness 
tablets in all the diluent used in the preparation these formulations. For example, the hardness 
of LS tablets containing HVO demonstrates lower hardness (57.8N) compared to PM 
compacts (185.2N) (Table 6.2).  
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6.3.5 Drug release studies 
The dissolution rate of DTZ from LS compacts prepared using various diluents compared to 
their counterpart conventional PM compacts is shown in (Figure 6.4). It can be seen that LS 
compact demonstrated slower release rates of the drug compared to the conventional 
compacts irrespective of the diluent used in the formulations (Figure 6.4). This is supported 
by the dissolution parameters that showed LS compacts to have lower DEs values than their 
counterpart PM tablets. For example, the LS formulation containing HVO produced lower 
DE (18.1% ± 0.4%), higher MDT (185.6% ± 2.4%) and lower MDR (0.08 min
-1
 ± 0.01 min
-1
) 
compared to the conventional compacts (DE = 26.0% ± 2.2%, MDT = 173.2 min
-1 
± 8.42 
min
-1 
and MDR = 0.12 min
-1 
± 0.01 min
-1
) (Table 6.3).  
 
Figure 6.4: Dissolution profiles of DTZ from physical mixture (PM) and liquisolid (LS) 
matrix tablets containing various diluents. 
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The presence of the non–volatile solvent could be the reason for as mentioned in previous 
Chapters. Comparing the different diluents showed that HVO provided the slowest release 
pattern of DTZ across diluents used in the preparation of both the LS compacts and PM 
tablets (Figure 6.4).  
This could be attributed to hydrophobicity imparted by HVO to matrix system, which upon 
contact with aqueous medium it takes a longer time to penetrate into the tablet and therefore 
diffusion and dissolution of the drug were found to be less than hydrophilic diluents. The 
excipients, which are used in the formation of hydrophobic matrix tablets and have no 
dissolving or swelling properties, are usually polymers and waxes. Waxes are high MW 
excipients without liquid components composed of hydrocarbons comprising straight, 
branched or cyclic alkanes (Walters and Brain, 2001). The lipophilicity of wax matrix system 
delays entry of aqueous medium in matrix producing retardation properties in release profile 
of drug (Li et al., 2006). In general, release retardation effect was found to be in order of 
HVO > lactose > compressol
SM
 > mannitol > sorbitol. It was also observed that the drug 
release from the various diluent did not correlate the diluent solubility. Lactose retarded the 
drug release better compared to sorbitol, mannitol and compressol
SM
, however, HVO was 
more robust compared to lactose. This was further confirmed by dissolution parameters that 
showed LS compacts formulated with HVO to have a lower DE (18.1% ± 0.4%) and lower 
MDRs (from 0.08 min
-1
 ± 0.01 min
-1
) than those LS compacts formulated with compressol
SM
, 
mannitol, sorbitol and or lactose (DE: from 19.4% ± 3.4% to 30.1% ± 2.2 %). The same 
consideration was also obtained from PM powders. The ‘n’ values obtained from both the LS 
formulation and PM powders in (Table 6.3) followed anomalous transport mechanism with 
values ranging from 0.612 to 0.791 (Table 6.3). 
 
161 
 
Table 6.3: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR) and in vitro release kinetic parameters; n 
value of diltiazem HCl obtained for liquisolid (LS) formulations containing various grades diluent in comparison to their physical mixture (PM) 
counterparts. The results are expressed as the mean ± SD. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Formulation (s) DE (%) 
       PM            LS 
MDT (min
-1
) 
    PMs               LS 
MDR (min
-1
) 
      PMs        LS 
n value 
PMs         LS 
DTZ–Sorbitol   40.3 ± 3.18 30.1± 2.22 183 ± 0.89 202 ± 8.62 0.18 ± 0.01 0.13 ± 0.02 0.612 0.665 
DTZ–Mannitol  35.7 ± 3.11 25.3 ± 3.23 189 ± 8.90 203 ± 26.4 0.16 ± 0.02 0.10 ±0.01 0.615 0.748 
DTZ–CompressolSM  32.0 ± 1.82 21.5 ± 1.06 206 ± 12.5 190 ± 8.96 0.13 ± 0.02 0.09 ± 0.01 0.791 0.729 
DTZ–Lactose  27.0 ± 1.39  19.4 ± 3.40 206 ± 1.58 197 ± 5.05  0.12 ± 0.01 0.08 ± 0.01 0.706 0.781 
DTZ–HVO 26.0 ± 2.23 18.1 ± 0.45 173 ± 8.42 185 ± 2.38 0.12 ± 0.01 0.08 ± 0.00 0.661 0.644 
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 Conclusion 6.4
From the five diluents (HVO, compressol
SM
, mannitol, lactose and sorbitol) studied, HVO 
produced tablets with the highest mechanical strength in the case of LS compact. It can be 
observed that there was a general increase in tablets mechanical strength and a decrease in 
DTZ release. The type of diluents has a considerable effect on the DTZ release from LS 
compacts. HVO caused retardation of DTZ as compared to formulations containing 
compressol
SM
, mannitol, lactose and sorbitol respectfully. Therefore, the HVO was shown as 
the main factor leading the control of drug release from both the LS and PM formulations. 
Regardless of different diluents used, LS formulations produced slower DTZ release profile 
than those obtained in PM tablets. DTZ release from both the LS and PM tablets followed 
anomalous transport mechanism. FT–IR was investigated, and found interaction between drug 
and various diluent within both the LS and PM formulations and XRD had a crystalline solid 
state in nature. In conclusion, a careful selection of diluent is vital in slowing more highly 
soluble model drug release from LS matrices. 
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 CHAPTER 7: INFLUENCE OF POLYMER TYPE 7
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 Introduction 7.1
Psyllium fiber is gel–forming mucilage which lowers blood lipid concentrations due to its 
effectiveness, cheap therapy for chronic diarrhoea and promoting healthy bowel function as a 
bulking agent or laxative (Fischer et al., 2004). Moreover, it appears as a substrate for 
microbial growth that increases stool mass (Spiller 2001). Psyllium lowers post–prandial 
glucose concentrations in men with type II diabetes (Ziai et al., 2005). Recently, Psyllium was 
employed for the controlled delivery of peptides such as insulin22. However, Psyllium can be 
employed in the therapy of critical bowel syndrome (Washington et al., 1998), which inhibits 
the carcinogenic and sustaining remission in ulcerative colitis processes (Morita et al., 1998). 
Psyllium also has shown to reduce the concentration of cholesterol and low–density 
lipoprotein in the plasma (Fukagawa et al., 1990). Psyllium not only has a pharmacological 
effect but it can be applied to sustained release matrix compacts and hydrogels. Psyllium has a 
unique way of producing a viscous gel almost immediately upon contact with dissolution 
medium, thereby retarding the release rate of a drug quicker (Fischer et al., 2004). The 
hydrogel matrix developed by psyllium resists hydrolysis; consequently, psyllium can 
therefore resist colonic bacterial degradation and the double potential of the psyllium 
hydrogel can be employed to provide novel drug–delivery systems (Singh et al., 2008). 
Psyllium is also cost-effective, safe with low toxicity (Oliver, 2000) and has a global 
consumer recognition having been employed for hundreds of years in traditional medicines 
which have been approved by the FDA (Anderson et al., 2000). Various studies carried out 
their investigations on the modified psyllium husk powder to improve its importance in drug-
delivery systems. The modified psyllium husk powder gave better gelling and swelling 
properties when tartaric, and succinic acid was used in developing a suitable sustained release 
compact from DTZ using direct compression (Gohel et al., 2003). Modified psyllium 
hydrogels in the presence of acrylic acid and radiation showed the psyllium hydrogels formed 
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can produce drug release in a sustained and controlled manner and to be employed as a 
possible double drug–delivery device in the colon (Singh et al., 2008). Siahi-Shadbad et al., 
(2011) investigated the effect of various concentration of hypromellose K4M, sodium 
alginate, sodium carboxymethylcellulose (NaCMC) on the release rate of propranolol HCl 
from psyllium matrices. The finding showed that the binary mixtures of psyllium and 
hypromellose, psyllium and sodium alginate and NaCMC and psyllium in different ratios 
produced a significant decrease in the release behaviour of propranolol HCl. It was also 
reported that psyllium was shown to be a promising polymer to sustain the THP release rate 
from granulated formulations in comparison to their counterpart PM. The results showed 
more effective controlled drug release with no burst release and the inclusion of 
Hypromellose within psyllium formulations modified the THP release kinetics from Fickian 
diffusion to anomalous transport (Kaialy et al., 2014). Hypromellose gains much attention due 
to its unique features, and they can exhibit good compression properties, including when 
directly compressed. They are non–toxicity and can produce a high level of drug loading, and 
also having enough swelling characteristics that enables a rapid form of an external gel layer 
which plays or retards an important role in controlling drug release. Besides, Hypromellose is 
fully identified as pH-independent materials; this advantage allows them to resist fluctuations 
of pH caused by intra and inter–subject differences of both GI transit time and gastric pH. 
They have been employed alone or in mixture in the formulation of matrix compacts, hence 
the gel–forming hydrophilic matrix compacts are widely employed for extended oral release 
dosage forms due to their cost–effectiveness, simplicity and reduction of the risk of systemic 
toxicity which occurs as a result of dose dumping (Huang et al., 2005). Eudragit
®
 polymers 
are a range of acrylate and methacrylate polymers obtainable in various ionic forms.  
Eudragit
®
 RLPO and Eudragit
®
 RSPO are water–insoluble but can yield pH–independent 
release profiles, and they are permeable. The permeability of Eudragit
®
 RLPO and RSPO in 
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aqueous media could be due to the presence of quaternary ammonium groups in their 
formation; Eudragit
®
 RLPO has a greater relationship of these functionalities groups and as 
such is more permeable than Eudragit
®
 RSPO grade (Haznedar and Dortunç, 2003). However, 
the effects of polymer type in the release rate of a model soluble drug, DTZ, from LS matrices 
up to date have not been investigated. Therefore, this Chapter aimed to retard the release of a 
model highly water–soluble drug, DTZ, from LS matrix compacts in comparison to their PM 
tablets. 
 Formulation 7.2
The solid phase consisted of AEROSIL
® 
(0.6 g), each polymer type under investigation
 
contain (6 g), and lactose (5.2 g in the case of PM formulations and 6.0 g in the case of LS 
formulations), whereas the liquid phase consisted of commercial DTZ powder dispersed in 
polysorbate 80 (PS 80) (60 ºC, 200 rpm) at a drug:solvent ratio of 1:1 (w:w). Also a binary 
mixture of Polyox
TM
:Psyllium at ratios of 1:1, 1:3 and 3:1 was prepared for further 
investigations in this Chapter using the same procedure. The solid phase was introduced to a 
mortar and the mixing process was carried out as described earlier section 2.5. Accurately 
weighed samples of each liquisolid (750 mg) and PM (650 mg) formulation were separately 
weighed and then compressed on 8 mm punch and die using a manual tableting machine at a 
fixed pressure of 2000 psi. 
 Results and discussion 7.3
7.3.1 Solid state 
This study was carried out to investigate if there is any chemical interaction between pure 
DTZ and various polymer and binary mixture of psyllium and Polyox
TM
 in the ratios of 1:1, 
3:1 and 1:3 in both the LS formulations and PM powders (Figure 7.1 and Figure 7.2). The 
FT–IR observed in both LS formulations and their counterpart PM showed a considerable 
change when compared to that of pure DTZ, where a complete disappearance of the band at 
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2393 cm
-1
 was observed as seen in the previous Chapters. This confirmed the interaction 
between DTZ and various polymers and ratio. Additionally, the PXRD patterns of LS 
formulations were investigated and compared to that obtained from the PM powder (Figure 
7.2). This study revealed a slight reduction in the intensity of LS formulations in comparison 
to their PM powders as also reported from previous Chapters.  This may be attributed to the 
presence of a solvent in the LS formulation that renders it different.  
 
Figure 7. 1: FTIR patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various diluents (i.e. (a) Pure DTZ, (b) DTZ–Psyllium, (c) DTZ–PolyoxTM, (d) 
DTZ–Hypromellose, (e) DTZ–Eudragit® RS, (f) DTZ–Eudragit® RL, (g) DTZ–
(Psyllium:Polyox
TM
) 1:1, (h)DTZ–(Psyllium:PolyoxTM) 1:3 and (i) DTZ–(Psyllium:PolyoxTM) 
3:1. 
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Figure 7.2: PXRD patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various Polymers (a) Pure DTZ, (b) DTZ–Psyllium, (c) DTZ–PolyoxTM, (d) DTZ–
Hypromellose, (e) DTZ–Eudragit® RS, (f) DTZ–Eudragit® RL, (g)(DTZ–Psyllium:PolyoxTM) 
1:1, (h) (DTZ–Psyllium:PolyoxTM) 1:3 and (i) (DTZ–Psyllium:PolyoxTM) 3:1. 
7.3.2 Particle size distribution 
The polymer’s distinct properties such as VMD and span of the LS formulations and the PM 
powders comparing each property are shown in this table 7.1. Regardless of their polymer 
type, all LS formulations showed a significant difference in the VMD than their counterpart 
PM powders. For example, the VMD in LS formulations ranged from 118.7 μm ± 2.9 μm to 
911.3 μm ± 2.8 μm whereas the range for the PM powders was 68.0 μm ± 0.6 μm to 672.3 
μm ± 8.6 μm due to the occurrence of aggregated particles.  Due to the particles aggregation, 
formulations that were produced through LS showed smaller span values (narrower size 
distribution) compared to their PM powders (Table 7.1) as indicated by the higher d10% 
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values, fine particulates content showed a significant reduction for LS formulations compared 
to their PM counterparts (Table 7.1), that could account for their improved size homogeneity. 
This could be ascribed to the adhesion of such fines on the surfaces of larger particles in the 
case of LS formulations (Table 7.1). The breadth of the particle distribution and span value 
was higher for the formulation containing psyllium (3.6 ± 0.1) and lower for PolyoxTM (2.2 ± 
0.1) in the case of PM powders. Therefore, psyllium demonstrated higher polydispersity than 
PolyoxTM. Eudragit® RS had the highest span value of (8.2 ± 0.7) in the case of LS 
formulations. The VMD of both the LS formulations and PM powders showed increasing 
trend with an increase in a PolyoxTM to Psyllium ratio. LS formulations demonstrated 
significantly higher VMD value (p<0.05) than those of the PM powders (Table 7.1) which 
indicate broader size distributions. Images analysis from SEM in LS formulations and PMs 
powders showed that the particles of Eudragit
®
 RL and Hypromellose powders were found 
irregular in shape, the particles of Eudragit
®
 RS powders consisting of irregular and needle 
shape, and the particles of psyllium were nearly spherical and the Polyox
TM
 was found to be 
irregular. From this Figure 7.3 and Figure 7.4, it can be observed that the powders exhibited 
various shapes. The mixture of Polyox
TM
: Psyllium at (1:3 and 3:1) ratio was found to be 
spherical and consisting of small angular shape (Figure 7.4). 
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Table 7.1: Particle size distribution (i.e. particle size at 10% (d10%), 50% (d50%), 90% (d90%), volume mean diameter (VMD), and span; mean ± 
SD, n = 3) of DTZ–PolyoxTM liquisolid (LS) formulation powders and their physical mixture (PM) counterparts. 
 
 
 
Formulation Polyox
TM
:Psy
llium 
d10% (μm) d50% (μm)  d90% (μm) VMD (μm) Span 
      PM                   LS  PM                        LS                        PM                      LS               PM                   LS          PM LS PM LS
PM–DTZ–Psyllium  15.9 ± 1.0   126.2 ± 95.1 427.3 ± 19.7 743.3 ± 53.0 1560.0 ± 26.5 1930.0 ± 45.8 611.3 ± 17.9    911.3 ± 2.8 3.6 ± 0.1 2.4 ± 0.2 
PM–DTZ–PolyoxTM  18.8 ± 2.1 56.1 ± 1.4 100.7 ± 1.4 143.3 ± 3.1 247.3 ± 2.8   289.3 ± 3.1 121.7 ± 2.0 156.7 ± 4.2 2.2 ± 0.1 1.6 ± 0.2 
PM–DTZ–Hypromellose  10.2 ± 0.3  33.3 ± 0.3 49.2 ± 0.5 82.1 ± 0.5 156.0 ± 1.0 254.7 ± 6.4 68.0 ± 0.6  118.7 ± 2.9 2.9 ± 0.0  2.7 ± 0.1 
PM–DTZ-Eudragit
®
 RS  28.4 ± 2.3   63.4 ± 3.5 482.0 ± 20.1 283.3 ± 35.3 1710.0 ± 87.1 2373.2 ± 119 672.3 ± 8.6   859.0 ± 8.7 3.5 ± 0.5  8.2 ± 0.7 
PM–DTZ-Eudragit
®
 RL  11.2 ± 0.6   40.1 ± 0.1 48.9 ± 0.4 98.2 ± 1.6 166.7 ± 2.5 307.0 ± 15.8 70.1 ± 0.22  141.0 ± 7.0 3.1 ± 0.1 2.7 ± 0.1 
DTZ-Polyox
TM
:Psyllium 1:1:1 8.1 ± 0.7 14.7 ±4.1 33.6 ± 0.8 48.6 ± 2.2 261.3 ± 32.7 249.7 ± 80.5 81.1 ± 21.3 91.8 ± 21.3 7.5 ± 0.8 4.7 ± 1.4 
DTZ-Polyox
TM
:Psyllium 1:1:3 7.0 ± 0.1 21.3 ± 0.5 32.0 ± 0.4 106.4 ± 8.7 174.0 1.0 1396.6 ± 35.1 92.2 ± 0.61 446.3 ± 18.5 5.2 ± 0.1  13.0 ± 0.7 
DTZ-Polyox
TM
:Psyllium 1:3:1 15.6 ± 0.7 21.5 ± 0.7 205.7 ± 82.8 286.0 ± 80.7 1806.6 ± 49.3 1803.3 ± 23.1   638.7 ± 28.4 649.7 ± 24.9 10.1 ± 5.0 6.5 ± 1.6 
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7.3.3 Powder density 
LS formulations showed a lower flowability in comparison to their PM powders (Table 7.2). 
Moreover, the addition of liquid might increase cohesive and adhesive forces among particles 
due to the wall effect. Hence, a reduction in flow rate is likely for LS formulations which 
agree with other investigations (Nazzal et al., 2002). The values of CI obtained from PM 
formulations was higher for Eudragit® RS (32.0%), indicating that it is a highly compressible 
powder, whereas CI is lower for the Psyllium (23.8%) which indicates its free–flowing 
behaviour. As observed in (Table 7.2), LS formulations showed increasing flow properties 
based on CI value ranges from Eudragit
®
 RS > Eudragit
®
 RL > Polyox
TM
 > Hypromellose
 
> 
Psyllium. It was observed that for all LS formulations, with the exception of Eudragit
®
 RS 
and Eudragit
®
 RL produced CI values less than 25%, which indicates they have better flow 
properties. Psyllium produced better flow behaviours indicating a lower degree of cohesivity 
in both formulations, therefore, improved powders flowability. This could be due to the 
existence of its spherical shape from these particles (Table 7.2). The improvement of flow 
properties recommends that they can easily handle during processing. The mixture of 
(Polyox
TM 
and Psyllium) at 1:1, 1:3 and 3:1 (Polyox
TM
:Psyllium) ratio also produced good 
flow properties that show a nearly spherical shape in LS and PM formulations (Table 7.2). 
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Figure 7.3: SEM of diltiazem HCl (DTZ) from physical mixture (PM) and liquisolid (LS) 
formulations containing polymer type and ratio. 
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Figure 7.4: SEM of diltiazem HCl (DTZ) from physical mixture (PM) and liquisolid (LS) 
formulations containing polymer type and ratio.
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Table 7.2: Bulk density, tap density and Carr’s index (CI) and Hardness (mean ± SD, n = 5) for DTZ– Polymer type and PolyoxTM:Psyllium 
ratio liquisolid (LS) formulation powders and their physical mixture (PM) counterparts. 
 
Formulation Ratio Bulk density (g/cm
3
) Tap density (g/cm
3
) CI (%) Hardness (N) 
  PM LS PM LS PM LS PM LS 
DTZ–WSR 303  0.36 ± 0.02 0.32 ± 0.01 0.46 ± 0.10 0.42 ± 0.02 22.3 ± 1.2 23.7 ± 0.02 155 ± 0.2 13.7 ±1.4 
DTZ–HPMC  0.45 ± 0.01 0.41 ±0.02  0.66 ± 0.01 54.5± 0.01 30.8 ± 1.11 23.2 ± 0.03 78.0 ± 1.3 21.3 ± 2.8 
DTZ–Psyllium  0.42 ± 0.01 0.39 ± 0.00 0.55 ± 0.01 0.50 ± 0.01 23.8 ± 0.50 22.8 ± 0.50 61.2 ± 1.4 9.61 ± 0.5 
DTZ– Eudragit® RS  0.44 ± 0.00 0.39 ± 0.00 0.65 ± 0.01 0.53 ± 0.01 32.0 ± 0.82 28.2 ± 0.82 112 ± 5.3 46.6 ± 0.5 
DTZ– Eudragit® RL  0.46 ± 0.01 0.37 ± 0.01 0.67 ± 0.01 0.54 ± 0.01 31.5 ± 0.57 28.5 ± 1.00 113 ± 8.0 56.4 ± 2.3 
DTZ-(PolyoxTM:Psyllium)  1:1 0.42 ± 0.02  0.46 ± 0.02 0.53 ± 0.01 0.58 ± 0.01 22.3 ± 0.43 20.0 ± 0.51 80.9 ± 3.6 17.7 ± 0.0 
DTZ-(PolyoxTM:Psyllium)  1:3 0.39 ± 0.00 0.45 ± 0.00 0.51 ± 0.00 0.57 ± 0.01 23.3 ± 0.52 21.8 ± 0.54 48.3 ± 0.9 14.2 ± 0.6 
DTZ-(PolyoxTM:Psyllium)  3:1 0.35 ± 0.01 0.51 ± 0.01 0.38 ± 0.01 0.48 ± 0.01 27.8 ± 0.51 22.0 ± 0.02 116 ± 2.6 23.8 ± 1.5 
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7.3.4 Hardness 
The hardness value of tablets made by various polymer in LS formulations produced weaker 
tablets than those prepared by PM powders (Table 7.2). For example, LS tablets containing 
Eudragit
®
 RL showed lower hardness (56.4N) compared to PM compacts (113.1N). This was 
due to the presence of the PS 80 as shown in the previous Chapters. However, formulations 
containing Eudragit
®
 RL recorded higher hardness tablets values in comparison to those 
matrices containing other polymers in LS formulations (Table 7.2). The hardness was in the 
following rank order Eudragit
®
 RL > Eudragit
®
 RS > Hypromellose > Polyox
TM 
>Psyllium. 
In contrast, the tablets containing Polyox
TM
 showed higher hardness (or breaking force) 
among the various polymers used in the case of PM (Table 7.2). This may be due to the 
formation of stronger hydrogen bridge linkages between the primary particles of Polyox
TM
. 
Formulation containing psyllium recorded lower hardness value from both the LS and PM 
formulations. This was also reported by (Saeedi et al., 2010b), where psyllium produced 
lower hardness values from (3.85 ± 0.24 to 5.09 ± 0.31). The matrices tablets containing (3:1) 
Polyox
TM
:Psyllium ratio obtain from both the LS formulations and their counterpart PM 
powders showed higher hardness as compared to those formulations made by 1:1 and 1:3 
Polyox
TM
:Psyllium ratio (Table 7.2).   
7.3.5 Drug release studies 
Drug release from LS tablets was affected by the various polymers. The release was in the 
order of: Eudragit
®
 RL > Eudragit
®
 RS > Hypromellose > Polyox
TM 
> Psyllium. Hydrophilic 
Psyllium provided a slowest DTZ release across the various polymer used in both the LS and 
PM compacts (Figure 7.5). The swellable hydrophilic matrix initiates the release of a drug 
with the penetration of water into the matrix. The drug is homogeneously dispersed in the 
matrices system throughout a rate controlling medium. Then, the drug is dissolved and the 
polymer hydrated by penetrated water causes swelling to form a gel–like structure, thereby 
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producing a polymer chains relaxation and consequently, the polymer size increases. This 
allows the drug to diffuse into the swollen network of the matrix out of the external 
environment. Hence, the release of the drug is very firmly related to the swelling property of 
the psyllium hydrogel.  This was confirmed by the dissolution parameters which showed that 
both the LS and PM compacts formulated with psyllium to have lower DEs and lower MDR. 
For example, in LS formulations, psyllium tablets to produce lower DE (18.9% ± 1.1 %) and 
a lower MDR (0.08 min
-1
 ± 0.01min
-1
) than those obtained from formulations containing 
Polyox
TM
 (29.1% ± 0.9 %) and (0.13 min
-1 
± 0.01min
-1
), Eudragit
®
 RL (47.5 % ± 0.2 %) and 
(0.49 min
-1
 ± 0.01min
-1
),  Hypromellose (54.7% ± 0.3 %) and (0.21 min
-1
 ± 0.01 min-1) and 
Eudragit
®
 RS (56.5 % ± 1.1 %) and (0.42 min
-1
 ± 0.01min
-1
) (Table 7.3) . The same 
consideration was also seen in the case of PM compacts. The release rate of DTZ was 
generally faster in both the PM and LS formulations containing Eudragit
®
 RL and RS 
polymer although they have clear similarity in their properties (Figure 7.5). This might be due 
to the greater permeability of Eudragit
®
 RL and higher number of quaternary ammonium 
groups. When exposed to the aqueous media, the media penetrates into the free spaces within 
macromolecular chains of Eudragit
®
 RL (Haznedar and Dortunç, 2003). The dimensions of 
the polymer molecule increase due to polymer relaxation by the stress of the penetrated 
media after solvation of the polymer chains. This phenomenon may be attributed to initial 
disaggregation or surface erosion of the matrix tablet prior to gel layer formation within the 
tablet core. These results are in complete agreement with those published by (Wadher et al., 
2011), for metformin. These authors showed that when Eudragit
®
 RL was used as the 
retarding agent, the entire metformin content was released within 2 hrs. 
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Figure 7.5: Dissolution profiles of DTZ from physical mixture (PM) and liquisolid (LS) 
matrix tablets containing various Polymer type. 
 
RS and RL do not dissolve in water. Hence, the drug can only diffuse out much faster within 
the polymer gaps and most of the drug release will depend on the disintegration or higher 
degree of erosion of the polymeric matrix leading to a faster drug release rate as 
demonstrated in (Figure 7.5). They are copolymers of partial esters of acrylic and methacrylic 
acids carrying low volumes of quaternary ammonium groups, roughly 5% and 10% for RS 
and RL, respectively (Haznedar and Dortunç, 2003). Statistical analysis confirmed that DTZ 
release profiles from both LS tablets and PM compact containing RS were not significantly 
different (f2>50) in comparison to RL (Table 7.3).  In general, the dissolution rate of DTZ 
from LS compacts prepared using various Polymers compared to the counterpart 
conventional PM compacts are shown in (Figure 7.5). It can be seen that the dissolution 
behaviours of LS compacts showed a slower release of DTZ compared to the conventional 
compacts (Figure 7.5) as seen in the previous Chapters. 
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Table 7.3: Dissolution efficiency, mean dissolution rate, mean dissolution rate, similarity factor (f2) and in vitro release kinetic parameters n 
value of diltiazem HCl obtained for liquisolid formulations containing various Polymers type and ratio in comparison to their physical mixture 
counterparts. The counterpart physical mixture was chosen as the standard for each liquisolid formulation when calculating f2 values. The results 
are expressed as the mean ± SD, n = 3 (*indicates significant difference, P< 0.05). 
Formulation Ratio DE (%) 
       PM            LS 
MDT (min
-1
) 
    PM                LS 
MDR (min
-1
) 
      PM        LS 
f2 
PM   vs   LS 
n value 
PM         LS 
PM–DTZ–Psyllium  31.0 ± 2.2 18.9 ± 1.1 146.4 ± 13.7 175.7 ± 9.4 0.16 ± 0.02 0.08 ± 0.01 48.4 0.413 0.654 
PM–DTZ–PolyoxTM  41.9 ± 1.1 29.1 ± 0.9 192.7 ± 1.0 172.3 ± 1.8 0.18 ± 0.01 0.13 ±0.01 48.1 0.615 0.748 
PM–DTZ–Hypromellose  68.4 ± 11.0 54.7 ± 0.3 167.6 ± 41.6 139.4 ± 26.3 0.29 ± 0.05 0.21 ± 0.01 46.0 0.663 0.653 
PM–DTZ–Eudragit® RS  62.5 ± 3.8 56.5 ± 1.1 104.0 ± 11.5 115.3 ± 6.7 0.43 ± 0.02 0.42 ± 0.01 61.1 0.505 0.566 
PM–DTZ–Eudragit® RL  57.3 ± 1.2 47.5 ± 0.2 59.2 ± 1.1 75.2 ± 0.5 0.59 ± 0.01 0.49 ± 0.01 51.6 0.971 0.725 
DTZ–(PolyoxTM:Psyllium) 1:1:1 25.1 ± 0.4 13.0 ± 0.4 218.1 ± 2.4 212.2 ± 4.9 0.11 ± 0.01 0.05 ± 0.01 47.4 0.684 0.915 
DTZ–(PolyoxTM:Psyllium) 1:1:3 25.9 ± 0.5 19.7 ± 0.9 180.0 ± 8.7 195.1 ± 7.0 0.12 ± 0.01 0.08 ± 0.01 49.37 0.641 0.748 
DTZ–(PolyoxTM:Psyllium) 1:3:1 29.2 ± 1.3 23.2 ± 0.3 191.1 ± 8.9 217.3 ± 16.2 0.13 ± 0.01 0.09 ± 0.01 49.44 0.673 0.822 
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 This is also supported by the dissolution parameters that showed LS compacts to have lower 
DEs and lower MDR than their PM counterparts regardless of the polymer used. For example, 
LS formulation containing Psyllium tablets to produce lower DE (from 18.9% ± 1.1%  and 
lower MDRs (from 0.08 min
-1
 ± 0.01min
-1
) compared to the conventional compacts (DE = 
31.0% ± 2.2% and MDR = 0.16 min
-1
 ± 0.02 min
-1
) (Table 7.3). Statistical analysis confirmed 
that DTZ release profiles from LS tablets were significantly different (f2<50) in the case of 
formulations containing all the hydrophilic polymers such as psyllium, Polyox
TM
 and 
hypromellose as compared to their PM tablets (Table 7.3).  
 
Figure 7.6: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from physical 
mixture (PM) and liquisolid (LS) formulations containing psyllium, Polyox
TM
 and 
Polyox
TM
:Psyllium. 
 
Two polymers (i.e. Polyox
TM
 and Psyllium) were selected for further investigation due to its 
excellent retardation properties from the previous studies. The influence of the inclusion of 
Psyllium into Polyox
TM
 at 1:1 ratio on the release profile of DTZ in comparison to the 
individual of Psyllium and Polyox
TM
 are shown in (Figure 7.6).  Interesting results were 
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obtained when binary mixtures of Psyllium and Polyox
TM
 were used as a release retardant. 
The release profiles of DTZ showed the use of a binary mixture of Psyllium and Polyox
TM
 
matrices produce slower release rate in both LS formulations and PM tablets. This was 
ascribed to the reduced entrance of aqueous media into the matrix due to the presence of the 
stronger viscose gel within the two hydrophilic matrices compared to individual psyllium and 
Polyox
TM
. A similar explanation is also studied previously showing the addition of Viscarin to 
Hypromellose in formulations gave slower release rate of ibuprofen for 10hrs which are 
possibly due to slower erosion of hypromellose (Nerurkar et al., 2005).  Polyox
TM
 has been 
reported in many combinations in sustained release formulations as seen in section 7.1. This is 
also confirmed by the dissolution parameters that showed (Polyox
TM
: Psyllium) to produce 
lower DE and lower MDR than the individual Psyllium and Polyox
TM 
alone. For example, in 
LS formulation, (Polyox
TM
: Psyllium) tablet produce lower DE (13.0% ± 0.4% and MDR = 
0.05 min
-1
 ± 0.01 min
-1
)
 
than Psyllium (18.9% ± 1.1% and MDR = 0.08 min
-1
 ± 0.01 min
-1
) 
and Polyox
TM
 (29.1% ± 0.9% and MDR = 0.13 min
-1
 ± 0.01 min
-1
) (Table 7.3). LS 
formulations produced better retardation properties in comparison to PM counterpart. 
Statistical analyses using f2 value confirmed that the release rate of DTZ from LS tablets was 
significantly different from PM tablets, i.e. they are not similar in all the formulations (f2 <50) 
(Table 7.3). This is also supported by dissolution parameters which confirmed LS tablets 
produced lower DE and lower MDR than PM tablets in respective of the polymer used. Based 
on the release profiles in (Table 7.3), I came to this conclusion that the inclusion of Psyllium 
into Polyox
TM
 at Polyox
TM
:Psyllium (1:1) gives more sustained release profile for a period of 
8hrs. Therefore, this ratio 1:1 was chosen for further investigation as discussed below.    
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Figure 7.7: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from physical 
mixture (PM) and liquisolid (LS) formulations containing binary mixture of Psyllium and 
Polyox
TM
 at different ratio. 
Following the previous results, Polyox
TM–Psyllium was selected for further investigation. The 
influence of Psyllium:Polyox
TM
 ratio at 1:1, 1:3 and 1:3 on drug release was assessed. The 
results were depicted in (Figure 7.7). The results showed that matrices containing 
(Psyllium:Polyox
TM
) at 1:1 ratio can slow down the drug release than the matrices compacts 
containing 1:3 and 3:1 (Psyllium:Polyox
TM
) ratio. , i.e., the dissolution rate has decreased with 
decreasing the percentage of (Polyox
TM
:Psyllium) (Figure 7.7). Statistical analyses confirm all 
formulations showed significant differences in the release rate of DTZ from LS formulation in 
comparison to their PM tablets (f2<50).  In general LS tablets produce slower drug release 
than their PM tablets. Dissolution parameters also supported the above results. For example, 
in LS containing 1:1 (Polyox
TM
: Psyllium) tablet ratio produce lower DE (13.0% ± 0.4% and 
MDR = 0.05 min
-1
 ± 0.01 min
-1
) than their counterpart PM (DE 25.1% ± 0.4% and MDR = 
0.11 min
-1
 ± 0.01 min
-1
).    
The kinetics release for the polymer type is shown in (Table 7.3). The results of this 
investigations demonstrated the release of DTZ from all the hydrophilic polymer matrices was 
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typically non-fickian (anomalous) fitting well to Korsmeyer-Peppas indicating DTZ release 
was by the incorporation of diffusion and erosion (Table 7.3). Other values of n obtained from 
matrices containing Eudragit
®
 RS and Eudragit
®
 RL indicating a diffusional–controlled 
release in both the LS tablets and PM formulations. With the exception of Eudragit
®
 RLPO, 
in the case of PM formulations released drug via case–II transport mechanism (n>0.89) which 
caused from the erosion of the matrix was the main factor controlling the release of a drug 
(Table 7.3). The binary mixture of psyllium and Polyox
TM
 in the ratios of 1:1, 3:1 and 1:3 
followed anomalous transport mechanism in the case of PM formulations whereas with the 
exception of binary mixture of psyllium and Polyox
TM
 in the ratios of 3:1, all LS formulations 
release drug via case–II transport mechanism (Table 7.3). Regardless of their ratio, the n 
values from all LS formulations were higher than the values obtained from PM formulations.  
 Conclusion 7.4
In this study, the possibility of using psyllium polymer–based matrix system for sustained 
release of highly water–soluble drug and the combination of PolyoxTM and psyllium were 
demonstrated. Psyllium was able to retard DTZ release from the various matrices tablet used 
in this formulation. Among them, drug release from Polyox
TM–psyllium based matrix system 
demonstrated the best–sustained release behaviour and was still slower by the modification of 
Polyox
TM
:psyllium ratio. The combination of the polymers has shown a very useful in being 
able to produce different drug release profiles.  
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 Introduction 8.1
Hydrophilic matrix tablets are broadly employed for oral sustained–release design dosage 
forms due to its cost–effectiveness, simplicity and less risk in term of its toxicity (Huang et 
al., 2005). The dissolution is a rate–limiting step for drug bioavailability from a hydrophilic 
based matrix system. Media penetrated into the matrix system then the drugs dissolve and 
diffuse it out of the matrices system in a controlled behaviour (Siepe et al., 2006). As mention 
in Chapter 1, Polyox
TM
 is linear, hydrophilic and uncrosslinked polymers (Kim, 1995). 
Polyox
TM
 hydrate rapidly upon exposure to GI fluid and then swell to form a hydrogel layer 
on the surface of the tablet. This is accompanied by erosion of the Polyox
TM
. The swelling 
and erosion characteristics of Polyox
TM
 control and delayed drug release (Petrovic et al., 
2009). Therefore, Polyox
TM
 has been broadly accepted in matrix tablets, including direct 
compression (Crowley et al., 2002), granulation (Petrovic et al., 2009), hot-melt extrusion 
(Nanjwade et al., 2011) and LS (Kaialy et al., 2016). Importantly, the Polyox
TM
 are widely 
available in a range of MWs between (1 × 10
5
 to 6 × 10
6
), giving them good candidates for 
control release, due to Polyox
TM
 containing low MW produce a complete release, while high 
MW Polyox
TM
 allows greater control release (Kim, 1995). In addition,  the drug release will 
offer better retardation properties when Polyox
TM
 have been employed in combination with 
other hydrophilic excipients, that including stearic acid (Tajiri et al., 2010), PEG (Lyons et 
al., 2008), poly (e-caprolactone) (Verhoeven et al., 2009), ethylcellulose (Vechia et al., 2011), 
hypromellose (Palmer et al., 2013), and sodium carboxymethylcellulose (Ma et al., 2014). 
Usually, the incorporation of hydrophilic excipients gives better drug release. Drug solubility 
administers the entire process in the dissolution medium. Many drugs have a pH-dependent 
solubility, showing different release rates with varying pH in the GI (Streubel et al., 2000). 
Penetration of GI fluids with changing pH causes reduction of the further ionizable drug 
(soluble form) to a less soluble form. Therefore, the diffusion rate of the drug is reduced 
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through the matrix. This conversion into an insoluble drug depends on the pH of the intestinal 
fluids and pKa value of the drug. It is desirable to obtain drug release with a pH-independent 
environment for making the necessary dose bioavailable (Streubel et al., 2000). As the pH of 
GI fluids cannot be modified, an optimised pH in the design dosage form can be employed to 
modulate the release. 
In this Chapter, Polyox
TM
 and Psyllium were selected as retardant agent for a sustained 
release matrix tablet. The matrix tablets with a combination of Polyox
TM
 and Psyllium were 
prepared at 1:1 Polyox
TM
:Psyllium ratio and the characterisation of dissolution properties in 
some test environments were evaluated, including pH and mechanical stress in the GIT. 
 Results and discussion 8.2
8.2.1 Drug release studies 
The LS and PM formulations containing 1:1 Polyox
TM
:Psyllium ratios that gave the slowest 
drug release were chosen to study the influence of changing the pH medium and rotational 
speed on drug dissolution profile (Figure 8.1 and 8.2). The drug release profile of DTZ 
obtained from LS and PM tablets were compared in various pH media, which include pH 1.2, 
2.2, 5.8, 6.8, 7.2 and 7.5 respectively, although DTZ release was sustained irrespective of 
their pH dissolution media. The dissolution behaviour of DTZ obtained from both LS and PM 
tablets showed a decreasing trend with increasing pH media, range (from pH 1.2 to pH 7.8).  
This is further supported by dissolution parameters, that indicate LS tablets prepared with pH 
7.8 have lower DE (13.7% ± 0.40%) than those obtained from matrices containing pH 1.2 
(24.5% ± 0.50%), pH 2.2 (20.5% ±0.82%), pH 5.8 (18.7% ± 0.40%), pH 6.8 (15.6% ± 0.70%) 
and pH 7.2 (14.8% ± 1.00%) (Table 8.1). Although using  f2 values, confirmed that such 
decrease in drug release rate is not significantly different (Table 8.1). The f2 value was higher 
than 50, showing that the release was independent of the pH (f2> 50).  
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Figure 8.1: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from physical 
mixture (PM) and liquisolid (LS) formulations containing various pH media. 
 
The drug release was not affected by the pH in the mimicked gastric condition. The results 
suggest that inclusion counter polymer Psyllium into Polyox
TM
 matrices is an effective way to 
achieving more sustained drug release with less pH dependency. Sustained release of DTZ has 
been reported previously to be unaffected by speed rate and pH (Peh and Wong, 2000). In 
general, the dissolution behaviour of LS tablets exhibited significantly slower release rates of 
DTZ than the PM tablets regardless of the pH media used (Figure 8.1), as validated by f2 
values below 50 (Table 8.1). This was further confirmed by dissolution parameters which 
showed the LS tablets to have lower DEs higher MDT than their counterpart PM tablets. For 
example, LS formulations containing pH 7.5 produced lower DE (13.7% ± 0.40%) compared 
to the conventional tablets DEs (27.1% ± 2.61%) (Table 8.1). 
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Table 8.1: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR), similarity factor (f2) and in vitro release 
kinetic parameters n value of diltiazem HCl obtained for liquisolid (LS) formulations containing various pH media in comparison to their 
physical mixture (PM) counterparts. The counterpart physical mixture was chosen as the standard for each liquisolid formulation when 
calculating f2 values. The results are expressed as the mean ± SD, n = 3 (*indicates significant difference, P< 0.05). 
 
 
 
pH Media DE (%) 
PM                    LS 
MDT (min) 
PM                  LS 
MDR (min
-1
) 
PM               LS 
f2 
LS vs PM 
n Value 
     PM                   LS 
DTZ–(PolyoxTM:Psyllium) pH 1.2 40.0 ± 0.73 24.5 ± 0.50 205.2 ± 3.10 201.0 ± 9.60  0.16 ± 0.01 0.10 ± 1.70 44.2 0.660 0.700 
DTZ–(PolyoxTM:Psyllium) pH 2.2 33.7 ± 1.71 20.5 ± 0.82 206.1 ± 2.70 199.8  ± 13.5 0.14 ± 0.01 0.08 ± 0.00 47.5 0.615 0.698 
DTZ–(PolyoxTM:Psyllium) pH 5.8 32.8 ± 0.90 18.7 ± 0.40 194.4 ± 1.10 201.9 ± 2.02 0.14 ± 0.00 0.07 ± 0.01 46.3 0.623 0.690 
DTZ–(PolyoxTM:Psyllium) pH 6.8 31.0 ± 1.64 15.6 ± 0.70 203.3 ± 11.4 231.1 ± 8.20 0.13 ± 0.01  005 ± 0.01 43.4 0.717 0.642 
DTZ–(PolyoxTM:Psyllium) pH 7.2 28.8 ± 2.42 14.8 ± 1.00 206.1 ± 18.4 207.0 ± 26.7 0.12 ± 0.01  0.05 ± 0.01 46.3 0.702 0.859 
DTZ–(PolyoxTM:Psyllium) pH 7.5 27.1 ± 2.61 13.7 ± 0.40 210.0 ± 19.1 214.0 ± 6.40 0.11 ± 0.01 0.60 ± 0.00 47.4 0.605 0.963 
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To investigate the effects of rotational speed on the release rate of DTZ, four different RPM 
(25, 50, 75 and 100) were studied for choosing the best-optimised formulation. The release 
rate of DTZ from both the LS formulations and PM tablets were similar despite having 
different rotational speed (Figure 8.2). Therefore, it could be detailed that the adhesive force 
between polymers and DTZ particles is great enough, not being affected at higher rotational 
speeds. To confirm the above finding, the similarity factor (f2) was calculated and f2 value 
(Polyox
TM
:Psyllium) is greater than 50 irrespective of their speeds, which indicate that there is 
no significant difference between drug release from various rotational speeds (f2>50). In 
general, LS tablets produced slower release rate of DTZ when compared to their conventional 
PM tablets.  To confirm the above finding, the similarity factor (f2) was also calculated and 
data are presented in (Table 8.1). This table shows that all f2 value (Polyox
TM
:Psyllium) is less 
than 50 irrespective of their speeds, which indicate that there is a significant difference 
between drug release from LS formulations in comparison to their PM various rotational 
speeds (f2<50) (Table 8.1) 
 
Figure 8.2: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from physical 
mixture (PM) and liquisolid (LS) formulations containing various rotational speeds. 
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To study the drug release mechanism, the drug release kinetics using different rotational 
speed were investigated by relating the empirical exponential equation (Mt/M∞ = ktn) (Table 
8.1). For matrix tablets, an n value of ~0.5 indicates diffusion control and an n value of ~1.0 
indicates erosion control. The n values of the Polyox
TM
:Psyllium matrix tablets were found to 
be between 0.620 and 0.684 in the case of PM formulations whereas LS formulations 
containing Polyox
TM
:Psyllium matrix tablets were found to be between 0.812 and 0.898 in the 
aqueous media, suggesting a non-Fickian or anomalous transport, which is a combination of 
both Fickian transport through the hydrated matrix gel layers and polymer chain 
relaxation/erosion (Baumgartner et al., 2006). These results showed that the drug release from 
the Polyox
TM
:Psyllium matrix tablet was categorised as a combination of diffusion and 
erosion control. Regardless of their rotational speed, LS formulations containing 
Polyox
TM
:Psyllium obtained higher n value than PM matrices tablets. This showed that LS 
matrices tablets are better candidates to produce more sustained drug release than their PM 
tablets. And for the formulations with various pH media, the drug release from both the LS 
formulation and PM tablet also followed anomalous transport mechanism (Table 8.1).
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Table 8.2: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR), similarity factor (f2) and in vitro release 
kinetic parameters n value of diltiazem HCl obtained for liquisolid (LS) formulations containing various pH media in comparison to their 
physical mixture (PM) counterparts. The counterpart physical mixture was chosen as the standard for each liquisolid formulation when 
calculating f2 values. The results are expressed as the mean ± SD, n = 3 (*indicates significant difference, P< 0.05). 
 
 
Rotational speed DE (%) 
PM                    LS 
MDT (min) 
PM                  LS 
MDR (min
-1
) 
PM               LS 
f2 
LS vs PM 
n Value 
     PM                   LS 
DTZ–(PolyoxTM:Psyllium) 25 25.2 ± 0.6 16.3 ± 1.1 193.6 ± 2.0 197.6 ± 5.8  0.11 ± 0.00 0.06 ± 0.01 56.0 0.678 0.898 
DTZ–(PolyoxTM:Psyllium) 50 27.6 ± 0.1 16.8 ± 0.7 184.2 ± 7.6 190.7  ± 15.9 0.11 ± 0.01 0.07 ± 0.00 49.6 0.654 0.809 
DTZ–(PolyoxTM:Psyllium) 75 25.1 ± 0.4 13.0 ± 0.4 218.1 ± 2.4 212.1 ± 5.0 0.11 ± 0.00 0.05 ± 0.01 48.7 0.684 0.822 
DTZ–(PolyoxTM:Psyllium) 100 27.8 ± 0.6 18.0 ± 1.2 194.1 ± 3.0 197.0 ± 11.5 0.12 ± 0.01  007 ± 0.01 47.2 0.620 0.812 
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 Conclusion 8.3
This study revealed that LS technique could be optimised for the preparation of sustained 
release matrices of water–soluble drug.  DTZ release matrix tablet with the inclusion of 
Polyox
TM
 and Psyllium was considered with respect to its dissolution properties. The 
dissolution profile from the Polyox
TM
:Psyllium matrix tablet could be controlled and showed 
a constant release profile in different media. Also, the Polyox
TM
:Psyllium matrices tablet was 
assessed to have adequate strength against mechanical stress. These results suggest that the 
combination of Polyox
TM
 and Psyllium showed robust dissolution against pH and rotational 
speed, and therefore indicates an appropriate sustained–release profile. 
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 CHAPTER 9: INFLUENCE OF DRUGS SOLUBILITY  9
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 Introduction 9.1
Solubility has been well explained in section 1.6.1 as one of the most important 
physiochemical properties of a drug. This is because following oral administration, the 
bioavailability of a drug depends primarily on its solubility in the GIT and its permeability 
across the cell membranes. The release rate for both water–soluble (promethazine HCl, 
aminophylline and propranolol HCl) and less soluble (indomethacin) drugs from 
hypromellose matrix systems was studied previously (Ford et al., 1985). For less soluble 
indomethacin, both the particle size of the drug and viscosity grade of hypromellose was 
reported to retard more drug release than those matrices obtained from water–soluble drugs. 
This was primarily attributed to the dominant erosion mechanism of drug release in the case 
of less soluble drugs. Excipients and high concentrations of insoluble drugs may cause non–
uniform swelling of the hydrophilic matrix tablet. It has been suggested that highly soluble 
drugs can be released by diffusing through the gel matrices and this is acknowledged to be the 
main passage way for their release. However, drug release also transpires through erosion of 
the gel matrix. With the formation of micro–cavities, highly soluble drugs can also act as pore 
formers, providing the gel structure more acceptable and weaker, therefore lead to increased 
drug release profiles. The release of poorly soluble drug is predominantly by erosion of the 
polymeric excipient, as the drug particles translocate and their behaviour compromises the 
structural integrity of the gel layer existing on the surface of the matrix tablet, thereby leading 
to drug release through matrix erosion (Bettini et al., 2001). Kim (1998), described the release 
profile of Diclofenac Na (solubility: 25 mg/mL) from the Polyox
TM
 (MW of 4,000,000) 
matrices was faster than that of Sulfathiazole (0.59 mg/mL). Chakraborty et al., (2009) also 
showed the release of Verapamil HCl (a highly water-soluble drug) from hypromellose 
matrices is faster when compared to matrices containing Aceclofenac (a poorly water–soluble 
drug). From the above discussion, there are various studies attempting to investigate the effect 
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of drug solubility for drug delivery purposes, but there is no data reported in the literature 
about the release profile of Polyox
TM
:Psyllium–based matrix tablets comprising various drugs. 
Therefore, in the present Chapter, the effect of drug solubility on drug release from a binary 
mixture of Polyox
TM
 and Psyllium in both LS and PM powder formulations was investigated. 
 Formulation 9.2
Each drug type, such as DTZ, THP and ZNM (4 g) under investigation was separately 
dissolved in 4 g of non–volatile water–miscible solvents, i.e., PS 80, used as liquid vehicles to 
form liquid medication phases. A fixed drug:solvent ratio of 1:1 (w:w) was used. An 
accurately weighed 6 g of each binary mixture Polyox
TM
 and Psyllium fixed at 1:1 was 
separately mixed with 1.2 g of the AEROSIL
®
 coating material and lactose (11.5 g) in the 
case of PM formulations and 14.1 g in the case of LS formulations). This blending was 
performed as described in section 2.5.  
Accurately weighed samples of each liquisolid (750 mg) and PM (650 mg) formulation were 
separately weighed and then compressed on 8 mm punch and die using a manual tableting 
machine at a fixed pressure of 2000 psi. 
 Results and discussion 9.3
9.3.1 Solid state 
The FT–IR spectrum of formulations containing THP and ZNM revealed considerable change 
within both the LS and PM formulations. In contrast PM and LS formulations indicated the 
presence of the characteristic bands of the DTZ almost at the same wave numbers especially 
for the bands observed at 1679 cm
-1 
which corresponding to carbonyl group stretching of the 
lactam ring and acetate group, respectively, but strong band at 2393 cm
-1 
which corresponding 
to N–H stretching of amine HCl were completely disappeared from both LS and PM 
formulations in the case of Pure DTZ. This disappearance in the band indicates the presence 
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of hydrophobic interactions between the DTZ and Polyox
TM 
(Figure 9.1). XRD pattern of pure 
drugs, PM and LS formulations of various drugs are shown in Figure 9.2. The highest 
crystalline Polyox
TM
 peak occurred at a 2θ angle of 23.5o and a smaller distinct peak was also 
observed at 2θ angle of 19.1°. Psyllium appears in an amorphous form. THP has distinct 
crystalline peaks at 2θ angles of 12.1° and a series of smaller peaks at 2θ angles of 24°, 25°, 
27° and 44°. The diffraction patterns of the LS formulations and PM powders exhibit 
crystalline peaks corresponding to DTZ with less intense. Whereas PM and LS formulations 
indicated the presence of distinct crystalline peaks at 2θ angles of 19.1° in the case ZNM. The 
XRD pattern of prepared LS formulations containing various drugs has the same diffraction 
pattern with relatively less intensity peaks compared to their the counterpart PM powder. This 
may be attributed to the presence of a fraction of the drug mass in a molecular state 
(dissolved) within polysorbate in liquisolid powders. This was in good agreement with the 
data reported by Javadzadeh et al, 2008, where they XRD pattern from both the LS and PM 
formulations have relatively the same diffraction pattern.  
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Figure 9.1: FTIR patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing Polysorbate 80 and various drugs i.e. (a) Pure DTZ, (b) Pure theophylline, (c) Pure 
zonisamide, (d) Polysorbate 80, (e) Pure Polyox
TM
 (f) Pure Psyllium (g) DTZ–
(Polyox
TM
:Psyllium), (h) THP–(PolyoxTM:Psyllium) and (i) ZNM–(PolyoxTM:Psyllium). 
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Figure 9.2: PXRD patterns of physical mixture (PM) and liquisolid (LS) formulations 
containing various drugs (a) Pure DTZ, (b) Pure theophylline, (c) Pure zonisamide, (d) 
Polysorbate 80, (e) Pure Polyox
TM
 (f) Pure Psyllium (g) DTZ–(PolyoxTM:Psyllium), (h) THP–
(Polyox
TM
:Psyllium) and (i) ZNM–(PolyoxTM:Psyllium). 
9.3.2 Particle size distribution 
Particle size distribution of formulations containing DTZ, THP and ZNM is shown in Table 
9.1. LS formulations demonstrated a considerably higher d10% values compared to their PM 
counterparts (Table 9.1) which could account for their improved size homogeneity. For 
example, d10% value of LS formulation obtained from ZNM has 46.9 μm ± 0.2 μm whereas the 
value obtained from ZNM is 16.2 ± 0.8 μm in the case of PM powder. This could be ascribed 
to the adhesion of such fines on the surfaces of larger particles in the case of LS formulations 
(Table 9.1). Regardless of their drug type, all LS formulations showed a significant difference 
in their median value than their counterpart PM powders (Table 9.1). The median value also 
showed increasing trend with a decrease in their drug solubility. For example, the mean 
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diameter of LS formulations increased from (48.6 μm ± 2.2 μm to 147.3 μm ± 8.6 μm), as the 
solubility of drugs decreased from (625 mg/mL to 0.8 mg/mL). This was in complete 
agreement to the findings of (Krejcová et al., 2006), which described THP having the lowest 
solubility has (d = 277.5 μm) largest particles and smaller mean diameter particles were 
observed from DTZ (d = 156.0 μm) with the highest solubility. In general, the span value 
obtained from LS formulations containing DTZ (4.7 ± 1.4) was smaller than the span values 
obtained from ZNM (5.4 ± 0.8) and THP (9.4 ± 0.6) (Table 9.1). This indicated that THP 
showed a wider PSD (high polydispersity) in comparison to DTZ and ZNM (Table 9.1). SEM 
images of drug type particles exhibited crystalline particles in both the LS and PM and there 
are no much morphological variations seen between DTZ and ZNM particles (Figure 9.3). 
DTZ and ZNM demonstrated spherical particles with nearly uniform (regular) shape. This 
might be the reason for the good powder flow properties in both the formulations. THP 
displayed the normal angular–subangular shape with less irregular particles (Figure 9.3). 
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Figure 9.3: SEM of commercial diltiazem HCl (DTZ), theophylline (THP) and Zonisamide 
(ZNM). 
 
 
 
 
 
 
 
 
200 
 
 
 
Figure 9. 4: SEM of diltiazem HCl (DTZ) from physical mixture (PM) and liquisolid (LS) 
formulations containing different drug type  
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Table 9. 1: Particle size distribution (i.e. particle size at 10% (d10%), 50% (d50%), 90% (d90%), volume mean diameter (VMD), and span; mean ± 
SD, n = 3) of various drug type liquisolid (LS) formulation powders and their physical mixture (PM) counterparts. 
Product (s) d10% d50% d90% VMD (μm) Span 
Pure DTZ 8.21 ± 0. 2 1 29.2 ± 0.3 147.3 ± 8.0 167.0 ± 4.5 4.0 ± 1.5 
Pure THP 11.1 ± 1.7                                                   63.8 ± 20.5 237.0 ± 12.0 98.3 ± 37.7 4.2 ± 1.8 
Pure ZNM 69.4 ± 4.7 271 ± 6.1 532.3 ± 3.1 290.7 ± 4.2 1.7 ± 0.1 
Pure Polyox
TM
 16.3 ± 0.1 39.5 ± 0.2 77.7 ± 1.3 43.7 ± 0.4 1.6 ± 0.1 
Pure Psyllium 10.1 ± 0.1 85.1 ± 2.1 231.3 ± 8.3 104.3 ± 3.2 2.6 ± 0.1 
        PM      LS          PM           LS                   PM               LS PM             LS PM               LS 
DTZ–(PolyoxTM:Psyllium)  8.12 ± 0.8 14.7 ± 4.1 33.6 ± 0.8 48.6 ± 2.2 
 
261.3 ± 32.7 
 
249.7 ± 34.7 
 
84.1 ± 8.8 
 
91.8 ± 21.3 
 
7.5 ± 0.8 
 
4.7 ± 1.4 
 
THP–(PolyoxTM:Psyllium)  7.10 ± 0.7 27.3 ± 0.3 35.8 ± 1.1 
 
86.1 ± 2.1 
 
136.7 ± 4.7 
 
586.7 ± 164.4 
 
54.9 ± 0.9 
 
463.3 ± 45.2 
 
4.0 ± 0.2 
 
9.4 ± 0.6 
 
ZNM-(PolyoxTM:Psyllium)  16.2 ± 0.8 46.9 ± 0.2 46.3 ± 0.2 
 
89.3 ± 3.1 
 
175.3 ± 2.9 
 
346.3 ± 149.3 
 
69.4 ± 0.8 
 
319.3 ± 47.1 
 
3.6 ± 0.0 
 
5.4 ± 0.6 
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9.3.3 Powder density 
In comparison to PM formulations, all LS formulations with various drug solubility produced 
higher bulk density and higher tapped density as depicted in (Table 9.2), indicating larger 
points of physical contact between particles within LS powders. PM powders and their 
counterpart LS formulations with different drug solubilities showed acceptable flow 
properties as indicated by the CI values (Table 9.2). CI value for LS formulations obtained 
from DTZ, THP and ZNM was 20.0 ± 0.5%, 21.6 ± 1.1% and 23.6 ± 0.4%. Whereas CI 
values for PM powders were generally higher and ranged between (22.3 ± 0.5% and 24.2 ± 
0.2%), i.e. both the LS formulations and PM powders showed increasing trend with deceased 
in drug solubility (Table 9.2).  
9.3.4  Hardness 
The hardness of tablets formulated using THP–based drug was found to be higher than tablets 
formulated using DTZ and ZNM, i.e. the hardness obtained from both the LS and PM tablets 
recorded lower hardness with formulation containing higher drug solubility to formulation 
containing THP (Table 9.2). For example, PM formulation containing THP tablets produce 
higher hardness 87.8 N compared to DTZ with the highest solubility produced lower hardness 
value 80.9N. The results are in agreement with those published by (Krejcová et al., 2006), for 
different drugs. The matrices tablet containing THP gives higher hardness compared to DTZ 
and diclofenac Na tablets. This was linked to the better binding properties between THP and 
Polyox
TM
:Psyllium that gives more available hydrogen bonding place beside physically 
combined polymer chains. A similar trend was also seen for the pure drugs where the THP 
produced higher hardness than DTZ and ZNM (Tablet 9.2). PM tablets recorded higher 
hardness values in comparison to their LS formulations (Table 9.2).  
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Table 9.2: Bulk density, tap density, Carr’s index (CI) and Hardness (mean ± SD, n = 5) for various drugs to PolyoxTM and Psyllium at 1:1 ratio. 
 
Product Bulk density (g/cm
3
) Tap density (g/cm
3
) CI (%) Hardness (N) 
Pure DTZ 0.33 ± 0.01 0.53 ± 0.01 38.0 ± 0.00 38.0 ± 0.94 
Pure THP 0.39 ± 0.00 0.61 ± 0.02 36.1 ± 1.84 60.5 ± 10.5 
Pure ZNM 0.74 ± 0.07 0.92 ± 0.09 19.1 ± 1.50 13.7 ± 1.39 
 PM LS PM LS PM LS PM LS 
DTZ–(PolyoxTM:Psyllium)  0.42 ± 0.02  0.46 ± 0.02 0.53 ± 0.01 0.58 ± 0.01 22.3 ± 0.43  20.0 ± 0.5 80.9  17.7 
THP–(PolyoxTM:Psyllium)  0.37 ± 0.04 0.36 ± 0.04 0.51 ± 0.06 0.54 ± 0.05 22.9 ± 0.50 21.6 ± 1.1 87.8 11.5 
ZNM–(PolyoxTM:Psyllium)  0.36 ±0.01 0.41 ± 0.01 0.54 ± 0.14 0.58 ± 0.02 24.2 ± 0.17 23.6 ± 0.4 74.1 7.8 
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9.3.5 Drug release studies 
The release profile of Polyox
TM
:Psyllium–based matrix tablets comprising various drugs were 
assessed. Figure 9.5 shows the release behaviour of three (3) different drugs from 
Polyox
TM
:Psyllium matrices. The solubility of drug type such as DTZ, THP and ZNM in 
aqueous media was found to be 625 mg/mL (Li et al., 2016), 8.0 mg/mL (Shojaee et al., 
2014) and 0.8 mg/mL (Shojaee et al., 2014) respectively. The dissolution rate of 
Polyox
TM
:Psyllium from different pure drugs tablet was extremely faster than their 
formulations from both LS and PM tablets (Figure 9.5). All formulations from both the LS 
and PM formulations showed sustained drug release patterns (Figure 9.5). The release rate for 
the drugs from Polyox
TM
:Psyllium matrix tablets inccreased with an increase in their 
solubility. The release rates from less soluble drug, ZNM demonstrate slower release profile 
than DTZ and THP (Figure 9.5). This could be attributed to their increase in aqueous 
solubility for DTZ and THP in comparison to ZNM. These results also suggested that DTZ 
could easily diffuse out through Polyox
TM
:Psyllium matrices, resulting in faster drug release 
rates than those of less water–soluble ones such as THP and ZNM. Drug solubility could 
enable the hydration process by allowing constant penetration of water via diffusion and 
dissolution. This was in complete agreement to the findings obtained by (Ford et al. 1985; 
Kim 1998; Chakraborty et al., 2009). A similar finding was also observed by (Shojaee et al., 
2014), where drug release is faster when highly water soluble drug was used compared to less 
water–soluble drug combined in PolyoxTM matrices. This was confirmed by the dissolution 
parameters which indicate that ZNM to have lower DEs, higher MDT and lower MDR in 
both LS and PM tablets (Table 9.4). For example, LS formulation containing ZNM to 
produce lower DE (5.66% ± 0.54%), higher MDT (263% ± 2.31%) and lower MDRs (0.02 
min
-1
 ± 0.01 min
-1
) compared to those formulations containing THP with DE (10.9% ± 
2.13%), MDT (235% ± 2.14%) and MDRs (0.05 min
-1
 ± 0.01 min
-1
)  and DTZ (DE 13.0% ± 
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0.40%), MDT (212% ± 4.93%) and MDRs (0.10 min
-1
 ± 0.01 min
-1
). However, despite the 
trend in their solubility, statistical analyse confirmed that there is no significant difference in 
dissolution profiles between the drug type f2>50 (Table 9.4).  
 
Figure 9.5: Release patterns (mean ± SD, n = 3) of diltiazem HCl (DTZ) from physical 
mixture (PM) and liquisolid (LS) formulations containing various drug type. 
 
In general, it is evident that the tablets prepared by LS formulations showed retardation 
properties compared to PM tablets. This could be attributed to the presence of viscous liquid 
medication (PS 80) as seen in section 3.3.4. This was further confirmed by the dissolution 
parameter which showed LS formulation gives lower DE and lower MDR than their 
counterpart PM tablets (Table 9.4). For example, ZNM produce lower DE (5.66% ± 0.54%) 
and lower MDRs (0.02 min
-1
 ± 0.01 min
-1
) than their PM  tablets DE (11.6% ± 0.25%) and 
MDRs (0.04 min
-1
 ± 0.00 min
-1
). 
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Table 9.3: Dissolution efficiency (DE), mean dissolution rate (MDT), mean dissolution rate (MDR) and in vitro release kinetic parameters; n 
value of diltiazem HCl obtained for liquisolid (LS) formulations containing various drug type in comparison to their physical mixture (PM) 
counterparts. The results are expressed as the mean ± SD. 
 
 
Formulation (s) DE (%) MDT (min
-1
) MDR (min
-1
) n value 
Pure DTZ 97.5  ± 0.02 15.3 ±0.11 0.83 ± 0.01  
Pure THP 92.2 ± 0.69 47.2 ± 4.19 0.52 ± 0.02 
Pure ZNM 74.1 ± 8.93 157.6 ± 12.6 0.29 ± 0.02 
        PM            LS     PMs               LS       PMs        LS PMs         LS 
DTZ–(PolyoxTM:Psyllium) 22.3 ± 0.26 13.0 ± 0.40 218 ± 2.36 212 ± 4.93 0.10 ± 0.01 0.10 ± 0.01 0.684 0.915 
THP–(PolyoxTM:Psyllium) 19.1 ± 1.09 10.9 ± 2.13 203 ± 2.61 235 ± 2.14 0.08 ± 0.01 0.05 ±0.01 0.730 0.800 
ZNM-(PolyoxTM:Psyllium) 11.6 ± 0.25 5.66 ± 0.54 271 ± 6.68 263 ± 2.31 0.04 ± 0.00 0.02 ± 0.01 0.865 0.889 
207 
 
Mathematical models were also applied to assess the kinetics and mechanisms of drug release 
from the tablets. It was concluded from these results that regardless of drug solubility, the 
release from tablets containing a mixture of Polyox
TM
 and Psyllium followed anomalous 
transport mechanism (Table 9.4) in the case of PM tablets. All LS formulations showed 
higher n values regardless of drug solubility. The LS formulations containing highly soluble 
drug DTZ followed Case II transport, whereas the diffusion component of LS formulations 
containing THP and ZNM ranging from 0.800 to 0.950 was much nearer to the upper 
boundary value (0.89/1.00) than the lower boundary value (0.43/0.50). It was therefore 
concluded that Case II transport resulted from the erosion of the matrix was the predominant 
factor controlling the drug release.  
 Conclusion 9.4
The results in this Chapter showed that both the LS formulations and PM powders containing 
DTZ with higher water solubility were released faster from the Polyox
TM
:Psyllium matrices 
than THP and ZNM. The drugs release increases with increasing drug solubility. However, 
despite the trend in their solubility’s, there is no significant difference in dissolution profiles. 
The results suggest that inclusion of psyllium into Polyox
TM
 matrices is an effective way to 
attaining more sustained release with various drugs. 
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 Summary and Conclusion 10
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Liquisolid technique is a relatively new approach to formulating sustained release dosage 
forms. In the study on polymer particle in hydrophilic matrix system, Polyox
TM
 MW was 
identified as the key step in obtaining consistent sustained drug release profile. The 
dissolution rate of DTZ from both LS and conventional compacts decreased as the MW of 
Polyox
TM
 increased. An interesting trend was obtained when plotting the differences in DE 
from both LS and PM formulations against the MW of Polyox
TM
. Polyox
TM–based LS tablets 
have a potential to produce sustain release for a highly water–soluble drug, DTZ, although a 
careful selection of Polyox
TM
 grade is nevertheless vital to producing slower release pattern 
of LS tablets in comparison to PM tablets. DTZ was also influenced by the Polyox
TM
 Particle 
size and ratio. The rate of DTZ released from both LS and conventional tablets generally 
showed decreasing trends with increasing Polyox
TM
 concentration and decreasing Polyox
TM
 
particle size distribution. At 1:3 and 1:4 drug:Polyox
TM
 (w:w) ratios, and regardless of 
Polyox
TM
 particle size distribution, LS formulations produced statistically similar release 
profiles compared to conventional formulations. However, LS formulations produced slower 
release profiles compared to conventional formulations when the concentration of Polyox
TM
 
increased to 1:5 drug:Polyox
TM
 (w:w) ratio. Polyox
TM
 level is often the dominant factor 
controlling drug release rate from matrix systems. The increase in polymer level can suppress 
the impact of drug particle size as well as polymer particle size. Maintaining Polyox
TM
 ratio 
at 1:5 was helpful in developing a robust matrix system.  The release profile of the DTZ from 
both LS tablets and their counterpart PM tablets showed decreasing trends with increasing  
hydrophilic AEROSIL
®
 surface area (from 65 m
2
/g to 225 m
2
/g). LS tablets produced slower 
release patterns compared to PM tablets regardless of the hydrophilic AEROSIL
®
 surface 
area used. This showed that AEROSIL
®
 surface area as coating materials affects the DTZ 
release profile. Therefore a careful selection should be considered when using AEROSIL in 
both methods. The polymer type also influenced drug release. Drug release was in the order: 
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HVO < lactose < compressol
SM  
<
 
mannitol < sorbitol. The incorporation of polymers further 
elicits a decrease in drug release rate from individual polymer matrices. Increasing drug 
solubility, irrespective of the preparation methods, increased the drug release. In general, this 
thesis showed that LS technique could be a promising approach in retarding the dissolution rate 
of highly soluble drug, DTZ and formulating sustain release dosage forms in comparison to their 
counterpart PM. Further work is therefore required to explore the hardness of LS tablet 
comprehensively. This will aid in the design and development of improved ER delivery systems 
in the future. 
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